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Abstract 
 
Treatment strategies for advanced malignancy remain limited in their success, despite 
major advances in the understanding of cancer aetiology and molecular biology. The 
incidence of many cancers, including melanoma, continues to rise, with a huge 
demand for therapies even if treatment goals are purely cytostatic. One particular 
therapeutic strategy is the metronomic (continuous and low) dosing of conventional 
chemotherapy. There is evidence to suggest that tumour vasculature is the main target 
of this dosing schedule resulting in an overall ‘non specific’ anti-angiogenic effect. It 
is now being studied in clinical trials alone and in combination with specific anti-
angiogenic agents.  
 
This thesis had two main aims: firstly to investigate the additive or synergistic anti-
endothelial effects of a number of conventional cytotoxic agents (Temozolomide, 
Paclitaxel, Vinorelbine, Etoposide, Carboplatin) in vitro given in a metronomic 
schedule in combination with a specific anti-angiogenic compound (Sorafenib) and a 
non-specific sompound (Combretastatin). The anti-proliferative, cytotoxic activities 
of the metronomic combinatorial schedules were assessed on microvascular 
endothelial cells and cancer cells using an MTT proliferation assay. Results 
confirmed significant (p<0.001) endothelial-specific anti-proliferative effects induced 
by cytotoxics given at metronomic doses (e.g. Temozolomide at 10µM, Paclitaxel at 
125µM, Vinorelbine at 1nM). These anti-endothelial effects were significantly 
enhanced by the addition of sorafenib (p<0.001) in all except for with Vinorelbine, 
but were not enhanced by the addition of combretastatin. 
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Secondly, the aim was to isolate circulating endothelial cells (CECs) and circulating 
endothelial progenitor cells (CEPs) in patients with advanced (stage IV) melanoma. 
This was a scientific clinical sub-study of an on-going clinical trial to assess the 
efficacy of metronomically-dosed temozolomide and estramustine. After optimisation 
of the isolation techniques for CECs and CEPs from whole blood samples, the 
metronomically-dosed participants were compared to conventionally-dosed 
participants. This required an appropriate MREC amendment to the already existing 
clinical trail. Although numbers were very small and the study was aimed at 
hypothesis - generation, results showed a trend towards increased CECs mid-
treatment in the metronomic group (mean: 6.6 CEC/µL of whole blood pre-treatment 
versus 11.25 CEC/µL of whole blood mid-treatment). There was otherwise no 
significant difference between the two groups.  
 
In summary, this thesis is a study of a combinatorial strategy to enhance the anti-
angiogenic effects of the metronomic approach. This is a generic ‘cancer treatment’ 
approach, but is studied here more specifically in the setting of melanoma. It shows 
successful further development of an in vitro anti-endothelial assay which can 
potentially be used as a preclinical screening tool to determine efficacy of numerous 
agents and combinatorial regimens. It also demonstrates the isolation of potential 
biomarkers for anti-angiogenic therapy (i.e. CECs and CEPs) in a small but unique 
subset of patients with stage IV malignant melanoma.  
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Chapter 1 
 
Angiogenesis, Melanoma and Metronomic Chemotherapy 
 
 
1.1 Introduction 
 
 
Cancer remains one of the leading causes of death in the Western World. It is a major 
cause of morbidity in the United Kingdom, and each year more than a quarter of a 
million people are newly diagnosed with cancer. Cancer is primarily a disease of 
older people; therefore a person’s risk of developing cancer is dependent on age. 
Overall, it is estimated that more than 1 in 3 people will develop some form of cancer 
during their lifetime, compared to an estimated risk of 1 in 27 for people aged up to 
50 year. Less than 1% of all cases occur in children, aged 0 to 14 years 
(CancerResearchUK 2011).  
 
Despite an overall decreasing mortality rate for malignant neoplasms as a whole, the 
incidence of most cancers continues to rise. The most rapidly increasing incidence 
rates include a quadruple rise in incidence rates of malignant melanoma over the last 
thirty years, with around 11,760 cases diagnosed in 2008. A similarly significant 
increase in the incidences of liver cancer, non-Hodgkin lymphoma and prostate 
cancer are also reported. Along with this, an increase in mortality rates has been 
associated with such malignancies. In the 60-79 year old male group, a 790% increase 
in melanoma incidence was noted between 1975 and 2008 (CancerResearchUK 
2011). 
 
Although our understanding of cancer aetiology, molecular biology and treatment 
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strategies has without doubt advanced dramatically in the last few decades, treatment 
strategies for advanced malignancy remain limited in their success. The compilation 
of different chemotherapeutic regimens and other cancer therapies, such as 
immunotherapy, continue to often be empirically devised or based on lower level 
evidence (Balch C et al 1997; Huber P et al 2005; CancerResearchUK 2011).  
 
The era of cancer chemotherapy began in the 1940s with the first use of nitrogen 
mustards and folic acid antagonist drugs. Cancer drug development has exploded 
since then into a huge industry, and now targeted therapies have started to 
revolutionise the methods of cancer treatment. However, many of the early principles 
still apply.  When Louis Goodman and Alfred Gilman – both pharmacologists - were 
recruited by the United States Department of Defense to investigate potential 
therapeutic applications of chemical warfare agents, they discovered at autopsy that 
profound lymphoid and myeloid suppression had occurred in people exposed to 
mustard gas. They applied this finding to the treatment of lymphoma in mice and later 
in humans, and found there to be a dramatic reduction in patients’ tumour mass as a 
result of the agent (Goodman L et al 1946; Gilman A  et al 1963) . 
 
Shortly after World War II, a second approach to cancer therapy began. Sidney 
Farber, a pathologist at Harvard Medical School, studied the effects of folic acid on 
leukaemia patients. Folic acid, a crucial vitamin for DNA metabolism, was found to 
stimulate the proliferation of acute lymphoblastic leukaemia (ALL) in children. 
Following this observation, Farber and colleagues synthesised folate analogues e.g. 
aminopterin and then amethopterin (now methotrexate) which acted antagonistically 
to folic acid, and were found to induce remission in children with ALL. Farber’s 
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report at the time was met with ridicule and it was felt that the children should be left 
to die in peace (Farber S et al 1948). 
 
Following the work of Farber, the rationale behind his drug design led to an era of 
anti-metabolite development, whereby small changes were made to molecules 
required for cell division. This led to the discovery of 6-mercaptopurine, which was 
subsequently shown to be a highly active anti-leukaemic drug. Around the same time, 
the Eli Lilly natural products group found that alkaloids of the Madagascar periwinkle 
(Vinca rosea) were able to block proliferation of tumour cells, later found to be via 
inhibition of microtubule polymerisation, and therefore cell division (Johnson I et al  
1963).   
As a result of these discoveries, the United States Congress created a National Cancer 
Chemotherapy Service Center (NCCSC) in 1955, in order to promote drug discovery 
for cancer. The NCCSC developed crucial methodologies and tools, such as cell lines 
and animal models, for chemotherapeutic development. This early revolution in 
cancer therapy was therefore largely a North American experience, fuelled by an 
optimistic United States Federal government, following the ‘big-idea’ philosophy that 
they also applied to the Apollo Program (Kennedy JF 1961). It was only later that the 
pharmaceutical industry became heavily involved, realising the potential for financial 
gain.  
 
In 1965, a major break-through in cancer therapy occurred when James Holland and 
his colleagues hypothesised that cancer chemotherapy, in particular that for 
leukaemia,  should follow a strategy of antibiotic therapy for tuberculosis with 
combinations of drugs (Holland J 1965). This was thought to reduce the likelihood of 
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tumour resistance to develop. The group devised a regimen of methotrexate (anti-
folate), vincristine (Vinca alkaloid), 6-mercaptopurine and prednisolone – together 
referred to as POMP regimen – and were able to induce long-term remission in 
children with ALL. ALL became largely a curable disease, as it is today. This 
approach was later applied to adult lymphoma, and currently all curative cancer 
chemotherapy uses a multiple drug paradigm (Yates J et al 1974). 
 
Next came the concept of adjuvant therapy, whereby tumour burden was first reduced 
by surgery, then chemotherapy would follow, in an attempt to clear any remaining 
malignant cells. This was shown to improve survival in some patient groups, and 
coincided with further drug design and development. The classes of agents that then 
came into the fore-ground included the taxanes – acting on the cellular  micro-
tubules, the vinca alkaloids and the camptothecins – inhibitors of topoisomerase I, an 
essential enzyme for the structuring of DNA (Wall M et al 1966). The taxanes act on 
the microtubules by stabilizing GDP-bound tubulin in the microtubule. This results in 
a ‘freeze’ of mitosis. Thus the taxanes are mitotic inhibitors. In contrast the vinca 
alkaloids destroy mitotic spindles, and therefore the 2 classes of agents have been 
widely termed spindle poisons. Some of these agents, along with the topoisomerase 
inhibitors, subsequently gained FDA approval for the treatment of varying cancers 
including ovarian (Paclitaxel) and colon (Irinotecan) cancer. 
 
Other classes of agents were also being developed and were shown to have some 
success in treating various malignancies, including platinum-based agents 
(e.g.Cisplatin) in testicular cancer. Interestingly, many derivatives from these 
different classes of agents were found to have different side-effects and often non-
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therapeutic overlapping properties e.g. cisplatin and oxaliplatin – where oxaliplatin 
can work in cases of cisplatin resistance when used as part of a multi-targeted 
approach (Stordal B  et al 2007). 
 
Throughout this period of surge in drug development, chemotherapeutic regimens 
were based on the ‘maximum tolerated dose’ (MTD) paradigm (Skipper HE et al 
1970). Phase I trials aim to determine the optimal dose of a new compound for 
subsequent testing in phase II trials. With cytotoxic agents, this dose has traditionally 
corresponded to the highest dose associated with an acceptable level of toxicitiy. This 
is based on the assumption that the higher the dose, the greater the likelihood of drug 
efficacy. In addition to the relationship between dose and anti-tumour response, 
cytotoxic agents also exhibit a dose-toxicity relationship. Therefore, dose-related 
toxicity is generally and traditionally regarded as a surrogate marker for efficacy 
(Skipper HE et al 1964). Clinical investigators soon realised that the ability to 
manage these dose-related toxicities was crucial to the success of cancer 
chemotherapy. Support on MTD regimens often involves platelet and red-cell 
transfusions, and antibiotic cover to treat any infective complications resulting from 
the myelotoxic effects of these cell poisons. Most of the traditional chemotherapeutic 
agents also induce nausea and vomiting - often unbearable to patients - although anti-
emetic agents e.g. ondansetron, have reduced the severity of these side effects.    A 
low percentage of ‘toxic’ deaths (usually less than 1.5%) is well described and has 
become ‘acceptable’.  
 
 Although transient disease regressions in advanced dsease are not uncommon with 
the MTD approach, eventual drug resistance is almost always acquired by the tumour 
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phenotype (Longley DB and Johnston PG 2005). Furthermore, the potentially severe 
and systemic adverse effects of MTD cytotoxic therapy can lead to a reduced quality 
of life and even death, in patients in whom prognosis is poor and treatment is 
palliative from the outset. There was therefore felt to be a huge need to develop 
alternative and more successful strategies for the treatment of all cancers, particularly 
for those with a rising incidence and where treatment options so far have had little 
impact on overall survival e.g. malignant melanoma. Achieving this in a more 
targeted sense with commensurate reduction of toxicity would be a welcome 
development, and is currently a rapidly expanding field in cancer treatment and 
research. 
 
It is still early days in understanding the machinery of the cancer cell and its genetic 
make-up; however insight into some of the mechanisms underlying cancer growth, 
invasion and metastases has been paramount in the development of targeted cancer 
therapy. Prior to this new approach, chemotherapeutic agents had been discovered 
either by chance, or by inhibiting metabolic pathways crucial to the division of all 
cells, but none were yet specific to the cancer cell. The exception to this was the 
development of 5FU by Robert Duschinsky, a German scientist, in the late 1950’s. 
His scientific goal was to develop a drug that demonstrated specific uracil 
antagonism, since uracil is a normal component of RNA, exploiting the rapid division 
of cancer cells (Heidelberger C et al 1957). This agent has subsequently gone on to be 
the key agent used in many chemotherapy regimens used in cancers such as colon, 
pancreatic and breast. Figure 1.1 summarises the sites of action of cytotoxic agents 
on dividing cells. 
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Figure 1.1: Cell Cycle Summary and Site of Action of Cytotoxic Agents on 
Dividing Cells  
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One of the most exciting alternative treatment strategies, which has received much 
interest over the last decade, is that of inhibiting tumour blood vessel growth, 
otherwise termed anti-angiogenesis strategies. Angiogenesis is the process by which 
tumours acquire a blood supply for continued growth and survival, and therefore 
represents a potentially effective cancer target. The list of agents that seem to have an 
anti-angiogenic approach is expanding exponentially (Quesada A et al 2006; Albini A 
et al  2007; Ribatti D et al 2010) and features not only small-molecules which target 
specific signalling pathways, but also some of the conventional cytotoxic agents. The 
relatively novel idea that traditional cytotoxic agents may in fact induce an anti-
angiogenic effect when given continuously at low-doses has been termed the 
‘metronomic approach’, and will be discussed in detail later in this chapter (section 
1.3). This may potentially play a major part in the future of modern cancer treatment. 
The focus had been, until relatively recently, on the development of further 
conventional chemotherapeutic agents. These agents however, have fallen short of the 
high expectations of curing the most common of cancers, particularly once these 
cancers have metastasised. A new era of targeted cancer therapy is now well 
underway and much overdue. The trend is shifting towards the development and use 
of small molecular inhibitors of aberrant proteins and immunotherapy, in an attempt 
to develop more tumour specific, patient-friendly and effective regimens.   
 
This introductory chapter discusses the background, evidence and justification for 
adopting targeted cancer strategies, in particular, those which target angiogenesis and 
their use in the treatment of malignant melanoma.  
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1.2 Angiogenesis 
 
1.2.1 Definition 
 
Angiogenesis is the formation of blood vessels and vascular networks from pre-
existing vasculature. It is an important natural process occurring within the body, both 
in health and disease (Carmeliet P 2003). In health, this process helps to heal wounds 
and restore blood flow after injury or insult. In females, angiogenesis occurs during 
the monthly cycle to help rebuild the uterine wall, and during pregnancy, it occurs in 
the construction of the placental circulation. In such healthy situations, there is a fine 
balance between stimulation and inhibition, and in general, the angiogenesis switch is 
off (Hanahan D and Folkman J 1996).  
 
The primary formation of blood vessels is termed vasculogenesis, and occurs via 
differentiating angioblastic cells (Risau W 1997). In the embryo, this is via 
mesodermal angioblastic cells which go on to form a capillary plexus, whereas in the 
adult, it is via recruitment of the bone marrow angioblastic cells (Augustin HG 2001).  
The process of angiogenesis is therefore secondary to vasculogenesis (Figure 1.2) as 
it occurs from pre-existing vessels. It can be ‘sprouting’, involving anastomoses 
formation, or ‘non-sprouting’, which involves intussusceptive microvascular growth 
resulting in a tissue pillar or the fold-like splitting of a vessel. Both these processes 
contribute to the formation of a complex and vascular network, which can allow 
directional blood flow. Biomechanical and cellular factors contribute to the shaping 
of vascular structures, and finally micro-environmental factors e.g. the extracellular 
matrix, regulates the organ-specific differentiation of the neovascular tree (Zhu W et 
al  2000).  
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Figure 1.2: Development of vascular systems  
 
During vasculogenesis, endothelial progenitor cells give rise to primitive 
arteriovenous labyrinths; in angiogenesis, this is expanded by additional pericytes 
(PCs) and smooth muscle cells (SMCs) to form organised vascular networks. 
 
 
 
Diagram adapted from Carmeliet 2003.  
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Readaptation of existing mature vasculature is termed ‘remodelling’, and this may 
occur in response to acute or chronic stimuli e.g. hypertensive biomechanical forces. 
An existing vascular bed that contributes to tumour vascularisation, may well undergo 
similar remodelling processes, and this is termed ‘co-option’ (Augustin HG 2001). 
 
It has become apparent that angiogenesis is a complex process and our understanding 
of all the pathways involved is still far from complete. Its relevance to tumour 
growth, however, is unquestionable and this chapter will explain the significance of 
this. 
 
1.2.2 Background to tumour neovascularisation  
 
The field of angiogenesis has grown exponentially over the last 30 years, but it by no 
means is a ‘new’ area of study. Dating back as far as 5AD, Aulus Cornelius Celsus 
pronounced the signs of inflammation to be calor (heat), rubor (red), tumor (swelling) 
and dolor (pain) (Celsus AC 1935). At the time, these clinical signs were associated 
with an excess of blood. However, the actual circulation of blood and the concept of 
microvasculature were not elucidated until the work of William Harvey (1578-1657), 
who never ventured to ancient Rome or Greece, and hence the link was not made.  
The French surgeon, Ambroise Pare (1510-1590), went on to discuss the use of 
cautery in the management of cancer, noting the importance of targeting tumour 
blood supply. Pare explains that “…the fashion of a Crab doth represent the horrid 
forme of that ulcer” (Pare A 1634), comparing the projecting legs of the crab to the 
abnormal tumour vasculature.  
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Later, in the Eighteenth century, John Hunter – Scottish surgeon and scientist - noted 
that vessels have an immense ‘power of perfecting themselves’ and that ‘it is they 
which perform the operation of restoration on the other parts’ (Hunter J 1728-1793). 
As such, Hunter recognised the significance of angiogenesis, and also went on to 
unravel one of the major anatomical mysteries of his time – the lymphatic system. 
 
Many more acclaimed scientists and surgeons continued to observe the phenomenon 
of tumour growth and their vasculature. In October 1907, Professor Golmann of 
Freidurg gave a lecture at the Royal Society of Medicine in London, outlining the 
chaotic irregularity of tumour vasculature, and the theory that tumours exerted an 
angiogenic influence on surrounding tissue (Goldman E 1907).  
 
In 1945, Algire and Chalkley studied the vascular reaction of host tissue to tumour 
growth. They compared the vascular growth in wounds, in implanted benign tissue 
and in implanted sarcomas and carcinomas. New vessel growth, quantified 
microscopically, was seen at three days in the cancers and six days in benign lesions 
and wounds. They concluded that the tumours produced a specific substance which 
induces vessel growth (Algire GH et al 1945). Following on from this, Pietro 
Rondoni, Professor of Pathology at the Univesity of Milan (1946) wrote that “ a 
tumour acts both angioplastically and angiotactically” (Rondoni P 1946) and 
hypothesised that a cancer induces formation of new blood vessels from those that 
surround it (Ribatti D et al 2001). 
 
The search for a solution continued, and by 1971, Judah Folkman presented the 
theory that tumours were entirely dependent upon vessel formation for growth, 
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progression and metastasis (Folkman J 1971). His work, using an isolated organ 
perfusion system, demonstrated the reliance of tumour survival on endothelial 
recruitment. This placed angiogenesis at the centre of tumour biology. Following on 
from this, Gimbrone et al investigated the existence of a fundamental relationship 
between angiogenesis and the ability of a tumour to grow malignantly. They found 
that prevention of neovascularisation led to tumour dormancy. This was seen in 
epitheliomas transplanted into the irises of rabbits (Gimbrone MAJ et al 1972). 
 
Further work concluded that tumour cells have a stimulating influence on endothelial 
cells, noting that capillaries grow towards tumours from the host unlike skin grafts 
which send out new capillaries. It was also evident that there were characteristic 
phases in tumour growth i.e. a pre-vascular phase of minimal growth, followed by a 
vascular phase of exponential growth. It was at this point that the idea of targeting 
angiogenesis both directly and indirectly was put forwards as a novel therapeutic goal 
(Folkman J 1972). 
  
Various techniques were also developed to look at patterns and distributions of 
tumour vascularity. These ranged from immunohistochemistry to scanning electron 
microscopy and digital computer technology. Jain and colleagues did extensive 
studies using some of these techniques which showed that tumour vessels have 
defective cellular linings, composed of disorganised, branched, overlapping or 
sprouting endothelial cells. They also showed that openings between these cells 
contribute to tumour vessel leakiness and may provide a potential route for 
therapeutic agent molecules (Less J et al 1991; Lichtenbeld H et al 1996). Other 
studies looked at the measurement of microvascular density (MVD) in tumours, 
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thought to have some prognostic significance, supported by the angiogenesis theories 
to date. The first quantitative evidence was produced by Srivastava et al in 1986 
looking at melanoma (Srivastava A et al 1986). This showed a positive correlation 
between the percentage of area occupied by vessels at the tumour-dermal junction and 
the thickness of the melanoma (r=0.687, p<0.002). However, there was no correlation 
between vascularity and clinical outcome shown by this study, and these methods 
have not been adopted as useful prognostic tools. MVD has been studied again more 
recently as a biomarker for response to anti-angiogenic treatment strategies, with 
variable results (Willett C et al 2005; Jubb A et al 2006). 
It is now well established that tumour growth and subsequent metastatic spread are 
critically dependent on the tumours blood supply (Liotta LA and Stracke M 1998; 
Melero-Martin JM and Dudley AC 2011). Embryonic and tumour tissue are both able 
to intrinsically build their own blood supplies. In the case of tumours, this is termed 
tumour neovascularisation, and is made up of angiogenesis, vasculogenesis, 
intussusception and co-option (Figure 1.3). There may also be an element of chaotic 
tumour vessel-like formation that allows some blood flow and is otherwise known as 
‘mimicry’ (Sood AK et al 2002; Heidemann J et al 2006). This is where aggressive 
tumour cells, rather than endothelial cells, form a pattern of vasculogenic-like 
networks that are highly permeable and aid in further tumour neovascularisation 
(Dvorak HF et al 1995).  
1.2.3  Significance of angiogenesis to tumour growth 
 
Early investigations by Folkman et al into the importance of angiogenesis in tumour 
growth revealed that for a tumour to grow beyond a threshold size, neovascularization 
had to precede growth (Folkman J and Klagsbrun M 1987; Folkman J and Shing Y 
1992; Folkman J 2003).  
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Figure 1.3: Mechanisms of tumour vascularisation 
A) Classical angiogenesis – new blood vessels from existing bed 
B) Vasculogenesis by recruitment of CEPs, which differentiate to ECs and 
establish new microvessels. 
C) Vascular mimicry describes describes small perfused channels within 
clusters of tumour cells. The term vessel mosaicism refers to microvessels where the 
continuous endothelium is interspersed with tumour cells. 
D) Vascular co-option is whereby tumour cells surround supporting 
microvessels (I), causing EC apoptosis. Subsequent hypoxia leads to upregulation of 
angiogenic mediators by tumour cells, resulting in strong angiogenesis at the 
periphery of the tumour (III). 
 
 
 
 
 
 
Diagram modified from Heidemann et al 2006. 
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Experiments demonstrated that if angiogenesis is inhibited surrounding a developing 
tumour, the tumour will not exceed 1 to 2 mm3 in size; with a diameter which 
corresponds to the maximum distance oxygen can diffuse. Also, Folkman’s theories 
suggested that without angiogenesis, tumour cells were unlikely to be shed into the 
circulation and therefore the tumour remained dormant.  
 
Earlier studies on neoplastic transformation focussed on events that occur within 
transformed cells, but it has since been shown that the pathogenesis of most cancers 
includes complex and numerous tumour-microenvironmental interactions. The 
phenotypic switch to angiogenesis, as shown by Folkman and in later studies, is 
usually accomplished by a subset of tumour cells that induces new capillaries which 
then converge toward the tumour. These new vessels feed the tumour, and their 
endothelial cells produce a spectrum of growth factors that have a stimulatory effect 
on the tumour cells and also a variety of matrix-degrading proteinases that facilitate 
invasion (Nicosia R et al 1986).  
 
But what instigates this change from dormant, avascular tumour, to active, vascular 
tumour which has a metastatic capacity? Folkman and colleagues had already shown 
that tumours tend to cluster around capillaries, and that tumours situated far away 
from a potential blood supply, had a significantly lower mitotic rate (Folkman J 1986; 
Folkman J 1990). They also showed that the process of a tumour gaining a vascular 
network relied upon release of pro-angiogenic molecules from the actual tumour 
cells. These in turn activate certain genes in the surrounding normal host tissue, and 
hence proteins are produced which are necessary for the production of new tumour 
vasculature. In this way, neoplastic cells only form a clinically observable tumour if 
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the host produces a vascular network sufficient to sustain their growth. Furthermore, 
new blood vessels provide them with a gateway through which to enter the circulation 
and metastasise (Ribatti D et al 2007).  
 
Vascular quiescence in normal tissue is maintained by the dominant influence of 
endogenous angiogenesis inhibitors over angiogenic stimuli. In health, endothelial 
cell turnover time is measured in hundreds of days (Ortega N et al 1999). There are 
the occasional exceptions to this e.g. pregnancy and wound healing, where there are 
transient bursts of blood vessel growth and an increase in endothelial cell turnover to 
an average of 5 days.  
 
However, in tumour angiogenesis, there is an increased secretion of angiogenic 
factors and/or downregulation of inhibitors, leading to a tip of the balance (Figure 
1.4). This concept has since been termed the ‘angiogenic switch’, whereby a tumour 
leaves its avascular growth phase, and enters its vascular, exponential growth phase. 
The balance between these two phases is altered by increasing activator gene 
expression, changing the bioavailability or activity of the inducer pro-angiogenic 
proteins, or reducing the concentrations of endogenous inhibitors via changes in gene 
expression or processing (Bouck N et al 1996; Hanahan D and Folkman J 1996).  
These factors are not only produced from tumour cells, but also from the surrounding 
stroma and extra-cellular matrix also (Fukumura D et al 1998).  
When the concept of the angiogenic switch was first introduced, it was termed 
‘tumour angiogenesis factor’ (TAF). It was shown that by blocking its production or 
targeting its site of action, tumour neovascularisation could be inhibited. In turn, this  
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Figure 1.4: The Angiogenic Switch 
 
Endogenous factors regulate angiogenesis. The net balance of angiogenic and 
angiostatic factors controls the extent of angiogenesis. ELR + / - chemokines relates 
to the presence of a specific amino-acid sequence. ELR+ chemokines induce the 
migration of neutrophils and are therefore pro-angiogenic.  
 
 
 
 
 
 
 
 
 
Diagram modified from Heidmann et al 2006. 
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would prevent expansion or metastatic spread of a tumour, leaving it in a dormant and 
small state (1-2mm in diameter) (Folkman J 1990). In contrast to these theories, 
Sakariassen and colleagues showed that it was possible for invasion and angiogenesis 
to be completely uncoupled in stem-like tumours i.e. tumours with stem-like cancer 
cells that had no angiogenic potential but still had locomotion (Sakariassen P et al 
2006). 
  
The predominant stimulus switching on angiogenesis in tumours is thought to be 
tumour-associated hypoxic conditions. This occurs when tumour mass is critical. 
Hypoxia leads to activation of hypoxia inducible factor-1α (HIF-1α) which promotes 
the upregulation of several proangiogenic factors, most importantly vascular 
endothelial growth factor (VEGF), which will be discussed further in section 1.2 (Rak 
J et al 1995). Other positive regulators of angiogenesis include fibroblast growth 
factor-2 (FGF-2), IL-8, transforming growth factor beta (TGF-β), platelet-derived 
growth factor (PDGF) and others. These can be exported from tumour cells (Kandel J 
et al 1991), mobilised from the extra-cellular matrix (Vlodavsky I et al 1990) or 
released from host cells (e.g. macrophages) recruited to the tumour (Leibovich SJ et 
al 1987). At the same time, expression of endogenous inhibitors, such as 
thrombospondin-1 (TSP-1) or interferon beta may be down-regulated (Rastinejad F et 
al 1989; Dameron K et al 1994). Thus, the ‘angiogenic switch’ is a net balance of 
positive and negative regulators. It is subsequently followed by an angiogenic 
cascade, which leads to remodelling and formation of vascular channels. This process 
can be divided into an activation and a resolution phase. 
 
The question then poses itself, as to how and why a tumour develops the capacity to 
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turn on the angiogenic switch? It has long been accepted that the progression of a 
tumour reflects their genetic instability and a high mutation rate. Genetic control of 
the physiological levels of endogenous angiogenesis inhibitors may well be a line of 
defence against the conversion of dormant tumour cells to a malignant, pro-
angiogenic phenotype (Ribatti D et al 2007).  There is evidence to show that genetic 
instability must promote the ‘angiogenic switch’. Watnick and colleagues observed 
that the switch in a cell transformation model was dependent on oncogenic RAS 
expression. They showed that low expression levels of RAS induced cell 
transformation and increased VEGF (a known pro-angiogenic molecule) expression, 
along with repression of the anti-angiogenic factor TSP-1 through activation of 
another key gene, Myc. In this way, oncogene expression was shown to influence the 
balance and hence the ‘angiogenic switch’ (Watnick R et al  2003). 
 
This concept was also illustrated in another set of experiments carried out by 
Dameron and colleagues. They established a direct link between the p53 tumour-
suppressor gene, tumour angiogenesis and TSP-1. To examine the effect of p53, they 
cultured fibroblasts from patients with the Li-Fraumeni syndrome who have inherited 
one wild-type allele and one mutant allele of the p53 gene. When the wild-type allele 
was lost, these cells acquired potent angiogenic activity coincidental with the loss of 
TSP-1 production (Dameron K et al 1994).  
 
A much debated issue in this field of research is the contribution of bone-marrow-
derived endothelial progenitor cells (EPCs) to the process of angiogenesis. Bone 
marrow-derived stem cells may indeed be a source of EPCs which are then recruited 
for tumour neovascularisation.  In 1997, Asahara and colleagues reported the 
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isolation of putative EPCs from human peripheral blood, on the basis of cell-surface 
expression of CD34 and other endothelial cell markers. These cells were reported to 
differentiate in vitro into endothelial cells and seemed to be incorporated into active 
areas of angiogenesis in various animal models. Ischaemia, along with pro-angiogenic 
molecules such as VEGF, were reported to contribute to the mobilisation of the EPCs 
into sites of neovascularisation (Takahashi T et al 1999). These cells have 
subsequently been shown in further studies to ‘home-in’ and become incorporated 
into sites of vascular injury and ischaemia (e.g. a tumour microenvironment) (Lin Y 
et al  2000; Rafii S et al 2002). More recently, Peters and colleagues analysed the 
tumour endothelial cells in six individuals who developed cancers after bone-marrow 
transplantation with donor cells derived from individuals of the opposite sex and 
found that an average of only 4.9% of cells of the total endothelial cell population 
were derived from the transplanted bone-marrow (Peters B 2005).  
 
Aside from the bone-marrow source of endothelial cells, the endothelial cell layer of 
healthy tissue normally remains relatively quiescent, with an estimated turn over 
period of between 47 and 23,000 days, as shown by labelling studies (Hobson B and 
Denekamp J 1984). Elevated numbers of circulating endothelial cells have been 
described in patients with various cancer types, including melanoma, glioma, breast, 
colonic, gastric and testicular cancer (Mancusco P 2001; Beerepoot L et al 2004; 
Goon et al 2006). They appear in the circulation of such cancer patients, either as a 
result of being shed from localised damaged or activated tumour vessels, or via a 
more generalised systemic activation - derived from bone-marrow progenitor cells. A 
number of studies have been carried out to assess the relationship between blood 
levels of CECs and CEPs and tumour progression in human patients, showing some 
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interesting results. These will be discussed further in chapter 5. Along with this, the 
study of angiogenesis has been advanced by the ability to culture endothelial cells in 
vitro, initially using large vessel endothelial cells, such as those isolated from the 
human umbilical vein (HUVECs), and more recently using micro-vascular 
endothelial cells (MVECs). These in vitro models are discussed further in the 
following 3 chapters, and realising the limitations of in vitro work, can be used in pre-
clinical angiogenesis studies, do aid future work.  
 
1.2.4 Background to potential molecular targets and signalling systems 
 
 
It is clear that angiogenesis is a complex process which relies on numerous factors 
and steps in order to occur. This creates a vast expanse of potential molecular targets 
against which agents can be developed in order to inhibit or contribute to the 
inhibition of tumour angiogenesis.  A number of these have been discussed already. 
This section covers some of the finer details of this area, and how angiogenic 
pathways can be targeted.  
 
Pro-angiogenic factors are molecules or growth factors such as peptides and lipids, 
and they fall into two main categories. The first group acts directly on the tumour 
endothelium to promote mitosis, and the second acts indirectly by signalling cells to 
release endothelial growth factors. Angiogenic factors are found in all cells, whether 
involved in new vessel growth or not, and are part of a very intricate regulation 
system (Larcher F et al 1998).  As previously mentioned, the tip of the balance of the 
‘angiogenic switch’ towards angiogenesis is the result of genetic instability leading to 
tumour neovascularisation. This suggests that inhibition of pro-angiogenic molecules 
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is a potential therapy target. 
 
In the early 1980’s the first angiogenic factor was identified, namely basic fibroblast 
growth factor (bFGF) (Tallquist M et al 1999). Since then numerous angiogenic 
factors have been purified from extracts of tumour cells, cultured endothelial cells 
and wound fluid, including fibroblast growth factor (FGF-over-expressed in 
melanoma), vascular endothelial growth factor (VEGF), angiogenin, transforming 
growth factors (TGF-α and TGF-β), platelet derived growth factor (PDGF) and 
clotting cascade proteins such as tissue factor (Larcher F et al 1998). These act on 
various protein kinase receptors - for example vascular endothelial growth factor 
receptor (VEGFR) - which will be detailed in section 1.3. This leads to the 
stimulation of endothelial cell locomotion and proliferation via an intracellular 
signalling cascade and resultant activated proteins, all working toward angiogenesis. 
The protein kinases receptors are therefore also a potential target for anti-angiogenic 
therapy (Bergers G et al 2003). 
 
A protein kinase is a kinase enzyme that modifies other proteins by chemically 
adding phosphate groups to them (phosphorylation). This usually results in a 
functional change to the target protein (substrate) by changing enzyme activity, 
cellular location or association. Kinases are known to regulate the majority of cellular 
pathways, especially those involved in signal transduction i.e. the transmission of 
signals within the cell. Because kinases have profound effects on the cell, their 
activity is highly regulated. If this activity becomes dysregulated, it can frequently 
cause disease. The kinases in question are the receptor tyrosine-kinases e.g. VEGFR-
1, VEGFR-2, FGFR. These receptors are transmembrane proteins, with a tyrosine 
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kinase domain protruding into the cytoplasm. The extracellular domain serves as the 
ligand binding part of the molecule, the transmembrane part is a single α helix, and 
the intracellular domain is responsible for the kinase activity as well as regulatory 
functions. The active tyrosine kinase goes on to phosphorylate specific target 
proteins, which are often enzymes themselves. An important target is the Ras protein, 
a stepping stone to the mitogen activated protein (MAP) kinases signal-transduction 
chain, leading to down-stream gene-regulatory proteins (Lodish H et al 2000). See 
figure 1.5 for the VEGF pathway which includes down-stream proteins and shows 
sites of action of pertinent targeted therapies, including sorafenib – one of the anti-
angiogenic agents studied in this thesis.   
As previously mentioned, after the discovery of pro-angiogenic molecules and 
resultant pathways, specific angiogenic inhibitory molecules were also found. This 
group of endogenous structurally diverse proteins include thrombospondin-1 (TSP-1), 
interferon α/β, angiostatin, endostatin, antithrombin III, among many others. Many of 
the precursors of these proteins are components of the extracellular matrix or clotting 
pathways. Up-regulation of these inhibitory molecules therefore provides another 
potential target for anti-angiogenic therapy.  
 
VEGF was found to have a central role in angiogenesis. It is a glycoprotein and a 
potent pro-angiogenic factor which is highly specific for vascular endothelial cells. 
Endothelial cells express its complementary receptor and it has been identified as a 
major mediator in angiogenesis (Ferrara N and Henzel 1989). VEGF-A (an isoform) 
and its receptors are the best characterised signalling pathway in developmental 
angiogenesis, and loss of a single VEGF-A allele results in embryonic lethality 
(Yancopoulos G et al 2000; Ferrara N et al 2003). 
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 Figure 1.5: The VEGF pathway - including down-stream proteins and sites of 
action of targeted therapies, including sorafenib. 
 
 
 
Diagram adapted from Rini B 2005. 
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Apart from summoning endothelial cells, VEGF acts as an anti-apoptotic and an 
inductor of vascular fenestrations – hence its former name, vascular permeability 
factor. In order for it to fulfil its role of new vessel formation, space must be made in 
the extracellular matrix for the new vessels, which is achieved by matrix 
metalloproteinases (MMPs). Matrix degradation by MMPs also plays a major part in 
angiogenesis, and also tumour invasion and metastasis (Hiratsuka S 2002). VEGF 
isoforms along with MMPs are therefore potential targets for anti-angiogenesis 
therapy.  
 
There are many different isoforms of VEGF, including VEGF-A as previously 
mentioned. These correspond to different polypeptide sizes due to alternative splicing 
of the VEGF messenger RNA (Ferrara N et al 2003). Variants mediate their activities 
through the transmembrane receptor tyrosine kinase family members i.e. VEGFR-1,-2 
and -3. VEGFR-2 plays a major role in capillary permeability and angiogenesis, and 
the other two receptors are important in recruitment of endothelial precursor cells 
(VEGFR-1), and lymphatic differentiation (VEGFR-3) (Matsumoto T and Claesson-
Welsh L 2001; Hattori K et al 2002; Karkkainen MJ et al 2002). Tumour cells have 
been shown to over-produce VEGF-A, and inhibition of this can lead to suppression 
of tumour growth (Ferrara N 2001).  Renal cell carcinomas in particular have been 
shown to express particularly high levels of VEGF-A, providing an explanation for 
their responsiveness to VEGF-A blockade (Yang J et al 2003).  
VEGF-A stimulates angiogenesis via VEGFR-1 and -2. The intracellular reactions 
which allow these receptors to fulfil their roles are both complex and varied. As 
previously mentioned, the MAP kinase pathway is a prominent signalling pathway, 
and is induced by VEGF (see figure 1.5). Activation of MAP kinase pathway by 
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VEGF regulates vascular development through the induction of mitogens (chemicals 
which trigger cell division), inactivation of apoptosis and induction of chemotaxis 
(Dvorak HF et al  1995). It has been found that deletion of genes involved in the 
regulation or relay of this signalling pathway leads to defective vasculature 
development during embryogenesis and also tumour angiogenesis (Kranenburg O et 
al  2004). See Figure 1.6 for a summary diagram showing some of the various 
strategies to inhibit VEGF signalling. Other isoforms of VEGF, namely VEGF-C and 
–D, bind and activate their receptor VEGFR-3, and were the first molecules shown to 
promote lymphangiogenesis. Expression of VEGF-C and –D has been shown to be 
upregulated in only certain cancers, correlating with increased lymphatic invasion and 
metastasis (He Y et al 2004; Scavelli C et al 2004). In a pre-clinical model, mice 
heterozygous for VEGF-C were shown to develop lymphodema and chylous fluid in 
the abdomen, suggesting insufficient lymphatic vessels formation. VEGF-C null mice 
were non-viable (Karkkainen M et al 2004).  
 
Another key factor which has been previously mentioned and is co-expressed with the 
VEGF family in several cancers is hypoxia inducible factor-1 (HIF-1). As tumours 
grow, some tumour cells, especially central ones within a mass, become hypoxic. The 
hypoxic signal is crucial to summon a new blood supply. This release of HIF-1 leads 
to erythropoietin secretion and further angiogenesis stimulation through upregulating 
several of the proangiogenic factors, including VEGF and basic fibroblast growth 
factor (bFGF) (Rak J et al 1995; Harris A 2002; Semenza G 2002).  The degradation 
of HIF-1 is also dependent on the activation of p53 (a tumour suppressor gene). In 
some tumours e.g. colorectal and pancreatic, expression of HIF-1 has correlated well 
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        Figure 1.6: Various strategies to inhibit VEGF signalling 
 
Strategies to inhibit VEGF a)monoclonal antibodies targeting VEGF-A  
                                           b)+c)monoclonal antibodies targeting VEGFR-1 / 2 
                                           d)chimaeric soluble receptors such as the ‘VEGF-trap’ 
                                           e)extracellular inhibitors are aptamers that bind the 
heparin-binding domain of VEGF165 (pegaptanib). 
Other small molecule VEGF RTK inhibitors that inhibit ligand-dependent receptor 
autophosphorylation of VEGFR-1 and VEGFR-2 are being tested. 
 
 
 
 
 
Diagram adapted from Ferrara and Kerbel 2005. 
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with markers of angiogenesis and prognosis, and degradation of HIF-1 may well be a 
critical step in the conversion of a dormant tumour to an active one (Safran M and 
Kaelin W 2003). It is therefore another potentially useful target molecule for drug 
development (Patiar S and Harris A 2006). 
 
Other signalling molecules that have an established role in the development and 
differentiation of the vessel wall include platelet-derived growth factor (PDGF-β) and 
the angiopoietins, which may also be potential therapeutic targets (Yancopoulos G et 
al 2000). PDGF acts on an important receptor group, and functions to regulate 
smooth muscle cell development. A mutation in one of these receptors e.g. PDFGRβ, 
leads to inadequate microvasculature, with subsequent haemorrhages and oedema 
(Tallquist M et al 1999; Yu J et al  2003). Under normal circumstances these 
receptors, and their corresponding ligands i.e. PDGF isoforms, promote the 
development and maintenance of vasculature, and are mainly expressed on pericytes. 
PDGF-β isoform is required for recruitment of pericytes and maturation of the 
microvasculature (Lindhal P et al 1997). The combination of PDGF and VEGF 
inhibitors (Sunitinib, Sorafenib, Imatinib) have therefore been proposed as another 
potentially attractive anti-vascular strategy (Dong J et al 2004). These agents have 
however been linked to increased invasive and metastatic capacity of certain tumours 
(Ebos et al 2009, Paez-Ribes et al 2009).   
 
Angiopoietins are ligands (binding molecules) for other important protein kinase 
receptors namely Tie1 and Tie2, which are similar to VEGFR, and are specific to 
vascular endothelial cells. Mice lacking Tie1 or Tie2 die due to loss of 
microvasculature and a reduction in vascular integrity respectively (Dumont D et al 
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1994; Patan S 1998). Both these receptors and their ligands are therefore crucial in 
endothelial cell assembly, cell-to-cell interaction, endothelial cell survival and 
extracellular matrix interaction. Inhibition of these angiopoietins and their receptors is 
therefore another potential anti-angiogenic strategy. 
 
More recently, the role of axon-guidance receptors and ligands has gained much 
attention in this field. There are four main families of these, but those of particular 
interest include another group of receptor tyrosine kinases are known as the Eph 
receptors and their ligands, ephrins (Pasquale E 2005). These have been shown to 
have an important role in morphogenesis and capillary sprouting. They interact to 
control cell localisation and enhance vascular development by activating specific 
molecules (Patan S 2004). The Eph family have also been shown to have major 
‘locomotion’ inducing properties. Interfering with signalling of one of these ligands, 
namely EphA, has been reported to result in some inhibition of angiogenesis in 
tumour models (Dobrzanski P et al 2004; Astin et al 2010).  Figure 1.7 shows some 
of the above mentioned specific targets in antiangiogenic therapy compared with 
traditional chemotherapy. 
 
These molecular cascades, some of which have been described above, eventually lead 
to new capillary formation. This occurs via complex and numerous factor-receptor 
interactions.  Overall, this complex process of angiogenesis requires (as shown in 
figure 1.8): 
1.Degradation of the basement membrane (of the parent venule) and extracellular 
matrix around the vessels – induced by MMPs and other proteases. 
2.Endothelial cell migration (chemotaxis) toward the angiogenic stimulus – induced 
 45
by VEGF-A, bFGF, angiopoietins, IL-8, VEGF-C, and other proangiogenic 
molecules acting on their paired receptors. 
3.Proliferation and alignment of endothelial cells with each other to form a solid 
sprout – induced by PDGF isoforms acting on their paired receptors, along with 
other proangiogenic pathways. 
4.Remodelling of basement membrane as vascular tubing reforms and a lumen is seen 
– induced by angiopoietins acting at their various tyrosine kinase receptors, along 
with other proangiogenic pathways. 
 
Almost every component of the haemostatic system including platelets, endothelial 
system, coagulation cascade (tissue factor) and fibrinolytic system, also contribute to 
this process (Auguste P et al 2005).  
 
Discovering many of the intricacies of angiogenesis has led to a whole new world of 
potential therapeutic targets, in both malignancy and various disease processes 
(Matsuzaki S et al 1998; Ribatti D 2010). Multi-targeted, patient-friendly regimens, 
aimed at the molecular make-up of a particular tumour and its vasculature are being 
introduced into the clinical setting, and hold promise of a shift away from 
conventional cytotoxic regimens. This is a major concept shift in cancer treatment as 
we move closer toward understanding tumours at a molecular level and understanding 
processes that may produce ‘controlled disease states’ with the patient surviving with 
their cancer for ever lengthening periods of time.  
 
 
 
 46
Figure 1.7: Targets in antiangiogenic therapy versus traditional chemotherapy 
 
The multitude of potential antiangiogenic specific cellular targets allows for more 
diverse mechanisms of action. 
 
 
 
 
 
Diagram modified from Kerbel 2001. 
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Figure 1.8: Summary of stages in angiogenesis. 
 
Diagram to show degradation of the basement membrane and extracellular matrix 
around the vessels, followed by endothelial cell migration toward the angiogenic 
stimulus.  Proliferation and alignment of endothelial cells then occurs to form a solid 
sprout.  This is followed by remodelling of the basement membrane as vascular 
tubing reforms and a lumen is seen. 
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1.2.5 Inhibition of angiogenesis as anti-cancer therapy 
 
The role of anti-angiogenic therapy in cancer treatment is based on a number of 
theories:- 
? It is less toxic and more specific in its target 
? There is no need for regular breaks in treatment to allow healthy tissues to recover 
as it is specifically targeted to tumour endothelium with minimal adverse effects 
elsewhere in the body compared to convetional chemotherapy. 
? It can be used to reduce the repopulation of cancer cells during the intervals 
between traditional chemotherapy / radiotherapy. 
? It may avoid cumulative toxicities of traditional cytotoxic regimens and enables the 
possibility of adding agents into a regimen, hence avoiding overlapping toxicities. 
Inducing apoptosis in endothelial cells with stable machinery i.e. a stable cellular 
configuration, is easier than inducing apoptosis in cancer cells with unstable 
machinery. This is also a way of avoiding the development of resistance.  
 
Many angiogenesis inhibitors are currently in clinical trials and over ten have now 
been FDA approved (Ribatti D 2010). Alongside the development of such agents, 
there is also a new class of agents known as ‘vascular-disrupting’ drugs e.g. that can 
cause acute vascular occlusion and disruption of tumour blood flow (Siemann D et al 
2004). Numerous specific anti-angiogenic molecules have been created by 
biotechnology and pharmaceutical companies. Table 1.1 summaries their phase of 
clinical development and principal molecular targets. 
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Table 1.1: Summary of principal molecular targets of novel anti-cancer and anti-
angiogenic agents – their phase of clinical development, with indications 
approved (if any) (adapted from Tourneau C at al 2008) 
Key: ALL – acute lymphoblastic leukaemia; CML – chronic myeloid 
leukaemia; GIST – gastrointestinal stromal tumour; RCC – renal cell 
carcinoma. * AEE788 also inhibits HER2. 
 
Drug                    Company Phase of 
clinical 
develop 
-ment 
Indications 
approved Principal molecular targets 
Imatinib Novartis III ALL,CML,
GIST 
PDGFR, KIT, BCR-ACL 
Avastin Genentech III mCRC,  
NSCLC, 
breast 
VEGF 
Sunitinib Pfizer III GIST,RCC VEGFR, PDGFR, KIT, FLT3, 
 RET 
Sorafenib 
 
Bayer III RCC VEGFR, PDGFR, KIT,RET, 
 RAF 
Dasatinib Bristol-Myers  
Squibb 
III-CML 
I -solid 
ALL,CML PDGFR, KIT 
Vatalanib 
 
Novartis/Bayer III  VEGFR, PDGFR, KIT 
ZD6474 
 
AstraZeneca II  VEGFR, EGFR, RET 
Axitinib 
 
Pfizer II  VEGFR, PDGFR, KIT 
GW786034 
 
GlaxoSmithKline II  VEGFR, PDGFR, KIT 
AZD2171 
 
AstraZeneca II  VEGFR, PDGFR, KIT 
AEE788 
 
Novartis I  VEGFR, EGFR 
BIBF1120 
 
Boehringer I  VEGFR, PDGFR, FGFR, SRC 
BMS582664 
 
Bristol-Myers I  VEGFR, FGFR 
AMG706 
 
Amger I  VEGFR, PDGFR, KIT, RET 
CHIR258 Novartis 
 
I  VEGFR, PDGFR, KIT,FGFR, 
 FLT3 
BAY 57-9352 Bayer I  VEGFR, PDGFR, KIT 
XL999 Exelixis I  VEGFR, PDGFR, KIT,FGFR, 
 FLT3, SRC 
XL820 Exelixis I  VEGFR, PDGFR, KIT 
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These molecules are produced by: 
? The identification of a target molecule and development of an antibody to (e.g. anti-
VEGF antibody) or a synthetic inhibitor of receptors (e.g anti-VEGF-A monoclonal 
antibody – bevacizumab, and tyrosine kinase inhibitor – sorafenib (Ferrara N et al 
2004; Wilhelm S et al 2004). 
? The discovery of anti-angiogenic properties of an already existing drug (like 
thalidomide and paclitaxel (Browder T et al 1995) – discussed further in section 1.3. 
? The discovery of a specific endogenous anti-angiogenic molecule (like endostatin-
fragment of collagen XVIII - a specific endothelial inhibitor) (Heljasvaara R et al 
2005).  
 
Figure 1.7, as previously mentioned, shows the diversity of targets in conventional 
chemotherapy and antiangiogenic therapy of human tumours. The multitude of 
potential anti-angiogenic cellular targets permits more diverse mechanisms of action 
compared with conventional chemotherapy (Kerbel R and Folkman J 2002).  
 
The unique structural features of tumour vasculature mean that, in general, tumour 
angiogenesis can and should be targeted, and promising results of clinical trials have 
supported this. FDA approval or NCCN recommendations have already been made 
for  some specific antiangiogenics to be used in conjunction with existing regimens as 
first line treatments, e.g. bevacizumab in conjunction with IFN in renal cell 
carcinoma  (Rini B et al 2004; Escudier B et al 2008) or as single agents (Yang et al 
2003). Interestingly, the results of angiogenesis research have also led to the use of 
anti-angiogenics in diseases characterised by over-exuberant angiogenesis such as 
neovascular and exudative ocular diseases. The results of clinical trials have now led 
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to FDA approval and the incorporation of ranibizumab-derived from bevacizumab- 
into the NICE guidelines for treatment of wet age-related macular degeneration 
(Rosenfold P et al 2006) .Successes in treating such diseases are helping to push 
forward the boundaries in the area of cancer, which is so crucially needed. Table 1.1  
gives a summary of the principal molecular targets of the targeted anticancer agents, 
with their approved indication (Tourneau C et al 2008). 
 
Despite the initial presumption that endothelial cells would remain relatively stable to 
such treatments, acquired resistance has been associated with anti-angiogenic 
therapies. There has been emerging evidence that, in the case of VEGF-A inhibition, 
other angiogenic pathways will eventually override as the disease progresses. Other 
possible mechanisms for acquired resistance include selection and overgrowth of 
tumour cell variants that are ‘hypoxic resistant’ and are thus less angiogenesis-
dependent (Kerbel R 2001; Sweeney C et al 2003). Other studies have suggested that, 
in some cases, endothelial cells associated with tumours are not genetically stable, 
and have demonstrated cytogenetical abnormalities (Hida K 2004; Bergers G and 
Hanahan D 2008).  
Consideration of all these factors needs to be taken into account in devising 
successful and multi-targeted cancer treatment strategies for the future. 
 
1.3 Metronomic Chemotherapy 
 
1.3.1 Basic concepts 
 
Metronomic chemotherapy is one area of active research into novel cancer treatment 
concepts. It has received much attention in the medical literature over recent years. 
As efforts continue to develop more targeted and user-friendly cancer regimens, there 
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is increasing pre-clinical evidence to support the notion that ‘metronomic’ type of 
dose scheduling of conventional chemotherapy agents may become a clinically 
important modification.  
 
Metronomic is derived from the Greek words ‘metron’ – to measure and ‘nomos’ – to 
rule or divide. The English translation is ‘of or relating to a metronome’, also 
meaning unvaryingly regular in rhythm. The term metronomic in this context is given 
to continuous i.e. daily low-dose regimens of chemotherapy. It has similarly been 
associated with rhythmic musicians and their music, and ticking clocks. It is therefore 
seemingly obvious why the term metronomic was originally given to this type of 
treatment regimen.  
 
However, ‘metronomic’ simply explains the way in which these regimens are 
administered. It does not reflect the molecular or clinical justifications for these 
regimens, and may indeed be a confusing misnomer. This section highlights the 
potentially confusing terminology, discusses the justification for specific and targeted 
chemotherapy regimens, and summarises the new advances in ‘metronomics’. 
Conventional chemotherapy was intended to kill or inhibit as many cancer cells as 
possible. As previously explained, the design of new drugs had traditionally been 
focussed on the destruction of cancer cell DNA and utilising cancer cell proliferation 
to take effect (Skipper HE et al 1970). The maximum-tolerated dose approach 
therefore came in to widespread use and the design of most chemotherapy regimens 
has relied on this model ever since.  
 
Around the same period, as previously mentioned in section 1.2.2, Folkman described 
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a new target for cancer therapy by introducing the concept of angiogenesis. The 
evidence suggested that tumour growth was dependent on the development of a blood 
supply by the process of angiogenesis (Folkman J 1971). The vascular endothelial 
cells, their surrounding stroma and associated factors, were therefore recognised as a 
potential target for anti-tumour therapies.  
  
In 2000, Eberhard et al and Klement et al independently showed the presence of 
dividing endothelial cells in newly forming tumour blood vessels. It was anticipated 
that these endothelial cells – being genetically stable - would remain sensitive to 
chemotherapy, regardless of tumour cell resistance (Eberhard et al 2000; Klement G 
et al 2000). This added further weight to the development of anti-angiogenic therapy. 
Postulating this type of anti-cancer mechanism also gave theoretical justification to 
the concept that drug doses, well below the original cytotoxic ranges of bolus MTD 
approaches, could either become or be incorporated into anti-cancer regimens. This 
change in actual chemotherapy administration was found to reduce adverse effects 
significantly, with resultant improved benefit to toxicity profiles in preclinical models 
and favourable effects on patients’ quality of life in early clinical studies (Browder T 
et al  2000; Shaked Y 2005). 
The term ‘metronomic’ in relation to chemotherapy, was first described by Hanahan 
and colleagues in 1996 (Hanahan D and Folkman J 1996). This study looked at the 
effects of using continuous low-dose (10-33% of maximum tolerated dose –MTD) 
cytotoxic agents, without any extended rest periods. It showed that total dose 
achieved could be higher than MTD by using this style of drug administration. 
Gasparini showed similar results, again using 10-33% of MTD (Gasparini et al 2001).  
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Work carried out by Browder et al in 2000, showed that continuous low-dose 
cytotoxic agents could inhibit tumour angiogenesis (Browder T et al 2000). This was 
seen in mice bearing different solid tumours. It was also around this time that the term 
metronomic became synonymous with anti-angiogenic, or anti-endothelial. In the 
same year as Browder’s work, Klement showed that cyclophosphamide and 
vinblastine could be exploited for their antiangiogenic effects when given as 
continuous low-dose regimens in vivo, with promising results (Klement G et al 
2000). Kerbel then went on to show that a variety of single chemotherapeutic agents 
when given in low doses, had the common ability of inhibiting angiogenesis, but also 
inhibited tumour growth  (Kerbel R 2000). Since then, a number of in vitro studies  
(see table 1.2) have shown more promising data on the selective responsiveness of 
endothelial cells towards metronomic schedules (Bocci G 2002; Grant DS 2003). This 
added further weight to the move towards metronomics, although proof of efficacy in 
the clinical setting was yet to be seen. See Table 1.2 for a summary of in vitro studies 
showing selective responsiveness of endothelial cells to metronomic chemotherapy. 
 
Studies listed in Table 1.2 reported no evidence of cytotoxicity on endothelial cells, 
although their proliferation was inhibited. Bocci et al did however report apoptosis in 
cells treated for over 6 days, which may be explained by an indirect mechanism of an 
imbalance between inhibiting and proangiogenic molecules (Bocci G et al 2002; 
Kerbel RS and Kamen 2004). One of the potential mediators of the anti-angiogenic 
properties of metronomic chemotherapy is thrombospondin 1 (TSP1) – a well known 
endogenous angiogenic inhibitor (Lawler J 2002). TSP1 was shown to increase 
dramatically following continuous dosing with cyclophoshamide in in vitro vascular 
endothelial  
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Table 1.2: Summary of in vitro studies of endothelial cells -responsiveness to 
metronomically dosed chemotherapy. 
 
Key:IC50=concentration of drug required to inhibit 50% of cell growth 
 
 
 
      Drug regime & 
         Reference 
Assay Reported response 
1.Methotrexate 
 (Hirata S 1989) 
Inhibition of proliferation EC inhibited by low concs 
(5nM) 
2. Paclitaxel  
(Belotti D 1996) 
Inhibition of proliferation, 
motility 
 and cord formation 
Inhibition of EC proliferation 
(IC50=0.5-4nM) and 
chemotaxis & invasiveness 
(10pM) 
3. Vinblastine  
(Vacca A 1999) 
Inhibition of 
proliferation,migration 
and MMP secretion 
ECs inhibited by ultra-low 
concs (0.1-1pM), leucs, 
fibroblasts and tumour cells 
not inhibited 
4. Paclitaxel & Vinblastine 
 (separately)  
(Klement G 2002) 
Inhibition of proliferation HUVEC proliferation 
inhibited (IC50=0.4-0.5nM for 
both drugs); tumour cells 
inhibited by IC50=2-27nM in 
monolayer culture & 3.4-
10.1µM in spheroid culture 
5. Paclitaxel, 
Cyclophosphamide 
& Epothilone B  
(separately) 
(Bocci G 2002) 
Inhibition of proliferation 
and induction of apoptosis 
Daily exposure of individual 
drug over 6 days inhibited EC 
proliferation (IC50=50-
100pM); IC50 values for 
tumour cells and fibroblasts 
at least 10x more than for 
EC; induction of apoptosis 
only detected in EC 
6. Paclitaxel  
(Wang J 2003) 
Inhibition of proliferation  
and tube formation 
EC selectively inhibited over 
3 days at extremely low drug 
concentrations (0.1-100pM; 
IC50=0.1pM); 6 different 
non-EC types inhibited at 
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104-105fold higher 
concentrations (IC50=1-
10nM); EC tube formation 
also inhibited in vitro. 
7. Paclitaxel & Docetaxel   
(separately) 
(Grant DS 2003) 
Inhibition of 
proliferation,migration 
and capillary sprouting 
EC found to be 10-100x 
more sensitive than tumour 
cells; docetaxel 10x more 
effective than paclitaxel. 
8. Temozolomide  
(Kurzen H 2003) 
Inhibition of proliferation, 
adhesion 
and tube formation 
HUVEC proliferation on 
Matrigel inhibited (5mM), 
proliferation and adhesion 
inhibited x5 higher concs. 
9. Adriamycin, Idarubicin, 
FU, Paclitaxel, Etoposide 
(separately) 
(Drevs J 2004) 
Inhibition of proliferation HUVEC proliferation 
inhibited at 4.02M 
10. Temozolomide, 
Estramustine, 
Paclitaxel, Compound 5h  
(Lam T 2007) 
Inhibition of proliferation  
and apoptosis 
Estramustine and 
temozolomide inhibited 
HUVECs with IC50 of 4.5µM 
and 6.6µM respectively, 
enhanced by antiangiogenic  
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cells (Hamano et al Y 2004). Hamano’s group also compared TSP1 deficient mice 
with normal mice, both bearing melanoma. They found that a metronomic schedule of 
cyclophosphamide caused melanoma regression in the normal, but not in the TSP1 
deficient mice. Similar results were seen by Bocci and colleagues when comparing 
TSP1 deficient to normal mice, both bearing Lewis lung carcinomas and treated with 
metronomic dosing of cyclophosphamide (Bocci G et al 2003). 
 
1.3.2 Therapeutic implications  
 
The current thinking is that by utilising the anti-angiogenic action of 
chemotherapeutics in combination with specific molecularly targeted drugs, tumours 
can become a chronic, stable disease process, whereby tumour load is kept to the 
lowest possible level (Hahnfeldt P et al 2003). Traditional regimens have very rarely 
led to tumour regression or eradication in solid adult malignancies. This is why the 
anti-angiogenic approach leading to, if not remission, at least stable disease is looking 
more and more appealing. It has long been known that survival need not be 
incompatible with the presence of tumour, as long as its growth is kept under control. 
This was shown in work by Takahashi emphasising that cytostatic as opposed to 
cytotoxic regimens made the most impact on patient survival (Takahashi Y and 
Nishioka K 1995; Takahashi Y et al 2000). 
 
However, the traditional method of giving conventional cytotoxic agents in several 
intense cycles remains the mainstay of treatment for adult solid malignancies. There 
are legitimate concerns that the methods we currently use to achieve the conventional 
cytotoxic effects of chemotherapy more often than not have detrimental effects on the 
patient and also on the tumour. The long rest periods given between these traditional 
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cycles to allow recovery of susceptible organs e.g. gastrointestinal tract and bone 
marrow, have since been found to actually encourage tumour angiogenesis and 
therefore tumour growth (Hannahan D et al 2000). Not only this, but such non-
specific cytotoxic regimens often lead to severe adverse effects and greatly impair 
quality of life. There is also evidence that the prothrombotic status that chemotherapy 
agents induce results in an acute phase reactant profile that may not only have pro-
thrombotic but also pro-angiogenic effects (Hembrough T et al 2003).   
 
Since the publication of the results of a clinical trial of metronomic 
cyclophosphamide and methotrexate for the treatment of advanced breast cancer by 
Colleoni et al 10 years ago (Colleoni M et al 2001), numerous studies evaluating 
variations of this approach in breast cancer (Bottini A et al 2006; Colleoni M et al 
2006), prostate (Glode L et al 2003) and ovarian cancer (Garcia A et al 2008) among 
other tumour types, have been reported (Kerbel RS and Kamen 2004; Gille J et al 
2005). All these studies confirm the excellent safety profile of metronomic 
chemotherapy, and results have generally warranted further clinical evaluation. With 
the proviso that these results are not all from phase III randomised trials yet, there are 
nevertheless promising tumour suppressive effects that have been reported, 
particularly in renal cell carcinoma, breast and lung cancer (Klement G et al 2000; 
Takahashi Y et al 2000; Kurzen H et al 2003; Burstein H et al 2005). 
   
Randomised phase III trials however are necessary for this concept to gain 
widespread acceptance. There is however, a potential limitation in the developmental 
design of these early clinical trials. They have been carried out with a stated 
metronomic intent, but no obvious predating developmental work was done to define 
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the dosing schedule used to determine the clinical metronomic dose. As previously 
stated, most of the commonly used anti-cancer chemotherapeutic agents have now 
been shown to be capable of inhibiting angiogenesis (mainly in vitro) when given in 
‘metronomic’ dosing schedules (Miller KD et al 2001; Kerbel R and Folkman J 
2002). Research ambiguity exists in this field since it is first necessary to define what 
dose or what dose-range is actually ‘metronomic’, be it in the clinical or pre-clinical 
setting. Many of the supposedly ‘metronomic’ trials have simply used an empirically 
derived extended dosing schedule with predominantly cytotoxic effects. Miller laid 
down some criteria in that any chemotherapeutic agent which required a higher dose 
to inhibit or kill endothelial cells than that required for tumour cells would not be 
classed as anti-angiogenic (Miller KD et al 2001). This however, is also ambiguous 
as many agents do not have extensive phase I data to define a distinguishable 
‘cytotoxic’ extended dosing schedule and therefore give the opportunity to distinguish 
this from a metronomic schedule.  
 
A different approach to these areas of ambiguity, at least in the clinical sense, has 
been proposed by Maraveyas et al (Maraveyas A et al 2005). The theory proposed, 
based on in vitro endothelial cell studies, is that there is a dose-response effect on the 
endothelium, even in the sub-clinical dose range. It is therefore not always 
appropriate to use an arbitrary 10-33% of the conventional dose. Also, given that 
bone marrow suppression is a proangiogenic stimulus, the clinical metronomic dose 
should be the maximum dose that can be delivered in a metronomic schedule without 
detectable bone marrow perturbation or induction of other proangiogenic stimuli such 
as activation of the coagulation pathway. This would potentially allow for a more 
principled approach to the delivery of metronomic chemotherapy, and is the 
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underlying theory behind both the in vitro and clinical studies of this thesis. The 
clinical study written up in this thesis shows, for the first time ever, the splitting of a 
conventional level schedule to a metronomic schedule based on dose-response 
(Maraveyas A et al 2005; Lam T et al 2006) 
 
1.3.3 Rationale behind combining metronomically-dosed traditional 
chemotherapy with specific angiogenesis inhibitors 
 
It has become increasingly likely that cancer therapy, with a few exceptions, will 
need to be combinatorial. It seems logical to target multiple pathways simultaneously. 
Combination regimens have been traditionally based on the avoidance of toxicities 
common to different agents and also on modest cancer-specific affects seen in the 
early stages of a drug’s development. While the number of agents available in the 
early days of cancer treatment was slow to increase, this empirical approach remained 
unchallenged.  
 
However, the last decade has seen the emergence of multiple novel agents with 
potential anti-cancer effects. Only a small proportion of these have been developed as 
chemotherapy in the conventional sense, while the majority have been developed as 
oral agents that are molecularly-targeted.  With the rate of novel agent development, 
the number of potential double and even triple combinations will become so large that 
not all the mice in the world, let alone humans would allow for potential study of 
possible regimens. 
 
One of the most prolific areas within agent development and testing has been that of 
angiogenesis inhibitors as previously described in section 1.2.5 (Ferrara N and Kerbel 
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2005). Furthermore, many conventional ‘older’ agents are now having anti-
angiogenic properties attributed to them e.g. taxanes (Belotti D et al 1996) using the 
metronomic approach. Combinational anti-angiogenic protocols have been used in 
vitro and in vivo studies, and have been shown to be more effective than single agent 
regimens (Retter A et al 2003; Longoria R et al 2005). The mechanisms of these 
synergistic or addititive anti-tumour effects seen in such combination regimens are 
not clear, in that it would seem counterintuitive that ‘tumour-starving’ anti-
angiogenic drugs that suppress blood flow in tumours actually increase the efficacy of 
chemotherapy (Ferrara N and Kerbel 2005).   
 
However, the realisation that single agent anti-angiogenic  treatments are unlikely to 
have the sustained therapeutic impact wished for anti-cancer treatment in many solid 
malignancies has meant that combinations regimens are now considered to be the way 
forward (Retter A et al 2003).What is not clear is whether in this setting, 
combinations have necessarily got to include chemotherapy conventionally dosed or 
in a low-dose metronomic fashion. Metronomic dosing is suitable for combinations of 
traditional cytotoxic drugs, especially those that are now being made available in oral 
form e.g. paclitaxel, as they can be administered easily with these newer molecularly-
targeted anti-angiogenic agents, the majority of which are available as orally 
administered agents. The paradigm from HIV and the multiplicity of the oral agents 
taken daily is obvious. Succesful combinations could become composite formulations 
in the future. Both pre-clinical and clinical evidence suggests that the anti-angiogenic 
effect of metronomic chemotherapy can be enhanced by the administration of various 
specific and molecularly-targeted agents (Kamen B et al 2000; Burstein H et al 2005; 
Longoria R et al 2005; Buckstein R et al 2006; Orlando L et al 2006; Lam T et al 
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2007). It is through these studies that the field of multi-targeted cancer therapy 
continues to grow.  
 
As ±previously mentioned, the vast proliferation of available anti-angiogenic agents, 
leads us to conclude that the combinatorial permutations far outstrip our capacity to 
study these through conventional clinical trial (Dark G et al 1997; Clark J et al 2005; 
Ribatti D 2010). There is therefore a growing need for the development of predictive 
tools to allow selection of the most promising combinations suitable for further 
clinical development. It is also essential to identify suitable cytotoxic agents for the 
metronomic approach and for each agent, to establish the optimal dose at which 
angiogenesis inhibition occurs (Parulekar WR and Eisenhauer E 2004; Maraveyas A 
et al 2005). Along with this, to determine drug resistance status in metronomic 
regimens and develop surrogate markers used to measure treatment success e.g. 
circulating endothelial cells as discussed in chapter 5 (Gasparini et al 2001; Bhatt R et 
al 2007). 
 
Many studies to date of the metronomic approach have been based on animal models, 
and these studies claim to allow for the detection of pharmacokinetic and 
pharmacodynamic properties, making one combination more promising than another. 
There are also advantages of animal models when it comes to studying potential 
effects of sequential rather than concurrent administration of agents.  However, with 
the vast number of currently available agents - many for whom mechanism of action 
is poorly understood - there remains a problematic dimension in initiating animal 
studies when in vitro work clearly demonstrates no potential synergy in combinatorial 
studies. Infact, in some cases antagonistic effects of potential combinations have been 
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shown on target cells (Budman DR et al 2002; Lam T et al 2007).  It is for these 
reasons that the use of endothelial cell models can provide a useful stepping stone to 
the clinic, and provide relevant data on potentially synergistic combinations in this 
potentially confusing era of multi-targeted therapy.  
 
1.3.4 Proof of concept of metronomic dosing and combination regimens  
 
Proof of concept of any type of therapy schedule, in this case ‘metronomic dosing’, 
requires the development of appropriate intermediate surrogate markers, which can be 
monitored before and after therapy. Since the avoidance of bone marrow perturbation 
is essential in the delivery of metronomic chemotherapy, bone marrow stem cells can 
be measured to show response to treatment. Development of cheap and reproducible 
assays for these potential surrogate markers, along with others are therefore crucial if 
this treatment strategy is to be successful (Bertolini F et al 2006). 
 
 Another important consideration is that the concept of longest possible drug exposure 
requires careful assessment of the drugs involved, their pharmacokinetics (Kamen B 
et al 2000) and the cumulative or separate effects of metabolites. The aim is to 
minimise resistance and prevent regrowth of tumour cells between administrations 
(Norton L 1997; Kim JJ and Tannock I 2005; Shaked Y et al 2006). Early clinical 
results are varied, depending on the drug used and the tumour type. Drugs which have 
been relatively extensively studied in the metronomic approach to date include 
alkylating agents e.g.  cyclophosphamide, taxanes, anthracyclines and vinca alkaloids 
(Johnson DH and Carbone D 1997; Seidman AD et al 1998; Miller K et al 2001; 
Colleoni et al 2002). However, the ability of metronomic chemotherapy to block 
angiogenesis in terms of effective prolongation of patient survival remains to be 
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proven in randomised phase III trial settings.  
 
Pre-clinical scientific evidence is necessary to provide rationale behind the selection 
of combination regimens. For example, synergism when angiogenesis inhibitors are 
combined with cytotoxic agents given in a metronomic regimen has been seen in 
early pre-clinical work (Gasparini G et al 1994; Kakeji Y and Teicher B 1997).  The 
synergistic effects in these studies were thought to be via the parenchymal and 
stromal targets of the cancer. Results of further studies by Browder and Klement 
show that the combination of selective angiogenesis inhibitors with metronomic 
scheduling of chemotherapy can improve the effects of these agents on intratumoral 
vasculature, enhancing therapeutic benefit. Klement and colleagues combined 
continuous low dose vinblastine with a monoclonal antibody that neutralised VEGF-2 
receptor (Klement G et al 2000; Klement G et al 2002). Similarly, Lam et al showed 
synergistic activity between estramustine and temozolomide when combined with 
anti-VEGFR-2 antibody, leading to inhibition of human umbilical venous endothelial 
cells (Lam T et al 2007). This pre-clinical work is crucial to the logical and rational 
development of combination regimens. 
 
The aim of this relatively new therapeutic strategy, whereby metronomic schedules of 
chemotherapy are combined with molecularly-targeted compounds, is to achieve a 
long-term dormant state in residual tumour focus, and minimise treatment side-effects 
(O'Reilly MS et al 1996).  In the end, clinical trials are going to have to demonstrate a 
significant improvement in hard endpoints, such as overall survival or progression 
free survival. Simply reducing toxicity and making the patient feel better, but also 
abrogating efficacy, is not an option.  
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The major challenge is to continue to develop suitable biological markers to monitor 
treatment responses, and to have a standard approach to testing suitable combination 
regimens in the pre-clinical setting that will potentially induce a beneficial effect in 
the clinical setting. This therapeutic effect should be aimed at disease control rather 
than cure.  
 
1.4 Melanoma 
1.4.1 Definition 
 
Malignant Melanoma is a malignant tumour arising from uncontrolled growth of 
melanocytes. These are pigment-producing cells, predominantly found in the skin, but 
also in the bowel and the eye. Melanocytes are neural crest derivatives and in the 
skin, these usually reside in the stratum germinativum, which is the lower layer of the 
epidermis. It is this layer which contains actively dividing cells. Melanocytes have a 
characteristic colour due to their production of the dark pigment ‘melanin’. Melanin 
acts to protect the surrounding skin by absorbing UV light.  
Malignant melanoma occurs when melanocytes undergo transformation into the 
malignant phenotype either within a preexisting mole (naevus) or de novo. In the 
clinical situation, change in size, shape or colour may make one suspicious of 
malignant change within a mole. Also, minor changes in diameter, signs of 
inflammation, itching, crusting or bleeding all make one suspicious.  
 
1.4.2 Background 
 
Malignant melanoma makes up 3% of all cancers worldwide. Whilst it accounts for 
only 5% of all skin cancers, it causes the majority (75%) of skin cancer related deaths 
(Boring C 1994, CancerResearchUK 2011). Despite decades of research, the greatest 
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chance of cure is in early resection of thin tumours. According to the WHO report, 
there are about 48,000 melanoma related deaths worldwide per year (Lucas R 2006) 
and the overall incidence is currently estimated at 1 in 75. This has risen drastically 
over the last few decades, and continues to rise annually (Thompson JF et al 2005). 
Caucasians living in Australia have a 1 in 14 incidence, compared to a 1 in 80 
incidence in the UK. Survival due to melanoma has been improving mainly due to 
early detection and currently ranges from 67% for black men to 93% for white 
women in the US (Thompson JF et al 2005). 
Risk factors for developing a Malignant Melanoma include: 
? Premalignant lesions (in 7% of the population) 
? Previous melanoma 
? Age (increasing age associated with increasing incidence) 
? Race (rare in Afrocarribean and Asian population) 
? Economic status (higher economic status increase risk) 
? Fitzpatrick Type I skin (Caucasian, blond or red hair, freckles, fair skin, blue eyes, 
very sensitive to sun – always burns and never tans) 
? Sunburn (four times more likely to get melanoma if episodes of sunburn under 10 
years of age) 
There are different histological types of melanoma which, among others, include 
superficial spreading (around 70% of all melanomas), nodular, melanoma in lentigo, 
acral lentiginous, amelanotic, desmoplastic. Each type has a different presentation 
and varying degrees of aggression. 
Median survival of patients with distant metastases is 30 weeks, and the majority of 
patients with such advanced disease will be dead at 2 years as per the NCCN. Despite 
continued research efforts into devising effective chemotherapeutic schedules for 
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patients with advanced disease, results have remained disappointing. Complete 
durable responses to systemic therapy occur in only a small minority. The 
development of better treatment regimens is therefore of utmost importance. The aim 
is to achieve higher response rates, extended time to progression of disease with 
reduced toxicity and greater ease of administration.  
1.4.3 Diagnosis and Staging 
 
Diagnosis of melanoma is made up of clinical evaluation of the patient and a 
histological examination of the lesion in question. Diagnosis should be made as 
promptly as possible to ensure early and effective treatment. Clinical features 
suggestive of malignant change within an existing or new skin lesion include change 
in size, shape or colour, and also itching, bleeding and inflammation. A popular 
method has been advocated to assist in recognising signs and symptoms of melanoma 
in the form of a mnemonic: ‘ABCDE’ (Abbasi N et al 2004) 
? Asymmetrical skin lesion 
? Border of the lesion is irregular 
? Colour: usually multiple colours rather than uniformly pigmented 
? Diameter: greater than 6mm is more likely to be melanoma than smaller lesions 
? Enlarging: enlarging or evolving 
A dermatoscope is used by the clinician in the clinic to aid in the diagnosis and it is 
important to remember that malignant melanomas often defy the ‘ABCDE’ 
mnemonic completely. The presence of any of these features does however increase 
the likelihood of a lesion being a melanoma and figure 1.9 shows examples of this 
mnemonic illustrated. Diagnosis requires experience, as early stages may resemble 
harmless moles or be completely without pigment. If there is any suspicion, then the 
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Figure 1.9: ABCDE in aiding melanoma diagnosis (adapted from Abbasi 2004) 
 
     A stands for ASYMMETRY; one half unlike the other half. 
 
    B stands for BORDER; irregular, scalloped or poorly defined.  
 
  C stands for COLOUR; varied from one area to another; 
shades of tan, brown and black; sometimes white, red or blue. 
 
  D stands for DIAMETER; melanomas are usually greater 
than 6mm (size of a pencil eraser) when diagnosed, but they can be smaller. 
 
 
E stands for EVOLVING; a mole or skin lesion that looks different from the rest 
or is changing in size, shape or colour. 
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primary management is to perform an excision biopsy. This provides the clinician 
with a histological diagnosis aswell as providing initial treatment for the tumour. The 
preferred surgical margin for the initial excision biopsy should be narrow (1-2mm) to 
prevent disruption of lymphatic drainage (Swanson N et al 2002). If the histological 
diagnosis of melanoma is comfirmed, the pathologist will provide a detailed 
information on the depth of tumour invasion using ‘Breslow thickness’ and ‘Clark’s 
level’, which are both indicative of tumour depth and linked to prognosis. Depth of 
invasion was first reported as a prognostic factor in 1970 by a surgeon named 
Dr.A.Breslow (Breslow A 1970)  Breslow thickness is the distance between the 
granular layer of epidermis and deepest part of the melanoma (Figure 1.10) using an 
ocular micrometer at a right angle to the skin. It is directly related to survival and is 
included in the AJCC staging guidelines as a major prognostic factor (Balch CM et al 
2001; Balch CM et al 2009). Clarks level describes the level to which tumour has 
infiltrated – level I (just epidermis), level II (papillary dermis), level III (junction 
between papillary and reticular dermis), level IV (into reticular dermis), level V (into 
subcutaneous fat). The feature of ulceration of the primary lesion has also been added 
to pathological staging criteria for melanoma (Balch CM et al 2001; Grande Sarpa H 
et al 2006; Balch CM et al  2009).  
  
Once histology is available, informed decisions can be made as to the secondary stage 
of treatment. This will involve taking a specific wider excision margin, dependent on 
the tumour depth and other features. The skin defect is repaired accordingly, by direct 
closure, skin graft or more complex reconstruction of the defect, carried out by the 
local plastic surgeon.  
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Figure 1.10: Breslow Thickness 
 
Depending on the Breslow depth of the melanoma, prognosis (5 year survival) can be 
approximated as follows: 
<1mm – 95-100% 
1-2mm – 80-96% 
2.1-4mm – 60-75% 
>4mm - 50% 
 
These survival figures are from the AJCC guidelines (Balch CM et al 2001; Balch 
CM et al 2009) 
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In patients who have clinically palpable lymph nodes, with histological evidence of 
melanoma, formal cancer staging is required. The introduction of sentinel lymph node 
biopsy has added another dimension to clinical and pathological staging. This is 
another important prognostic tool (Morton DL et al 2006), although there is a debate 
regarding its therapeutic efficacy (Balch CM and Cascinelli N 2006; Gonzalez U 
2007; Balch CM et al 2009). If spread of disease is shown to be localised to one 
lymphatic basin, a block dissection of the involved lymph node basin is offered to the 
patient. The TNM staging system is used to give patients more complete prognostic 
information and to discuss further treatment options as necessary, once investigations 
and further surgery are complete.  
 
The TNM Staging System was developed and is maintained by the AJCC. It was 
introduced as a tool for doctors to stage different types of cancer based on certain 
standard criteria. TNM is based on the extent of the tumour (T), the extent of spread 
to the lymph nodes (N) and the presence of metastasis (M). A new version of the 
2002 TNM staging system for melanoma (Balch CM et al 2001; Balch CM et al 
2009) has been recently published jointly by the AJCC and the International Union 
Against Cancer (UICC). The major change is the inclusion of mitotic activity as an 
important prognostic feature of the primary tumour. A mitotic rate of greater than 
1/mm2 indicates a higher risk of metastasis. This change was based on outcomes of 
60,000 patients (Balch CM et al 2009).  Table 1.3 demonstrates the TNM staging 
system for malignant melanoma, and Table 1.4 demonstrates staging with the 
associated predicted survival rates for 10 years as per the latest AJCC guidelines. 
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Table 1.3: TNM Staging in Malignant Melanoma: taken from revised 2009 – 
AJCC/UICC guidelines (Balch et al 2009) 
Stage 0: Melanoma in Situ (Clark level I), 99.9% 5 year survival   
Stage I/II: Invasive Melanoma, 85-95% 5 year survival 
T1a            < 1.0mm Breslow Without ulceration, Clarks II/III 
T1b < 1.0mm Breslow With ulceration / Clarks IV/V  
T2a 1.0mm – 2.0mm Breslow Without ulceration 
Stage II: High risk Melanoma, 40-85% 5 year survival 
T2b 1.0mm – 2.0mm Breslow With ulceration 
T3a 2.0mm-4.0mm Breslow Without ulceration 
T3b 2.0mm-4.0mm Breslow With ulceration 
T4a 4.0mm or greater Without ulceration 
T4b 4.0mm or greater With ulceration 
Nx: Regional nodes cannot be assessed 
N0: No regional node metastasis 
Stage III: Regional metastasis, 25-60% 5 year survival 
N1 Single positive lymph node A: micrometastasis 
B: macrometastasis/clinically apparent 
N2 2-3 positive regional lymph nodes or 
intralymphatic regional metastasis 
A: micrometastasis 
B: macrometastasis / clinically apparent 
C: Satellite or intransit metastasis without  
nodal mets 
N3 4 or more metastatic nodes, or matted nodes or intransit metastases/satellites with 
metastatic nodes. 
M0: No evidence of metastasis to distant tissues or organs 
 
Stage IV: Distant Metastasis, 9-15% survival 
M1a Distant skin, subcutaneous or n
metastases 
Normal LDH 
M1b Lung metastases Normal LDH 
M1c All other visceral metastases  
Or any distant metastases 
Elevated LDH 
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Table 1.4: Melanoma staging and predicted 10 year survival (Balch et al 2009) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stage TNM 5 year survival 10 year survival 
 
Stage IA T1aN0M0 99% 97% 
 
Stage IB T1b/2aN0M0 92% 86% 
 
Stage IIA T2b/3aN0M0 78% 66% 
 
Stage IIB T3b/4aN0M0 68% 59% 
 
Stage IIC T4bN0M0 56% 48% 
 
Stage IIIA T1-4N1aM0 / 
T1-4aN2aM0 
51-70% 46-65% 
 
Stage IIIB T1-4bN1/2aM0 / 
T1-4aN1/2bM0 /  
T1-4a/bN2cM0 
50-68% 44-60% 
Stage IIIC T1-4bN1bM0 / 
T1-4bN2bMO / 
Any TN3M0 
27-52% 22-37% 
Stage IV AnyT AnyN M1a-c  18% 14% 
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1.4.4 Treatment and clinical follow-up 
 
As previously mentioned, current treatment involves primary surgical excision of the 
lesion in question. Once a lesion has been histologically confirmed to be a melanoma, 
wider margins are taken at operation, with the standard margin being 1cm of skin 
excised for every 1mm depth in Breslow thickness. Numerous studies have shown 
that there is no difference between 1 and 3 cm excision margins in patients with 
melanomas <2mm in depth, and also that 2cm excision margins are adequate for 1-
4mm depth melanomas (Veronesi U and Cascinelli N1991; Balch CM et al 1993). A 
recent Cochrane review published in 2009 looked at all randomised controlled trials 
(RCTs) of surgical excision of melanoma comparing different width excision 
margins. Data was analysed looking at survival and recurrence, and found that 
recurrence free survival favoured wider excision margins, but that this was not 
statistically significant (Sladden M et al 2009).  
 
All patients with melanoma are closely surveyed post operatively in the clinic and 
monitored closely for recurrence or development of distant metastatic disease for 5 
years. If at follow-up, nodal or metastatic spread is suspected, then formal 
histological and radiological staging is performed.  
 
1.4.5 The oncologists’ challenge in melanoma treatment and novel  
therapeutic strategies 
 
Patients with metastatic melanoma (stage IV) have a short median survival in the 
range of 6 to 9 months, with a 14% 10 year survival rate as shown in table 1.4. 
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Discouragingly, the median survival has not improved appreciably despite decades of 
investigations of cytotoxic, immunologic, and now molecularly targeted agents. It 
remains one of the most chemoradioresistant adult malignancies and treatment of 
advanced melanoma poses a huge challenge to the oncologist. 
 
Single agent chemotherapy in melanoma produces objective response rates of less 
than 20%. Historically, dacarbazine (DTIC) has produced response rates of from 15% 
to 25% , but less than 5% of these are complete responses (Balch CM 1997). Long 
term follow-up of patients treated with DTIC alone shows that <2% can be 
anticipated to survive for 6 years. This remains the only cytotoxic drug approved by 
the U.S Food and Drug Administration (FDA) for the treatment of metastatic 
melanoma, despite its low single agent activity. A viable alternative to this agent is a 
closely related oral congener of DTIC, temozolomide, discussed in more detail in 
chapter 3. This has been established as a single agent in clinical trials, and shows 
similar efficacy, with the added advantages of its ability to penetrate the central 
nervous system, and therefore treat cerebral metastases, and its oral bioavailability, 
improving patient quality of life (Newlands ES et al 1992; Bleehen NM et al 1995; 
Middleton M et al 2000; Bafoloukos D et al 2002). More recently, the largest ever 
randomised, phase III trial conducted in stage IV melanoma, showed no survival 
benefit of using single agent temozolomide over DTIC (Patel PM et al 2008). Median 
overall survival reached 9.13 months with temozolomide and 9.36 months with 
DTIC. Median progression-free survival was similar and unimpressive at 2.30 months 
and 2.17 months, respectively. The principal investigator of this trial, Dr.Patel stated 
that ‘the standard of care for these patients has not really changed in the last 2 
decades’ (Patel PM et al 2008).   
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Other single agents that have been tested in the treatment of metastatic melanoma 
include cisplatin and carboplatin. Cisplatin has induced a 15% response rate with a 
short median duration of 3 months (Atkins MB 1997; Glover D et al 2003). Also, the 
nitrosoureas - carmustine and lomustine - have been shown to induce objective 
responses in 13 to 18% of patients. Their advantage was thought to be their ability to 
traverse the blood-brain barrier, but despite these showing little or no activity against 
melanoma brain metastases, they have frequently been included in multi-agent 
regimens (Boaziz C et al 1991; Calabresi E et al 1991). The most interesting agent, 
however, in this group is fotemustine which has been directly compared in a phase III 
study with dacarbazine. This study showed that overall response rate (ORR) was 
higher in fotemustine arm compared with dacarbazine in first-line treatment of 
disseminated melanoma (Avril MF et al 2004). 
 
The vinca alkaloids, particularly vindesine and vinblastine, have produced responses 
in approximately 14% of patients, and the taxanes in 16% of patients (Quagliana JM 
et al 1984; Einzig AI et al 1991; Aamdal S et al 1994). These agents are rarely used 
as single-agent therapy, but are frequently incorporated into combination 
chemotherapy or biochemotherapy regimens. More hopeful as a single agent is a 
potentially active new drug called abraxane (ABI-007), which is an albumin-bound 
nanoparticle formulation of paclitaxel. It has so far shown >30% overall response rate 
in phase II trials, and can now be explored in a randomised phase III trial (Hersh E et 
al 2006).  
 
Since single-agent treatment has shown only modest response rates in the treatment of 
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metastatic melanoma, combination regimens have been put forward for clinical trials. 
The development of these combination regimens was based on the minimal single-
agent activity seen, without any laboratory or clinical evidence of synergistic activity. 
Unsurprisingly, 2-agent regimens of the afore-mentioned compounds showed little or 
no superiority in response rates to single agent regimens i.e. 10 to 20% (Costanzi JJ et 
al 1975; Vorobiof DA et al 1986; Avril MF et al 1990). These disappointing trials 
were followed by phase II studies of 3 and 4 drug combinations, which generally 
produced response rates from 30 to 50%. However, when randomised studies were 
subsequently carried out to compare single agent DTIC to a triple agent regimen of 
cisplastin, vinblastine and DTIC (CVD), and also to quadruple agent therapy, there 
were no overall differences in either response rates or survival (Legha SS et al 1989; 
Rusthoven JJ et al 1996).   
 
Further combination studies have subsequently been carried out, in the quest to 
achieve better response rates and improved survival rates in this seemingly resistant 
metastatic cancer. Both tamoxifen and interferon α have been used in combination 
with DTIC and in other multi-agent regimens. Smaller phase II and III trials have 
suggested significant benefit in response rates with these additional agents. However, 
these benefits have not been confirmed in large, multicentred Phase III trials, 
suggesting probable selection bias (Flaherty LE et al 1997; Lens MB et al 2003).  
 
Biochemotherapy has also been evaluated in recent years, looking at the role of 
interferon α (IFNα) and interleukin 2 (IL2) in combination with traditional 
chemotherapy regimens. In a metaanalysis by Keilholz et al, patients with metastatic 
melanoma who were treated with IL-2/IFNα/chemotherapy, IL-2/IFNα without 
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chemotherapy and IL2/chemotherapy without IFNα had response rates of 45%, 21% 
and 15% respectively. However, there was no significant survival benefit for any of 
the regimens (Keilholz U et al 1998). Multiple biochemotherapy studies in differing 
regimens have been subsequently carried out, and the overall conclusion to date is 
that biochemotherapy should not be used outside of clinical trial in stage IV disease. 
It may be useful in the symptomatic patient with rapidly progressive disease.  
 
As has been so far demonstrated, the treatment of metastatic melanoma remains 
challenging, and it remains intrinsically resistant to most types of chemotherapy and 
biological therapies. This, as is the case for the treatment of many adult tumours, has 
led investigators to evaluate new approaches and to assess newer molecularly targeted 
therapies.  
 
There are many new agents currently under trial in the case of melanoma.  Some of 
the more recent trials include agents such as protein-kinase inhibitors e.g. sorafenib, 
agents that act on cytotoxic T-lymphocyte antigens (CTLA-4 or ipilimumab) or on 
apoptotic mechanisms e.g. oblimersen sodium and specific anti-angiogenic agents 
e.g. bevacizumab, SU5416, MEDI-522, PI-88 and B-RAF inhibitors e.g plexikon 
(ref). Some of these agents and associated melanoma trials are detailed below: 
 
Sorafenib targets the adenosine triphosphate-binding site of the B-RAF kinase. 
Melanoma exhibits 70% B-RAF mutation in comparison to 7% mutation in all other 
adult tumours, making sorafenib an ideal molecularly targeted melanoma therapy. It 
is a drug which not only inhibits B-RAF, but also tyrosine-kinases involved in 
angiogenesis and tumour progression. Results from phase I and II trials to date have 
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shown some promising results, both as a single agent and in combination with 
traditional chemotherapeutic agents. One phase II trial combined sorafenib at 3 
different doses with carboplatin and paclitaxel, showing a 31% response rate, and 
54% stable disease in a group of 35 patients with metastatic melanoma (Flaherty K et 
al 2005). It has also been combined with DTIC and compared with placebo showing a 
51.3 versus 45.6 month overall survival benefit (McDermott D et al 2008).  
 
Sorafenib and Temozolomide have been combined in the treatment of melanoma 
(Phase II). The selection of these agents has been based on melanoma-specific effects 
seen when both are given as single agents (Flaherty K et al 2005). Also, pre-clinical 
studies have demonstrated that Sorafenib enhances the therapeutic efficacy of a broad 
range of chemotherapeutic agents in xenograft models of various cancers (Queirolo P 
et al 2006). However, within the combination trial (Flaherty K et al 2005), the anti-
angiogenic effects of the regimen was not assessed, with the end-point being 
progression-free survival. The combination showed encouraging activity in patients 
with metastatic melanoma, particularly in those with brain metastases.  
 
However, results of a phase III randomised, placebo-controlled study of sorafenib in 
combination with carboplatin and paclitaxel as a second-line treatment for advanced 
melanoma showed that the addition of sorafenib did not improve any of the end-
points (PFS and OS) (Hauschild A et al 2009).     
 
Imatinib mesylate is an oral tyrosine kinase inhibitor of c-Kit, PDGFR and BCR-
ABL. Expression of c-Kit (a transmembrane receptor with TK intracellular domain) 
was seen in nearly 50% of early melanomas, but this is reduced in the metastatic 
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phenotype (Janku F et al 2003). A phase II trial of Imatinib was performed in 18 
patients with metastatic melanoma and at least 25% c-Kit expression. Only one 
patient had high expression of c-Kit (75%) and in this patient, a near complete 
response was observed. Unfortunately, all other patients progressed (Ugurel S et al 
2005). A further phase II study showed similar results in a patient with a metastatic 
acral lentiginous melanoma and high c-Kit expression (Kim K et al 2008). There is 
some evidence to show that the very rare mucosal melanomas may have greater c-kit 
expressiom, and therefore may be more responsive to this agent. 
 
Temsirolimus is a novel potent inhibitor of rapamycin (mTor). mTor is a serine-
threonine kinase that promotes phosphorylation of S6K1 and the eukaryotic initiation 
factor 4E- binding protein-1 (4E-BP1), involved in G phase progression. 
Temsirolimus acts as a rapamycin analog, and subsequently blocks the 
phosphorylation cascade (Meric-Bernstam F and Mills G 2004). A phase II study of 
intravenous temsirolimus every week in 33 patients with metastatic melanoma was 
undertaken (Margolin K et al 2005). Toxicities were mild, but only one patient had a 
partial response, concluding that, as a single agent, it was not effective in melanoma.  
 
Bevacizumab is a recombinant humanized monoclonal antibody designed to 
specifically bind VEGF (see section 1.2.4), and hence inhibit its biological activity, 
leading to reduced tumour microvasculature (Kerbel R and Folkman J 2002). VEGF 
is overexpressed  in melanoma and its expression strongly correlates with poor 
prognosis (Ugurel S et al 2001). A phase II trial of Bevacizumab (15mg/kg i.v every 
2 weeks) with or without daily subcutaneous interferon α was carried out. Out of 16 
patients with metastatic melanoma, 1 complete response, 1 partial response and 4 
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disease stabilisations were seen in patients who were receiving both agents (Carson 
W et al 2003).  
 
MEDI-522 is a humanized monoclonal antibody designed to target integrin 
alphavbeta3 (avb3). Avb3 has been linked to invasive growth and metastasis in 
melanoma, and also to up-regulation of bFGF (a pro-angiogenic factor). In a phase II 
trial of dacarbazine 1000mg/m2 every 3 weeks plus MEDI-522 (55 patients) or just 
MEDI-522 alone (57 patients), a 13% response rate was seen in the combination arm, 
and promising improvement in survival (11.8 months) with single agent (Hersey P et 
al 2005). 
 
PI-88 is a new anti-angiogenic agent. It mimics heparan sulphate, and competitively 
binds both angiogenic growth factors such as FGF and VEGF, inhibiting 
angiogenesis, and also heparanase, thus preventing degradation of the extracellular 
matrix (a major step in metastasis). In a phase II trial of PI-88, 250mg/day was given 
for 4 days every week to pre-treated patients. Disease control rate was 36% (Joyce J 
et al 2005; Thomson D et al 2005). 
 
The expanding list of targeted agents and potential combination regimens continues 
to increase exponentially, but sadly those trialled to date fail to show any significant 
survival benefits to the traditional DTIC based regimens. This failure may be 
attributed to the empiricism of trials that generally combined agents because they 
were there, rather than a scientific understanding of mechanisms of action and proven 
synergy (Agarwala S 2008). Malignant melanoma progression is determined by 
several parallel and interacting pathways affecting growth control, differentiation, cell 
 82
adhesion, invasion, angiogenesis and resistance to apoptosis. Integration of the 
increasing understanding at the molecular level of the generic mechanisms governing 
melanoma spread, along with the evidence of the effects of the host immune system 
on melanoma, may finally produce a way forward in this intractable disease. In the 
meantime, the best service clinicians can provide patients with advanced, devastating 
melanoma is to encourage enrolment onto clinical trials.  
 
1.5 Thesis Objectives 
 
From a basic science perspective, the objectives of this thesis are to assess the anti-
endothelial effects of cytotoxic agents given in a metronomic schedule as single 
agents and in combination with specific anti-angiogenic compounds. Optimization of 
the previously established technique of the HUVEC model will be a major component 
of the work (Lam T et al 2007). Along side this, to set up a scientific sub-study, as 
part of an existing phase I/II clinical trial of combined cytotoxic chemotherapeutic 
agents with a non-specific anti-angiogenic compound. This trial was using a 
metronomic dosing schedule in patients with metastatic malignant melanoma. 
Amongst the trial group, the aim was to assess the profile of circulating endothelial 
cells and circulating endothelial progenitor cells – potential biomarkers of response to 
anti-angiogenic therapy (see section 1.2.3 and 1.2.4). Comparison of this biomarker 
will be made between the traditional high-dose group and the metronomically dosed 
group of patients. 
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Chapter 2 
Materials and Methods 
 
This chapter includes two methodologies, the first in relation to the in vitro MVEC 
model experiments (section 2.1), and the second in relation to the clinical study 
(section 2.2) – isolation of CECs and CEPs in patients with metastatic melanoma. The 
optimisation of the technique used for the clinical study will be discussed along with 
the clinical results in chapter 5. 
 
2.1 The in vitro MVEC model 
The main aim of this part of the study was to investigate potential anti-endothelial 
properties of several orally bioavailable cytotoxic agents when given in a continuous 
low dosing schedule. These agents were assessed as single agents and in combination 
with specific anti-angiogenic agents i.e. sorafenib and combretastatin. The study used 
microvascular endothelial cell proliferation as a surrogate marker of in vitro anti-
endothelial response (see section 1.2.3). The study of angiogenesis has been 
significantly advanced by the ability to culture endothelial cells in vitro, recognising 
the limitations of in vitro models. This was initially introduced using large vessel 
endothelial cells, such as those isolated from the human umbilical vein (HUVECs). 
However, through previous work within this study group and from other researchers 
(Bocci G et al 2002; Lam T et al 2007) MVECs have been identified as a more 
suitable model to study anti-endothelial effects, and are VEGFR-2 positive (Bouis D 
et al 2001). Endothelial cells are heterogenous in phenotype, function, expression of 
surface molecules and responsiveness to growth factors. MVECs comprise only 1-5% 
of cells in a given tissue, grow slowly and are contact inhibited. The process of 
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neovascularisation involves recruitment of microvascular rather than large endothelial 
cells. MVEC expression of actin binding LIM protein 1, myosin 5C and myosin 7A 
relates to their ability to undergo extensive cytoskeletal remodelling and migration 
during angiogenesis (Manconi F et al 2000; Giusti B et al 2006). These cells are 
however very delicate, and require fastidious culture techniques, described in section 
2.1.1.2. 
 
For this study, MVECs were grown in monolayers and a protocol was then followed 
which allowed protracted drug exposure, guided by previous studies (Bocci G et al 
2002; Lam T et al 2007). In applying this metronomic principle to the in vitro setting, 
one is limited by the time at which cells reach confluence i.e. there is a finite duration 
of treatment. It was therefore necessary to perform optimisation experiments to 
determine the ‘optimum’ duration of cell growth in vitro.   
 
Once optimum duration of cell growth was determined, the chemosensitivity 
experiments were performed. Cell proliferation was the main parameter assayed, 
using growth inhibition as a marker of anti-endothelial efficacy, and to determine the 
presence or absence of a synergy in the combined schedules. The assays were 
conducted on human tumour cell lines for comparative purposes and, in the case of 
the melanoma cell line, to assess any additional anti-melanoma effect. 
2.1.1 General cell culture 
All media and tissue culture reagents used were purchased from Invitrogen (Paisley, 
UK) unless otherwise stated. Plastic ware was purchased from Sarstedt, UK unless 
otherwise stated. All media and reagents mentioned in this chapter are listed and 
described in Appendix 1. 
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2.1.1.1 Aseptic technique 
 
Aseptic techniques were conducted in a Class II microbiological safety cabinet (ICN 
flow) fitted with a UV sterilising lamp. All glass ware and heat-stable solutions were 
auto-claved prior to use at 121oC for 10 minutes.  
2.1.1.2 Maintenance of primary cells and cell lines 
 
Human dermal microvascular endothelial cells (MVECs) were purchased from TCS 
CellWorks (UK) (no. ZHK-2526). Human melanoma cell line SK-MEL-2 and human 
breast carcinoma cell line MCF-7 were purchased from the American Type Culture 
Collection, and the human lung carcinoma cell line A549 was purchased from the 
European Collection of Cell Cultures. The three human cancer cell lines were utilised 
as controls to assess the anti-cancer effects of each agent. 
 
MVECs were maintained in Medium 199 (no. M4530, Sigma-Aldrich) supplemented 
with MVEC Growth Supplement (no. ZHS-8947 - TCS) + antibiotics (no. ZHR-9939 
- TCS) – pre-equilibrated in a 37oC, CO2 incubator prior to culture of cells. 
SK-MEL-2, MCF-7 and A549 cells lines, as described above, were all maintained in 
medium plus supplements (see Appendix 1). Maintenance of all cells was in 75cm2 
tissue culture flasks, each flask containing 15ml of the relevant supplemented media. 
 This was in a humidified atmosphere of 5% CO2 at 37oC.  
 
All cells were used at passage 6 or below, as it is recognised that morphology and 
receptor status can alter with increasing passage. MVECs were harvested with a 
solution of 0.025% (w/v) trypsin / 0.01% (w/v) EDTA as recommended and provided 
by TCS CellWorks Ltd, U.K. The SK-MEL-2, MCF-7 and A549 cells were harvested 
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with TrypLE™ Select (Invitrogen), which has enhanced activity on strongly adherent 
cell lines (see Appendix 1 for further details). Passage of cells was carried out when 
growth was in a logarithmic phase, at 70-80% confluence. This was done by the 
addition of 5ml of the appropriate trypsin solution to each flask, which was then 
incubated at 370C until 90% detached and for no longer than 5 minutes. Detachment 
was increased by a gentle tap when examining flasks at intervals between 3 to 5 
minutes under the microscope. Once detached, an equivalent amount of media was 
added to inactivate the trypsin and the cells recovered by centrifugation at 220g for 3 
minutes. The cells were then passaged into fresh 75cm2 flasks (usually at a ratio of 
1:3), or frozen down in 1ml aliquots as required and depending on the passage. A 
confluent flask was split into 4x1ml aliquots for freezing down, at a concentration of 
0.5-1.0x106 cells/ml (see 2.1.1.4 for cell counting).  
 
For MVECs, prior to passage, flasks were first incubated with 5ml attachment factor 
(see Appendix 1) per 75cm2 flask for 1 hour. The excess was then aspirated off and 
the appropriate amount of cell suspension added to MVEC media. This ensured cell 
adherence as recommended by TCS cell works. 
 
2.1.1.3 Cell freezing and recovery 
 
In order to freeze samples, harvested cells, using steps described in section 2.1.1.3, 
were instead resuspended in freeze medium (see Appendix 1) at a concentration of 
0.5-1.0x106 cells/ml (see section 2.1.1.5 for cell counting). 1ml aliquots were then 
transferred to cryovials. The cryovials were kept in a -80oC freezer for up to 24 hours, 
and then transferred to liquid nitrogen for long term storage.  
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For recovery, cells were rapidly thawed by placing a frozen aliquot into a 37oC water 
bath for 1-2 minutes until fully thawed and the cell suspension was slowly added into 
a pre-warmed (37oC) culture medium – specific to each cell line (see Appendix 1) - 
and centrifuged at 220g for 3 minutes. The pellet was then resuspended in 
approximately 15ml of fresh medium and placed in a 75cm2 tissue culture flask.  
 
2.1.1.4 Cell counting 
To determine the concentration of cells a haemocytometer was used. Cell suspension 
(25µl) was diluted 1:1 with 0.1% (w/v) Trypan blue stain. Trypan blue is a vital dye 
that is excluded by viable cells. Non-viable cells show cytoplasmic staining due to 
Trypan blue uptake. This diluted suspension was well mixed, and placed into a 
haemocytometer chamber. The cell density was determined under the light 
microscope by enumerating the number of cells in a set area i.e. 5 large squares, and 
gaining an average of this count (divide by 5). The following formula was then used: 
Cell concentration (cells/ml) = cell count x 2 (dilution factor) x 104 
 
2.1.1.5 Optimisation and determining seeding densities 
 
Preliminary experiments were conducted to determine the optimal cell seeding 
density which enabled the longest period of uninterrupted growth in 96-well plates up 
to confluence. This was carried out by plating out all four cell types on day 1 at 
varying densities of 1000 to 5000 cells per well in 200µL of cell specific media. The 
specific media, attachment factor (for MVECs) and growing conditions remained the 
same for each cell type as previously mentioned. All cells were kept in a humidified 
atmosphere of 5% CO2 at 37oC. Confluence for each cell type and each seeding 
density was then assessed on each day, and expressed as an approximate percentage. 
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200µL of the appropriate cell-specific media was removed and replaced daily for 
each well and the experiment was carried out in triplicate for all cell types. Figure 2.1 
shows a summary of the method used to plate out for this assay. 
 
2.1.2 Chemosensitivity assay 
 
2.1.2.1 Drugs 
 
Purified temozolomide was provided by Schering-Plough, U.K. Purified Paclitaxel 
(no. T7402), etoposide (no. E1383), vinorelbine (no. V2264) and carboplatin (no. 
C2538) were from Sigma-Aldrich, UK. Purified sorafenib tosylat was provided by 
Bayer, U.S.A. Purified Combretastatin was provided by Oxigene, UK. Purified 
Bortezomib was provided by Millenium, UK.  For in vitro experiments, drugs were 
reconstituted following manufacturers instructions at 10mM in DMSO, except for 
Vinorelbine which was reconstituted at 10mM in sterile water, and Combretastatin 
which was reconstituted at 10mM in PBS. The 10mM solutions were then diluted in 
culture medium immediately prior to use, into appropriate aliquots at the specific 
concentration required. The concentration of DMSO in culture was kept at 0.1% 
(v/v), which therefore acted as control in all experiments. The effect of DMSO at 
varying concentrations was first assessed in all cell types to ensure that the chosen 
concentration of 0.1% did not cause any effect independent to the agents being tested.  
 
2.1.2.2 Treatment of cells with single agents and with combinations of cytotoxic 
and anti-angiogenic agents 
In vitro chemosensitivity testing was performed on cells grown as a monolayer on 96-
well flat-bottomed tissue culture plates (Sarstedt).  Each drug concentration was set  
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Figure 2.1: Summary diagram of plate set-up for the chemosensitivity assays 
On days 2,3 and 4, the dosing schedule for each drug was undertaken on the plate for 
each of the four cell types. The concentration of DMSO was kept at 0.1% throughout.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Key: Red – cells dosed with 0.1% DMSO and media daily i.e. column 1 
         Blue – cells dosed with increasing concentrations of drug i.e. column 2-9, in  
sextuplicate. 
         Yellow – media only  
 
 
 
 
↑ drug 
concentration
First column of cells dosed 
with media containing 
0.1% DMSO 
Media 
replaced 
daily 
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up in sextuplicate.  Preliminary experiments were then undertaken to determine the 
therapeutic range of each drug. Cells were treated with Temozolomide (0-100µM), 
Paclitaxel (0-2nM), Vinorelbine (0-10µM), Etoposide (0-5µM), Carboplatin (0-
500µM), Sorafenib (0-10µM), Combretastatin (0-25nM) and Bortezomib (0-100nM) 
as single agents. For all experiments, in order to maintain constant concentration of 
the drugs, the media was replenished with fresh solutions containing the appropriate 
drug concentrations on a daily basis 4 days, as determined by preliminary 
experiments to determine the duration of drug exposure for all cells. (Bocci G  et al 
2002; Lam T et al 2007). 
Initial dose ranges and drug concentrations were based on pharmacokinetic data from 
phase I clinical trials. For the five traditional cytotoxics, the clinical maximum 
tolerated dose (MTD) from these original studies, was converted into a molar 
concentration (see table 2.1) (Koeller J et al 1986; Sessa C et al 1995; Brada M et al 
1999; Malingre M et al 2000; Marty M et al 2001). Since ‘metronomic dosing’ is 
traditionally devised upon an empirical dose between 10-33% of the MTD 
(Maraveyas A et al 2005; Lam T et al 2006), a wide in vitro dose range was chosen 
from 0 to 50% of the MTD for each drug. This choice of in vitro dose ranging was 
similarly used by Lam et al (Lam T et al 2007) and in the study based on the HUVEC 
model which used by Bocci and colleagues (Bocci G et al 2002).  For the specific 
anti-angiogenic agent – sorafenib - the actual clinical dose – 400 mg twice daily, was 
converted into a molar concentration from Phase I data, equivalent to 4.5µM (Moore 
M et al 2005) and a wide dose range selected to include this in order to demonstrate 
anti-endothelial and potential anti-proliferative effects. For the non-specific anti-
angiogenic agents - combretastatin and bortezomib – a wide dose range was also  
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Table 2.1:  Published phase I pharmacokinetic data for oral formulations of the  
drugs used in this study 
 
 
 
Drug Published  
MTD 
 (mg/m2) 
Published  
Cmax for 
MTD 
Reference Equiv.  
molar  
conc.  
of Cmax 
(µM) 
In vitro 
dose range
selected 
(µM) 
Temozolomide 
(oral) mol wt 
194.15 
200 13.9µg/ml (Brada M 1999) 71.5 0-50 
Paclitaxel 
(oral) 
300 0.33µM (Malingre M 2000) 0.33 0-0.002 
Vinorelbine  
(oral) mol wt 
1079.2 
80 133.4ng/ml (Marty M 2001) 0.123 0-10 
Etoposide (oral)
mol wt 588.56 
220 21.1µg/ml (Sessa C 1995) 4.5 0-10 
Carboplatin  
(oral)  
1000 38.5µM (Gore M 1987) 38.5 0-500 
The Cmax data at the MTD was converted into an equivalent m
concentration and this was used to select an in vitro dose range. Referen
refer to both published MTD and Cmax for MTD. 
 
 
 
 
 
 
 
 
 
 92
 
selected, guided by previous in vitro and in vivo studies (Stevenson J et al 2003; 
Papandreou C et al 2004; Schwartz R et al 2004).  
 
2.1.2.3 Cell proliferation assay (MTT) 
 
To determine the effects of chemotherapy on cell proliferation, a standard MTT (see 
Appendix 1) assay was performed (no. M5655, Sigma-Aldrich,UK).  The optimal cell 
seeding density for each cell type was used, and cells resuspended in 200µL of 
appropriate media (attachment factor was used to prepare plates for MVECs as 
described in 2.1.1.2-20µL per well). Plates were then incubated for 24 hours at 370C 
in a humidified atmosphere of 5% CO2 to allow the cells to adhere to the well 
surfaces. The cells were divided into two groups, one used as a control in order to 
determine cell number at start of treatment (baseline). The other group was the 
treatment group.   The MTT assay was therefore performed immediately prior to drug 
addition in the control group. It was then performed at the end of the period of drug 
treatment (96 hours), and dose-response curves. 20µL of MTT solution was added to 
each well containing 200µL of cell-specific media, and the mixture incubated at 37oC 
for 4 hours. The substrate medium was then removed; 200µL of lysis buffer (see 
Appendix 1) was then added to each well and plates were incubated for a further 2 
hours. Optical density at 570nm was then read using a spectrophotometric plate 
reader.  
2.1.2.4 Calculation of the relative growth 
 
Using results produced from the spectrophotometric plate reader, cell growth from 
baseline was expressed as percentage change in absorbance values. To calculate the 
relative growth, the growth of control (untreated) cells was taken as 100%, and the 
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corresponding growth of treated populations of cells was expressed as a percentage of 
control growth.  
 
2.1.3 Statistical analysis of MTT data 
 
All data represent the mean of three independent experiments and each drug 
concentration was set up in sextuplicate. The results of relative cell growth are 
expressed as mean values +/- standard error. The data was analysed using a two-
sample t-test for populations of unequal variance to compare the effects of different 
drug doses and combinations. SPSS software version 14.0 (SPSS, Chicago, USA) 
was used for the statistical analysis. A confidence level of P< 0.05 was considered 
statistically significant. 
 
2.2 Isolation of circulating endothelial cells and circulating endothelial 
progenitor cells in patients with metastatic malignant melanoma  
 
2.2.1 Clinical study protocol and participant recruitment 
 
 
Before commencing the study, ethical approval was granted by the local research and 
ethics committee (06/Q1105/38) and by the Hull and East Yorkshire NHS Trust 
(R0397). All forms including consent and information sheets to be completed by 
study participants were also approved (see Appendix 2).    
 
The clinical study involved recruitment of participants from an existing trial entitled  
‘A Phase I/II study of Estramustine and Temozolomide in patients with metastatic 
malignant melanoma'. This trial is offered to patients with advanced malignant 
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melanoma, and had already been approved by the Hull and East Riding LREC in 
2002 (05/Q1105/76). This trial was set up to determine the metronomic dose of 
temozolomide and estramustine in this patient group, based on previously articulated 
dosing principles (Lam T et al  2006; Lam T et al 2007) The ultimate aim is to  add in 
a specific anti-angiogenic agent as a third agent once the metronomic dose was 
reached. The metronomic, combinatorial approach being used in this trial is therefore 
closely linked to the theory behind the in vitro MVEC model chemosensitivity assay 
as discussed earlier in this chapter (section 2.1).  
 
Practice concurrent with the period of the experimental work of this thesis was to 
treat patients with conventional DTIC based chemotherapy based on MTD or to offer 
patients’ entry in to the temozolomide-estramustine Phase I trial. This trial has two 
dosing schemes - one is that of MTD while the other is establishing a continuous 
daily dosing schedule, a ‘metronomic-like’ approach, using a temozolomide-based 
dose-escalation schema (Table 2.2). Patients from each of these treatment sub-groups 
were included in this thesis study, being separated in to patients treated with the MTD 
(conventional) schedule and patients treated with ‘metronomic-like’ schedule. . The 
study can therefore be classed as a scientific sub−study to the already existing 
treatment trial, and had no influence on patient management. Patients had the 
opportunity to discuss the study in detail in the clinic. The GCP consent process was 
followed.  The patients were asked to read through a patient information leaflet, either 
at the clinic or in their own time (see Appendix 2.1). Only once they had had the 
opportunity to ask questions and read the information leaflet, were they then asked if 
they were willing to participate, and if so, then sign the consent form (see Appendix 
2.2).  
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Table 2.2: Dose escalation schema for A Phase I/II Study of  Estramustine and 
Temozolomide in Patients with Metastatic Melanoma. 
 
The patients studied in the ‘metronomic’ arm of the study (described further in 
chapter 5) were on dose levels 5a and 6. As per metronomic principles,  (Maraveyas 
A et al 2005; Lam T et al 2007) bone marrow toxicity was not seen in levels 5a and 6.  
 
 Temodal schedule Temozolomide Estracyt schedule Estramustine 
Level -1 QD Days 1-7,15-21 75 mg/m2 BD/TDS daily cnt 7.5 mg/kg 
 
 
Level 1 QD Days 1-7,15-21 100 mg/m2 BD/TDS daily cnt 7.5 mg/kg 
 
 
Level 2 QD Days 1-7,15-21 100 mg/m2 BD/TDS daily cnt 10 mg/kg 
 
 
Level 3 QD Days 1-7,15-21 100 mg/m2 BD/TDS daily cnt 12.5 mg/kg 
 
 
Level 4 
(started June 06) 
QD Days 1-7,15-21 125 mg/m2 BD/TDS daily cnt 7.5 mg/kg 
 
 
Level 5 QD Days 1-7,15-21 125 mg/m2 BD/TDS daily cnt 10 mg/kg 
 
 
Level 5a QD daily 75 mg/m2 BD/TDS daily cnt 10 mg/kg 
 
 
Level 6 QD Days 1-7,15-21 125 mg/m2 BD/TDS daily cnt 12.5 mg/kg 
 
 
Level 7 QD Days 1-7,15-21 125 mg/m2 BD/TDS daily cnt 15 mg/kg 
Level 8 QD Days 1-7,15-21 150 mg/m2 BD/TDS daily cnt 7.5 mg/kg 
Level 9 QD Days 1-7,15-21 150 mg/m2 BD/TDS daily cnt 10 mg/kg 
Level 10 QD Days 1-7,15-21 150 mg/m2 BD/TDS daily cnt 12.5 mg/kg 
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For those patients who had given fully informed consent and wished to take part in 
this scientific sub-study, a 50 ml blood sample was taken before, during and after (0, 
6-12 and 24-48 weeks)  the onset of their treatment regimen, whether conventionally-
dosed or on the metronomic schedule. Blood samples were taken at the same time as 
routine blood tests, so that no extra needle-stick was incurred. If patients chose not to 
be part of this sub-study, it had no influence on their treatment options or 
management. 
 
Four healthy volunteers - age and gender matched - acted as the control group. These 
were patients attending a routine benign skin lesion clinic within the same hospital 
trust. They were asked to participate in a similar manner to the patient group. They 
were also given a relevant information leaflet (see Appendix 2.3) detailing the 
proposed study to read in their own time. If they then wished to participate, they were 
asked to sign a consent form (see Appendix 2.4). One 50 ml sample of the volunteer's 
blood was required, and then processed in the same way as the patient samples. 
 
All blood samples were coded anonymously before transfer to the laboratory. All 
patient and healthy volunteer details were maintained in the coded form and stored on 
a password protected computer.  
 
Patient Enrolment 
Inclusion Criteria – each patient had to meet all these to be considered for enrolment 
in the chemotherapy trial, and therefore in the scientific sub-study: 
 
? Malignant Melanoma AJCC stage IV 
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? Clinically staged and deemed suitable for a combined regimen of temozolomide 
and estramustine. 
? Able to give written consent 
Exclusion Criteria - a patient was not enrolled to either study if any of these criteria 
applied: 
 
? Tumour other than melanoma  
? Pregnant or lactating patients. 
? Patients with reproductive potential not taking adequate contraception. 
? Concurrent administration of other experimental or investigational agents. 
? Other illnesses that may have effects on progenitor cells (e.g. Lymphoma, 
autoimmune diseases etc). 
? Patients who had been previously exposed to any of the trial treatement 
regimens. 
 
2.2.2 Isolation of CEPs and CECs using MACS® Technology 
 
2.2.2.1 Preparation of PBMCs  
 
The isolation of CEPs and CECs from peripheral blood is a process which involves 
numerous steps. The first few steps were carried out in order to isolate the peripheral 
blood mononuclear cells from the fresh blood samples. Following this, MACS® 
Technology (Miltenyi Biotech) was used, which has become one of the standard 
methods worldwide for cell separation. When performing MACS® separations from 
human blood samples, whole blood as well as pre-enriched peripheral blood 
mononuclear cells (PBMCs) can be used.  
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2.2.2.2 Sample preparation from fresh whole blood 
 
Firstly, 50 mls of freshly drawn blood was taken from a consented participant using a 
pre-heparinised 50ml syringe under aseptic technique. Each syringe contained 1ml of 
heparin-sodium solution (1000U per mL heparin with a pH of 7.5). The sample was 
then taken to the laboratory for processing, which was carried out within a 2 hour 
window. During this time, samples were gently agitated to minimise risk of blood 
clotting or separating. Samples were then diluted with 2 times the volume of 
phosphate buffered saline (pH 7.4) (PBS- see Appendix 1).  
 
2.2.2.3 Density gradient centrifugation 
 
Each diluted whole-blood sample was then divided into 35 ml quantitites, and layered 
over 15ml of Histopaque (Sigma) in a 50ml tube and centrifuged at 400g for 30 
minutes at 40c in a swinging-bucket rotor (without brake). The middle layer was then 
aspirated, taking particular care to aspirate the mononuclear cell layer at the 
interphase between the top layer of serum and the bottom layer of red cells (See 
Figure 2.2).  The interphase cells (lymphocytes, monocytes and thrombocytes) were 
then transferred to a new 50ml tube, and washed again in PBS. This tube was then 
centrifuged at 300g for 10 minutes. The supernatant was then carefully removed 
completely. In order to remove platelets, the cell pellet was then resuspended in 50 ml 
of PBS and centrifuged again at 200g for a further 10 min. Most platelets remain in 
the supernatant upon centrifugation at 200g. The supernatant was then removed 
again, and a cell count performed, having resuspended the cells in 1ml of peripheral 
blood mononuclear cell (PBMC) freeze media (see Appendix 1).  
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Figure 2.2: Density Gradient Centrifugation for the isolation of PBMCs 
 
 
 
 
 
 
Photograph taken in laboratory during processing of whole blood samples 
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2.2.2.4 Sample storage  
 
Freezing 
Cryovials were labelled with the appropriate sample code, date and cell number 
information. Freezing medium (Appendix 1) was prepared from 90% fetal bovine 
serum and 10% dimethyl sulfoxide (DMSO), and then chilled on ice. Cells were then 
resuspended in freezing media at 1-1.5 x107 cells/ml (using same cell counting 
technique as in section 2.1.1.4) and transferred to the appropriate number of cryovials 
per sample (usually 2-3). The vials were then placed in the Nalgene ‘Mr Frosty’(as 
described below) which was pre-chilled in the refrigerator at 40C. Once the samples 
were transferred to the ‘Mr Frosty’, they were then transferred into a liquid nitrogen 
cell storage system 24 hours later. 
 
The Nalgene ‘Mr Frosty’ is a cryo 1oC freezing container. It has an internal high-
density polyethylene vial holder and foam insert within a polycarbonate unit. It is 
prepared by removing the holder and insert, and adding 250ml of 100% isopropyl 
alcohol to fill up to a pre-marked level which ensures that the vial holder will be 
surrounded by the isopropyl. The foam-insert and vial holder are then replaced, and 
the unit cooled in the refrigerator prior to the prepared vials being placed into holes in 
the vial holder. The whole unit is then placed in the -800C freezer, and allows a slow, 
even freezing process to take place, which aids in limiting cell damage and ice-crystal 
formation.     
 
Thawing 
The cryovial due to be processed was transferred from the liquid nitrogen into a 370C 
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water bath. It was held in the water bath, with the occasional ‘flick’ until a small 
amount of ice remained. The cryovial was then dried on its exterior to avoid 
contamination, prior to being transferred to the tissue culture. The cryovial contents 
were then transferred into a 15mL tube, and thaw media (90% RPMI + 10% FBS at 
40C) was then added drop wise to the cell suspension. Having added 1mL, further 
thaw media was added slowly, first 2mL, then 4mL. This was then centrifuged at 
250g for 10 minutes, and a further wash was then carried out – again using the thaw 
media. A cell count was then carried out before proceeding to the next step of 
magnetic labelling.  
 
2.2.2.5 MACS® Technology – cell separation 
 
MACS® Technology has become the standard method for cell separation, with 
numerous publications proving its versatility for multiple applications, from the 
laboratory bench to clinical applications, from frequently occurring cells to rare 
subsets (Jarrossay D et al 2001; Raia V et al 2007; Strijbos M et al 2008). The 
technology is based on MACS® Microbeads, MACS® Separators, and MACS® 
columns. MACS® microbeads are supermagnetic particles of approximately 50 
nanometers in diameter. They are composed of a biodegradable matrix made up of 
iron oxide and polysaccharide, and therefore it is not necessary to remove them from 
cells after cell separation as they typically degrade after a few days in culture. They 
do not alter structure, function or activity status of cells (Kronick P and Gilpin R 
1986; Miltenyi S et al 1990). MACS® Columns are the site of cell separation. 
Columns are placed in a MACS® Separator which is a strong permanent magnet. This 
creates a high-gradient magnetic field which is induced on the matrix of the column, 
strong enough to retain cells with minimal amounts of MACS® Microbeads. Cells 
 102
without microbeads attached (unlabelled cells) pass through the column and can be 
collected; cells with microbeads attached (labelled cells) are released after removal of 
the column from the magnet. Therefore, both labelled and unlabelled fractions can be 
easily isolated with a high level of purity (see Figure 2.3). 
 
MACS® Technology allows a number of different cell separation strategies, and in 
this case both ‘positive selection’ and ‘depletion’ strategies are employed. ‘Positive 
selection’ means that the desired target cells are magnetically labelled and isolated as 
the magnetically retained cell fraction within the column. This strategy gives a high 
level of purity, especially for rare cell enrichment. ‘Depletion’ or ‘untouched 
isolation’ is performed by depleting the undesired cells. Non-target cells are 
magnetically labelled and eliminated from the cell mixture. The non-magnetic, 
untouched cell fraction which passes through the column contains the target cells 
(Safarik I and Safarikova M 1999). This is used for removal of unwanted cells; if no 
specific antibody is available for the target cells or for subsequent isolation of a cell 
subset by means of positive selection. 
In this case, depletion was followed by positive selection, whereby the non-target 
cells are removed initially from the sample, and then the cell subset of interest is 
positively selected for. This is very useful as it depletes the non-target cells, leaving a 
pre-enriched fraction from which a pure cell sample can be eluted. 
2.2.2.6 Depletion stage with CD45 MACS® MicroBeads 
 
The application of CD45 Microbeads has been described (Meye A 2002) for 
enrichment of tumour cells from peripheral blood by the depletion of CD45+  
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Figure 2.3: MACS® Microbead Separation 
 
 
Antibody-microbead targets surface marker of specific cell – direct magnetic cell 
labelling 
 
                                       
 
                                       
 
Magnetic separation: 
The column is placed in the magnet, rinsed with buffer and labelled cells passed 
through. The effluent of unlabelled cells is collected, the column washed again with 
buffer, effluent is centrifuged and then a cell count is performed. 
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leucocytes. The CD45 antigen is expressed on all cells of haematopoietic origin 
except erythrocytes, platelets and their precursors. CD45 MicroBeads (cat #130-045-
801 Miltenyi Biotec) were used in this case for depletion of leucocytes from 
peripheral blood. Reagents required for this stage included MACS buffer (see 
Appendix 1). This was kept cold at all times between 2-8oC.   
 
The steps were carried out quickly, using pre-cooled solutions. This helps to prevent 
capping of antibodies on the cell surface and non-specific cell labelling. Capping has 
a number of proposed mechanisms, but essentially occurs on motile cells and is 
energy-dependant. It is a feature of molecules that are crosslinked, such as antibodies. 
If antibodies and cells are bound when cool (2-80C), patchy groups of antigen-
antibody complex form around the cell. However, if warmed, they move to the back 
of the cell to form a ‘cap’. Pre-cooling solutions aid in preventing this.  Volumes 
given for magnetic labelling apply to samples up to 107 cells. When working with 
higher cell numbers, reagent volumes were scaled up e.g. 2x107 total cells required 
double reagent volumes.   
Labelling 
Firstly, for each sample the cell number was determined using the same cell counting 
techniques as previously described (section 2.1.1.4). The cell sample was then placed 
in the centrifuge and spun at 300g for 10 minutes. The supernatant was then aspirated 
completely and the cell pellet resuspended in 80µL of MACS buffer in a 
microcentrifuge tube. For every 107 cells present in the tube, 20µL of CD45 
MicroBeads were added. The sample was then mixed well and incubated for 10 
minutes at 40c. The cells were then washed with 2mLs of MACS buffer (see 
Appendix 1) per 107 cells and centrifuged again at 300g for 10 minutes. The 
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supernatant was then aspirated completely and the pellet resuspended in 500µL of 
MACS buffer for any cell number up to 108. 
Magnetic Separation 
The LD column (cat # 130-042-901) was placed in the magnetic field of the MACS® 
Separator, and rinsed with 2mL of MACS buffer. The labelled cells were then passed 
through the column, and the effluent of unlabelled cells collected. The LD column 
was then washed with 2 x 1mL of MACS buffer, only adding the second 1mL of 
MACS buffer once the column reservoir was empty. The total effluent was then 
centrifuged at 300g for 10 minutes, the supernatant aspirated and the cell pellet 
resuspended in 300µL of buffer for up to 108 cells. At this point, a further cell count 
was carried out (see figure 2.4 for schematic).   
  
2.2.2.7 Positive selection with CD34 MACS® MicroBeads 
CD34 MACS® MicroBeads are used for identification and enumeration of CD34+ 
cells by flow cytometry or fluorescence microscopy. They are useful in studies of 
phenotyping haematopoietic stem cells and haematologic malignancies, but also in 
the study of non-haematopoietic stem cells and in this case, CECs and CEPs (Peichev 
M et al 2000; Rafii S et al 2002). The CD34 antigen is a single chain transmembrane 
glycoprotein, expressed on human haematopoietic stem and progenitor cells, 
enodothelial progenitor cells, vascular endothelial cells, embryonic fibroblasts and 
some cells in fetal and adult nervous tissue (de Wynter EA et al 1998). MACS buffer 
was used for all steps in the labelling and separation stages of this process. The buffer 
was made up in the same way as described in Appendix 1, and kept cold at all times 
between 2-8oc, working quickly through each of the stages. 
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Labelling 
The cell number for this step was determined as per previously described cell 
counting technique (section 2.1.1.4) at the end of magnetic separation with CD45 
MicroBeads (cat #130-045-801 Miltenyi Biotec). This was followed by addition of 
100µL of FcR blocking reagent (see Appendix 1) and 100µL of CD34 MicroBeads 
(cat #130-046-702 Miltenyi Biotec) to the sample, for any cell number up to a 
maximum of 108 cells. Incubation with FcR blocking reagent increases the specificity 
of antibody or MicroBead labelling, thereby improving the purity of target cells – in 
this case, endothelial cells. The sample was then incubated at 4oC for 30 minutes at 2-
8oc. The cells were then washed by adding 5-10mL of MACS buffer for up to 108 
cells and centrifuged at 300g for 10 minutes. The supernatant was then aspirated 
completely and the pellet resuspended in 500µL of MACS buffer.  
Magnetic Separation   
The MS column (cat #130-042-201 Miltenyi Biotec) was then placed in the magnetic 
field, and prepared by rinsing through with 500µL of MACS buffer. The labelled cell 
suspension was then applied onto the column, and the unlabelled cells collected 
(depleted of CD34+ cells). The column was then washed with 3x500µL of MACS 
buffer, only adding new buffer when the column reservoir was empty. The total 
effluent was then collected, being the unlabelled cell fraction. The column was then 
removed from the magnetic field and placed over a 15mL tube. 1mL of MACS buffer 
was then added to the column and the positively-selected CD34+ fraction was 
immediately flushed out by pushing the plunger into the column. Then the sample 
was washed with 10mL of MACS buffer, and spun at 300g for 10 minutes in the 
centrifuge. The spun sample was then resuspended in 100µL of MACS buffer and 
divided into two in order to generate a negative control for each sample (figure 2.4).    
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Figure 2.4: Schematic flow diagram to show steps of depletion followed by positive 
selection (MACS Technology)  
 
 
Undesired cells – CD45 positive, are retained in column. Unlabelled fraction 
containing target cells is then labelled with CD34 and target cells and positively 
selected. 
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2.2.2.8 Immunofluorescent staining with MACS® CD34-FITC and CD133/2 
(293C3) antibodies 
 
The CD34-FITC (cat #130-081-001 Miltenyi Biotec) in this case was used for 
identification and enumeration of CD34+ cells (CECs and CEPs) by flow cytometry. 
Identification occurs since the CD34-FITC is composed of monoclonal antibodies 
(Clone AC136) which recognise a class III epitope of the CD34 antigen with high 
specificity. Antibodies are conjugated to the FITC tag and are supplied in solution 
containing stabiliser and 0.05% sodium azide.  
 
CD133 is a relatively novel 5-transmembrane cell surface antigen (Miraglia S 1997). 
The CD133/2 (clone 293C3) antibody recognises an epitope of the CD133 antigen 
(Yin A et al 1997). The epitope is called epitope 2 in order to distinguish it from 
another epitope which is recognised by different clones. In the haematopoietic 
system, CD133 expression is limited to a subset of CD34 bright stem and progenitor 
cells in human fetal liver, peripheral blood, cord blood and bone marrow (Buhring H 
et al 1999). In 2000, CD133 was found to be expressed on circulating endothelial 
progenitor cells (Gehling U et al 2000; Peichev M et al 2000) as well as on other 
tissue-specific stem cells.  Therefore, in this case, the CD133/2 antibody (CD133/2-
PE: cat #130-090-853 Miltenyi Biotec) was used to identify and enumerate CEPs and 
isolate them from the rest of the CD34+ population.  
 
The immunofluorescent staining was carried out by taking the positively-selected 
CD34+ cell fraction produced from the previous magnetic separation step, already 
resuspended in 100µL of MACS buffer and divided into 2 in order to allow for a 
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negative control. 10µL of the CD34-FITC and 10µL of the CD133/2-PE antibodies 
were then added to one sample. This sample was labelled ‘positive’. 10µL of negative 
control mouse Ab-FITC tag and negative -PE were added to the other (cat # 130-091-
837 and #130-091-835 respectively). This was to act as the ‘negative’ control and the 
same process was carried out for each of the samples. Each was then mixed well and 
placed at 4oC for 10 minutes in the dark. When working with more than 107 cells, 
reagent volumes were scaled up e.g. with 2x107 cells, twice the volume of all reagent 
and total volumes were used.  The cells were then washed by adding 1-2mL of 
MACS buffer per 107 cells and spun in the centrifuge at 300g for 10 minutes. The 
supernatant was then aspirated completely, and the pellet resuspended in 100µL of 
FACS buffer prior to FACS analysis (see Appendix 1).  
 
2.2.3 Flow Cytometry and Fluorescence activated cell sorting (FACS) 
Flow cytometry has long been a widely accepted tool for immunophenotyping of 
cells. It offers a rapid, objective and quantitative method for analysis and purification 
of cells in suspension. The concept of flow cytometry is based on cells or other 
particles interacting with a light beam as they pass by single file in a liquid stream. A 
number of detectors are aimed at the point where the stream passes through the light 
beam: one in line with the light beam (forward scatter) and several perpendiculars to 
it (side scatter) (figure 2.5). If a fluorochrome is specifically and stoichiometrically 
bound to a cellular component, the fluorescence intensity will ideally represent the 
amount of that particular cellular component. Multiparameter flow cytometry, as used 
in this study, allows high-accuracy estimation of relative quantities of a variety of 
cells simultaneously. When measurements are recorded in a list mode, it is possible to 
attribute each of the several measured features to a particular cell and thus to obtain  
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Figure 2.5: Forward scatter / side scatter – flow cytometry schematic 
 
The schematic demonstrates the way in which both forward and side-scatter are used 
to generate data regarding cellular composition and size in flow cytometry. 
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correlated measurements of these features on a cell by cell basis. Cellular 
heterogeneity can thus be estimated and subpopulations with distinct characteristics 
can be discriminated (Watson J 1992; Shapiro HM 2003).  
Fluorescence-activated cell sorting (FACS) is a specialised type of flow cytometry. It 
allows individual cells to be physically separated from larger populations, based on a 
composite of parameters. Any set of criteria derived from the flow cytometric 
analysis can be used to activate the sorting decision for the single cell. This is based 
on cellular quantitative expression of molecules or their combination of predefined 
properties. In this study, efficiency and accuracy of cell sorting is increased by prior 
immunomagnetic separation.  
 
In the identification of CECs, and their subset CEPs, a cocktail of fluorochrome-
labelled monoclonal-antibodies can be used. The level of antigen expression is 
expressed as bright, dim or negative, allowing differentiation of these cell populations 
in FACS analysis.  Test samples, from patients with known metastatic melanoma 
stored from a previous study (LREC 05/Q1105/76), were used to set the appropriate 
anaylsis gates. The participants of this previous study had been fully informed and 
had consented to use of any surplus samples in future similar studies within the 
department. As the test samples were passed through the laser beam, forward scatter 
(relating to cell size) and side-scatter (relating to cell complexity and granularity) 
allow the generation of plots. These are combined by the FACS software in order to 
generate 2-dimensional dot or scatter plots which allow differentiation of the cell 
populations based on fluorescence intensity. This generated series of subset extrations 
are termed ‘gates’. A forward scatter threshold was set in all analyses for this study in 
order to eliminate small cells and debris.  A typical blood cell run would show 
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distinct cell populations (using CD45-PE) i.e. lymphocytes, monocytes and 
neutrophils (see figure 2.6). Each marked or labelled cell generates a certain amount 
of light, depending on the fluorescence, and this is converted into a voltage pulse, 
which is in turn converted into a numerical value, based on voltage pulse area or 
height. This value is then used to plot the intensity of the event, which is produced on 
a log histogram where cell count is plotted on the y axis, and fluorescence on the x 
axis. The use of 2 different fluorochromes i.e. Ab-FITC and Ab-PE in each cell 
sample tested which have different emission properties allows generation of a 4 
quadrant dot/scatter plot. .  
Based on cell position in the forward versus side-scatter histogram, a distinct 
population can be gated around. This was done by drawing a box using the FACS 
software, around the cell population of interest, and from this distinct population, a 
more accurate histogram to demonstrate sub-sets within this, i.e.CD34+CD133+ 
versus CD34+CD133- was generated. Compensation was made for spectral overlap of 
fluorescence by use of control samples prior to each study sample being passed 
through the flow cytometer. For each sample, after acquisition of at least 100,000 
cells, analyses were considered as informative when adequate numbers of events 
i.e.>100, were collected in the CECs and CEPs enumeration gates. Data was then 
analysed using the BD FACSCalibur (BD Biosciences UK) software - CellQuest. 
Optimisation of the technique will be discussed in chapter 5. 
2.2.4 Statistical analysis of results generated from FACS 
Statistical analysis was performed using SPSS. The Kolmogorov-Smirnov test was 
used to determine if the CEC and CEP were normally distributed. The null hypothesis 
of normality was rejected if the p value of the Z statistic was < .05. The 
measurements  
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Figure 2.6: Typical blood cell run showing distinct cell populations: 
lymphocytes, monocytes and neutrophils.  
 
FSC = forward scatter 
SSC = side scatter 
 
These examples are from test samples done for this study showing the three distinct 
cell populations and the generation of a log histogram from the scatter plot. This is 
using CD45-PE. 
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of CEC and CEP were summarized using descriptive statistics (means, standard 
deviations, and 95% confidence intervals). One-way analysis of variance (ANOVA) 
was used to test the null hypothesis that the mean baseline (pre-treatment) CEC and 
CEP values were the same in the three groups. One-way repeated measures ANOVA 
was used to test the null hypothesis that the mean differences between the repeated 
measures (pre-treatment minus mid-treatment, or pre-treatment minus post-treatment) 
were the same in the two treatment groups. The null hypothesis was rejected if the p 
value of the F statistic was < .05. Effect sizes were compared using the Eta2 statistic. 
Levene’s test was used to check for equality of variance. The null hypothesis of 
equality of variance was rejected if the p value of Levene’s statistic was < .05. 
Statistics advice was taken from Fishers statistics online tool (www.fisherstat.com) 
and Dr S Wright – University of Cardiff. 
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Chapter 3 
Chemotherapeutic and anti-angiogenic agents given as single agents in an 
extended-dosing schedule using the in vitro MVEC model.   
 
3.1 Aims and Introduction 
 
The aims of the first part of the in vitro study described in this chapter are: 
1. To establish the in vitro model, using micro-vascular endothelial cells 
2. To test the anti-endothelial and anti-cancer effects of oral chemotherapeutic agents 
and specific anti-angiogenic agents given in an extended low dosing schedule, given 
as single-agents  
3.  To determine the ‘metronomic’ dose of oral chemotherapeutic agents based on the 
dose at which significant anti-endothelial effects were seen. Suitable single-agents, at 
these determined doses, will be taken forward to use in combination with specific 
anti-angiogenics (described further in chapter 4). 
 
The strategy of metronomic chemotherapy (see section 1.3.1 and 1.3.2), especially in 
combination with novel specific anti-angiogenic agents (section 1.3.4), has shown 
promising outcomes in pre-clinical and clinical studies (Bottini A et al 2006; Colleoni 
M et al 2006; Lam T et al 2007; Lee S et al  2007; Vrendenburgh J et al 2007; Garcia 
A et al 2008). However, there are still numerous uncertainties surrounding this 
strategy. These include identifying the most suitable cytotoxic drugs; establishing the 
optimal dosing and frequency schedule; determining the biological activity through 
surrogate markers and determining the potential acquirement of drug resistance 
(Maraveyas A et al 2005). All these uncertainties require as many answers as possible 
for each drug and potential combinations of drugs before they go forward into the 
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oncology clinic to be used in treatment regimens (Lam T et al 2007). With the 
proliferation of agents, an increasing number of which are now available in the oral 
form, there is a need to develop a useful screening tool for defining these 
uncertainties. Since the underlying principle of metronomic scheduling is to induce an 
anti-angiogenic effect, the use of an in vitro endothelial model provides a useful 
starting point from which more extensive investigations can be carried out.  
 
Given that the term ‘metronomic’ seems to encompass a fairly broad dose range (10-
33% of MTD – section 1.3) it is not clear whether there is a greater or smaller benefit 
at higher levels of this range. The clinical principle formulated for these pleiotropic 
cytotoxic agents (both anti-tumour and anti-angiogenic) is that one should aim to 
deliver as high a dose as possible within the metronomic range before conventional 
bone marrow toxicity is seen (Maraveyas A et al 2005). The avoidance of bone 
marrow toxicity is crucial given that bone-marrow recovery is a profoundly pro-
angiogenic event and would potentially negate any anti-angiogenic gains.  
 
The concept of ‘high-time’ chemotherapy, defined as the longest possible period of 
drug exposure at a given desired drug concentration, is very useful for long-term 
therapy, but requires careful assessment of the pharmacokinetics and 
pharmacodynamics of the drugs involved (Kamen B et al 2000). Dose-density 
chemotherapy, however, is completely different, being based on administering 
multiple cycles of conventional dosed cytotoxic doses of chemotherapy often with the 
support of growth factors, with short intervals in between weekly or fortnightly 
schedules, to reach the highest possible dose (Fornier M et al 2007). It is therefore 
necessary to develop tools that allow determination of the correct optimal dose for 
 117
these cytotoxics to be given in extended schedules, as opposed to an empirically 
devised 10-33% of traditionally calculated MTD. This form of dosing ‘mantra’ in the 
absence of distinguishable supporting scientific principles may hinder acceptance and 
development of these strategies. 
 
The in vitro MVEC model is used in this study calls for a more rigorous 
determination of the ‘metronomic’ dose. This is based on the dose at which 
statistically significant in vitro endothelial cell inhibition occurs, rather than on an 
empirical value. Some inter-assay standardaization is possible this way and a 
comparison between the effects of different agents can be more robust. The dosing at 
which this is achieved can be extrapolated to known conventional dosing schedules of 
this drug, hence giving an indication of the potency of the dose at which 
‘metronomic’ effects are seen in the in vitro model we describe.  In vitro studies 
cannot be directly transposed to the clinic, but provide a starting point as to which of 
the many traditional agents might be suitable for the anti-angiogenic approach, and a 
guide-line as to which dose levels induce an anti-endothelial response. 
 
3.1.1 Rationale of using MVEC proliferation as a surrogate marker of 
angiogenesis in vitro.  
 
Angiogenesis involves endothelial cells in three principal events, namely migration, 
proliferation and maturation (Griffioen A et al 2000). The proliferation of endothelial 
cells is therefore a crucial step in the formation of tumour vasculature and many in 
vitro models of angiogenesis include this as a key parameter. A number of previous 
studies have looked at the antiangiogenic activity of metronomic chemotherapy. The 
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first in vitro ‘metronomic’ protocol was devised by Bocci and co-workers (Bocci G et 
al 2002). They looked at the effects of several cytotoxic agents including paclitaxel 
and cyclophosphamide on human microvascular and macrovascular endothelial cells, 
fibroblasts, drug-sensitive or multidrug-resistant breast cancer cell lines in cell 
culture. This was using either short-term (i.e. 24 hours) or long-term (i.e. 144 hours) 
continuous drug exposure times where the media was replaced every 24 hours. They 
found that continuous long-term exposure protocol demonstrated a dramatic trend of 
comparative vascular endothelial cell hypersensitivity in terms of growth inhibition to 
low drug doses compared with the other cell types.  
 
Following on from this, further studies have been carried out whereby in vitro 
endothelial cell proliferation is used as a marker of angiogenesis (Vacca A et al 1999; 
Yap R et al 2005; Lam T et al 2007). Anti-angiogenic efficacy in these studies has 
been shown to be enhanced when cytotoxic drugs were administered in ‘metronomic’ 
schedules and also when combined with molecularly-targeted anti-angiogenic agents. 
Clinical trials have been underway over the last seven years to confirm these pre-
clinical findings, showing promising results (Colleoni M et al 2001; Buckstein R et al 
2006; Colleoni M et al 2006; Orlando L et al 2006).  
 
However, the use of in vitro models based on MVECs or any other endothelial cell 
type to represent tumour endothelium is not without problems. The simplified 
demonstration of inhibitory effects on an endothelial cell model in vitro fails to take 
into account the anatomical complexity of tumour-related vasculature, including the 
stromal components. No in vitro model is truly representative of the in vivo process, 
and should always be regarded as an approximation as opposed to a true 
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representation. 
 
In vitro chemosensitivity assays, however, do play a crucial role in the development 
of novel therapeutic strategies, especially when devising phase I clinical trials (Schrag 
D et al 2004). They are easily reproducible, and provide a useful guide to define dose 
ranges, determine potentially useful combinations and determine the presence of 
synergy between agents. The use of microvascular endothelial cells, as in this study, 
has been shown to be more closely representative of the microvasculature within 
tumours than  HUVECs (Bocci G et al 2002; Lam T et al 2007) or other endothelial 
cell types. This adds weight to our findings.  
 
3.1.2 Selection of cytotoxic drugs for metronomic chemotherapeutic dosing and 
the rationale behind the chosen dose-range 
 
The following cytotoxic drugs are all traditional chemotherapeutic agents that have 
been used in the oncology clinic in the conventional sense i.e. MTD, for the treatment 
of a range of adult malignancies. The explanation and justification for using each of 
these agents in a metronomic schedule is given below. The dose-range chosen for 
each cytotoxic agent tested is also explained. 
  
3.1.2.1 Temozolomide 
Temozolomide is an alkylating agent descended from the anti-melanoma compound 
dacarbazine (DTIC). It is an analogue of mitozolomide, and when ingested, rapidly 
degrades to a highly reactive cation that methylates guanines in DNA, causing base 
pair mismatch. This eventually leads to inhibition of mitotic division via permanent 
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damage to the daughter strand (Darkes MJM et al 2002). It is therefore a prodrug, in 
that it is converted to its active product on ingestion, and has excellent bio-
distribution (Newlands E et al 1997). It was originally developed as an alternative to 
DTIC – which requires metabolic activation (see Figure 3.1a for structure). It is now 
licensed for use (FDA approval) as an oral agent in the treatment of metastatic 
melanoma and certain brain tumours – refractory anaplastic astrocytoma (Dhodapkar 
M et al 1997; Darkes et al MJM 2002; Azzabi A et al 2005).  
 
Since temozolomide is suitable for use in metronomic dosing schedules and also has 
generic anti-melanoma properties, it is an obvious compound to be included in this 
study (mention prodrug derivative). It is also one of the agents which comprise the 
treatment regimen for patients recruited into the clinical study (Chapter 5) – one 
group being on conventional intravenous DTIC and the other being on 
metronomically dosed Temozolomide.  
 
In Phase I clinical studies of Temozolomide, daily oral 5-day schedules of the drug 
demonstrated a maximum tolerated dose of 250mg/m2/day, with thrombocytopenia 
and neutropenia as major dose limiting toxicities (Dhodapkar M et al 1997). At 
50mg/m2/day and 225mg/m2/day, after 5 days of treatment, the Cmax values attained 
were 16µM and 63.9µM respectively. This provided preliminary evidence to support 
the use of Temozolomide in a combined metronomic protocol at 1-5% of MTD.   
 
A further Phase I study was conducted by Brock and colleagues in patients with 
malignant glioma (Brock C et al 1998). This explored the dose-limiting toxicity and 
MTD of Temozolomide when administered as a single, daily dose for 6-7 weeks. 
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They found that grade 4 myelotoxicity was seen at 100mg/m2/day, forcing dose 
reductions to 75mg/m2/day. At this level, haematological toxicities did not exceed 
grade 2 in ten patients treated. Significant clinical responses were seen in this patient 
group, and another more recent phase I trial confirmed these results, using a 21 day 
out of 28 day dosing schedule. A further study by Kurzen and colleagues showed that 
non-toxic doses of Temozolomide inhibited endothelial cell proliferation and 
differentiation (Kurzen H et al 2003).  
 
Temozolomide has been tested in vitro on HUVECs in combined metronomic 
schedules previously (Lam T et al 2007) and revealed promising results. On its own, 
Temozolomide inhibited HUVECs specifically at doses as low as 2.5µM (1-5% of 
MTD). In light of this, a rational approach towards defining starting doses for 
cytotoxic agents given in such metronomic schedules was proposed (Maraveyas A et 
al 2005). The dose range selected here (0-50µM) was therefore based on the previous 
in vitro work carried out and also by calculating the MTD from phase I data, and 
ensuring that the dose range selected covered a wide range but was well below the 
empirically recommended upper limit of 33% of MTD (see table 2.1 for summary).   
 
3.1.2.2 Paclitaxel 
 
Paclitaxel is a mitotic inhibitor that acts at a microtubular level. It was first isolated 
from the bark of the Pacific yew tree, Taxus brevifolia, four decades ago. This again 
is a well tolerated orally bioavailable agent, and has shown promising anti-tumour 
activity in a number of solid tumours including ovarian, breast, lung and prostate. See 
Figure 3.1b for chemical structure. It has proven efficacy in metronomic regimens, 
both as a single agent and in combinations in both in vitro and in vivo studies.(Belotti 
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D et al 1996; Bocci G et al 2002; Grant DS et al 2003; Wang J et al 2003; Lam T et 
al 2007). Anti-angiogenic properties have been shown by paclitaxel’s ability to 
inhibit endothelial cell proliferation at concentrations lower than those required to 
inhibit tumour cell proliferation (Belotti D et al 1996; Drevs J et al 2004; Albertsson 
P et al 2006). 
 
Previous pharmacokinetic studies involving paclitaxel have shown that 6 hour 
infusions and 24 hour infusions, each administered once every 3 weeks, resulted in an 
MTD of 250mg/m2 and corresponding Cmax values of 13µM and 1µM respectively 
(Rowinsky EK et al 1992).  The data suggests that paclitaxel may be used at less than 
15% MTD as part of a combined ‘metronomic’ protocol to induce a significant anti-
endothelial response. Bocci and colleagues demonstrated that ECS scheduling with 
several cytotoxic agents including paclitaxel caused significant apopotosis in 
endothelial cells after 6 days of treatment (Bocci G et al 2002). This was also 
demonstrated by Wang and colleagues (Wang W and Passaniti A 1999; Grant DS et 
al 2003). Other potential anti-angiogenic mechanistic effects of paclitaxel that have 
been demonstrated include reduction in endothelial cell interstitial pressure (Griffon-
Etienne G et al1999), increases in matrix metalloproteinases (MMP) and increases in 
tissue inhibitor of matrix metalloproteinases (TIMP) (Alonso DF et al 1999).  
Mention Phase I pharmacokinetic data (see table 2.1) 
 
Paclitaxel is currently used mainly in its intravenous form. It has a low therapeutic 
index and is virtually insoluble in water, hence its mixture with Cremophor EL – a 
mixture of ethanol and polyoxyethylated castor oil. Initial trials into its use as an oral 
compound showed poor bioavailability, most likely due to its affinity to the 
membrane-bound drug efflux pump P-glycoprotein (P-gp). However, when 
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administered with P-gp inhibitors, such as cyclosporin-A, oral bioavailability was 
greatly enhanced. This has shown potential in Phase II studies, making paclitaxel a 
potentially significant metronomic agent of the future (Yang S et al 2004). Paclitaxel 
was therefore deemed a suitable agent to use in this study, and interesting to compare 
the effects on MVECs to the effects on HUVECs as previously studied in our group 
(Lam T et al 2007). The dose range selected (0-2nM) was therefore based on the 
previous in vitro work afore mentioned and phase I data, covering a wide range of 
doses, all less than 20% of the MTD.  
 
3.1.2.3 Vinorelbine 
 
This is the first semi-synthetic vinca alkaloid, obtained from alkaloid extracts 
obtained from the rosy periwinkle (see Figure 3.1c for chemical structure). It gained 
approval to treat non-small cell lung cancer in 1991, and has since been used in the 
treatment of breast and prostate cancer also (Rowinsky EK et al 1994). An oral 
formulation was licensed for use in 2004 which has similar efficacy and safety profile 
to the intravenous form. This makes it another agent potentially suited to the 
metronomic approach and for use in this study (Rowinsky EK et al 1994; Marty M et 
al 2001). It has similarly been studied using an in vitro human endothelial cell model 
to assess its antiangiogenic effects, although clinical extrapolation of these princliples 
are still awaited (Pappas P et al 2008).   Vinblastine, a family member of vinorelbine,  
has also been shown to have impact on in vitro endothelial cell function, proliferation, 
chemotaxis and vascular morphogenesis (Vacca A et al 1999). 
 
Phase I pharmacokinetic data showed that after oral administration of 80mg/m2, 
vinorelbine was rapidly absorbed with a mean peak blood concentration (Cmax) of 
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133.4 ± 42.3 ng ml-1 at 1.4 ± 0.7 hr (Tmax). The dose range selected for vinorelbine in 
this study was therefore based on phase I data and on previous in vitro studies. 0-33% 
of MTD correlated to a dose range of 0-10 µM (see table 2.1).  
  
3.1.2.4 Etoposide 
 
Etoposide phosphate is an inhibitor of the enzyme topoisomerase II, with anti-mitotic 
and antineoplastic properties (see Figure 3.1d for chemical structure). It is used in the 
treatment of Ewing’s sarcoma, lung cancer, testicular cancer, leukaemias and 
lymphomas. It can be given in the oral or intravenous form, with comparable efficacy, 
again making it an appropriate agent for the anti-angiogenic approach (Markman M et 
al 1992; Sessa C et al 1995). Phase II trials have shown that, given in an extended 
dosing schedules, results are comparible with conventional dosing regimens in lung 
cancer, although further studies are required (Grunberg S et al 1993; Greco A and 
Hainsworth J 1994). The clinical formulation does however suffer from variable 
absorption and unpredictable bone marrow toxicity (Sessa C et al 1995). 
 
It has been shown to induce endothelial cell inhibition, with IC50 values significantly 
lower than tumour cells in previous in vitro studies using the HUVEC model, but this 
has not been demonstrated on an MVEC model before (Drevs J et al 2004). The dose 
range selected for etoposide in this study was therefore based on phase I 
pharmacokinetic data from intravenous administration. Sessa and colleagues 
determined that MTDs were defined as 175mg/m2 and 220mg/m2 in previously 
treated and untreated patients respectively (Sessa C et al 1995). 0-33% of the 
calculated MTD translated to a range of 0 to 5µM, the dose range used in this study 
(see table 2.1).  
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3.1.2.5 Carboplatin 
 
Carboplatin is a chemotherapy drug mainly used against ovarian carcinoma, lung and 
head and neck cancers. It was introduced in the late 1980s and has since gained 
popularity in clinical treatment due to its vastly reduced side-effects compared to its 
parent compound cisplatin (see Figure 3.1e for chemical structure). Cisplatin and 
carboplatin as well as oxaliplatin, are classified as DNA alkylating agents. 
Carboplatin causes highly reactive platinum complexes to form intracellularly and 
therefore inhibits DNA synthesis.  
 
Phase I data suggested that the MTD of carboplatin was upto 1000mg/m2 (Gore M et 
al 1987; Shea T et al 1989; Yoshizawa H et al 2003), and it is currently administered 
conventionally in doses of 600-700mg every 3-4 weeks. It is almost exclusively 
excreted by the kidneys, and therefore the total body clearances of ultrafiltratable 
platinum and that of the parent carboplatin molecule correlate linearly with the pre-
treatment glomerular filtration rate. Because of this, physiologic variables such as 
renal function, can affect the plasma concentration of carboplatin in proportion to 
total body clearance. Calvert and colleagues devised a formula which would allow for 
a degree of compensation for physiologic variables, taking into account the renal 
clearance (Calvert AH et al 1989). This minimised resultant toxicities (Alberts D and 
Dorr R 1998; Sato E et al 2006). 
 
Carboplatin as an oral agent, is currently being studied, and is again an interesting 
compound to include in this study. The phase I data (Gore M et al 1987) allowed 
correlation to a suitable dose range for this study, and was calculated as 0-500µM. 
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Figure 3.1: Chemical Structures of Cytotoxic Agents 
 
 
a)Temozolomide 
 
 
b) Paclitaxel 
 
                                               
 
c) Vinorelbine 
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d) Etoposide 
 
                                                     
 
e) Carboplatin 
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3.1.3 Selection of drugs for specific anti-angiogenic agents  
 
It is very important to make a clear distinction here between specific anti-angiogenic 
agents and cytotoxic agents being administered for an anti-angiogenic effect. A 
metronomic dose is not required for specific agents, as the pre-determined dose for 
these agents is already devised based on a safe, daily, oral regimen and they have 
been devised specifically to induce a targeted effect. The cytotoxics, however, have 
up until recently, only ever had MTDs attributed to them. A dose at which anti-
endothelial effects are seen has therefore yet to be determined, which is the 
underlying basis of this study. 
3.1.3.1 Sorafenib 
 
As previously stated (section 1.2.5), this is a small molecule inhibitor of the raf 
kinase, platelet-derived growth factor, VEGF receptors 2 and 3 kinases, and the c kit 
receptor (see Figure 3.2a for molecular structure). It prevents tumour growth by 
combining its anti-angiogenic and anti-proliferative effects (Wilhelm S et al 2004). 
Anti-proliferative activity has been observed in tumours with Ras mutations, as well 
as those in which Ras is activated through activation of growth factor receptors and 
with B-Raf mutations. It has so far shown varying success in clinical trials of renal 
cell carcinoma, hepatocellular carcinoma, malignant melanoma and lung cancer 
(Hanahan D and Folkman J 1996; Mross K et al 2006; Llovet J et al 2008). This drug 
is administered as on oral agent at a dose of 200-400mg twice a day. This translates to 
a suitable AUC of 10 µM. Drug concentrations reflecting this dose were used for the 
combination experiments. 
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3.1.3.2 Combretastatin (CA4P) 
 
This is a vascular targeting and anti-angiogenic agent, originally isolated from the 
southern African shrub, Combretum caffrum (see Figure 3.2b) for molecular 
structure). It has been shown to specifically target proliferating endothelial cells and 
to block mitosis through binding to tubulin causing destabilisation of the cytoskeleton 
and thus inducing apoptosis (Dorr R et al 1996; Dark G et al 1997). This leads to 
blood flow shut down to tumours rather than to surrounding normal tissues ultimately 
producing tumour cell death through oxygen and nutrient starvation. It therefore 
causes tumour necrosis, whilst also displaying antiangiogenic properties, being toxic 
to actively proliferating vascular endothelial cells and various cancer cells at low 
micromolar concentrations (Dorr R et al 1996; Vincent L et al 2005). In contrast to 
other tubulin-binding agents that have significant dose limiting toxicity, CA4P is 
active at one tenth of its MTD giving it an extremely wide therapeutic window (Dark 
G et al 1997). CA4P has shown promising results in clinical trials as a single agent 
and at present is entering a range of combinational therapy trials including a phase I 
trial with bevacizumab and a phase II trial with doxorubicin and cisplatin in patients 
with newly diagnosed thyroid cancer (Cooney M et al 2005; Nathan P et al 2008). It 
is also an orally available agent (Bilenker J et al 2005).  
 
 We preferred to classify this agent as a non-specific antiangiogenic agent more akin 
to chemotherapy rather that a specific agent despite the main body of literature 
alluding to it as an anti-angiogenic molecule. From phase I pharmacokinetic data, the 
dose range selected for CA4P was therefore 0-25nM within which the ‘metronomic’ 
range 10-33% would have been encompassed. . 
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3.1.3.3 Bortezomib 
 
Bortezomib is the first therapeutic proteasome inhibitor to be tested on humans, and is 
now approved in for treating relapsed multiple myeloma and mantle cell lymphoma in 
the US (Druck M et al 2006). FDA approval was granted for this based on striking 
phase II data (Richardson P et al 2003). It is a low-molecular-weight dipeptide which 
inhibits the proteosome by binding to chymotryptic-like enzymes (see Figure 3.2c for 
molecular structure). This prevents degradation of pro-apoptotic factors, permitting 
activation of apoptosis in neoplastic cells. It is therefore not a specific anti-angiogenic 
agent, although it is a molecularly targeted agent, which has good oral bioavailabilty. 
It antiangiogenic properties have been investigated in both preclinical and clinical 
studies, showing some efficacy – contributing to its success in treatment of multiple 
myeloma (Politou M et al 2005). This makes it suitable for comparative purposes in 
this study.  
Phase I data suggested MTD to be 1.3mg/m2 (Dees E et al 2008). A dose range 
including this dose within which the ‘metronomic range 10-33% would have been 
encompassed was 0-100nM. 
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Figure 3.2: Chemical Structures of Anti-angiogenic Agents 
 
a)Sorafenib 
 
 
 
                                 
b)Combretastatin 
 
c) Bortezomib  
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3.2 Results 
 
3.2.1. Determination of the appropriate cell density to achieve the longest 
possible duration of cell growth in chemosensitivity assays 
 
The optimal cell seeding densities were determined in order to achieve the longest 
period of uninterrupted growth in 96-well plates up to confluence. This was 
determined by MVECs, which grew for 4 days, and therefore determined the duration 
of drug exposure for all cells (96 hours) – see section 2.1.1.5.The longest growth 
period, which determined the duration of drug exposure for all cells was 4 days (96 
hours). This growth period was seen in the MVECs. Optimal seeding densities were 
thus determined as 3500 cells/well for MVECs, and as 2000 cells/well, 1500 
cells/well and 1000 cells/well for SK-MEL-2, MCF7 and A549 cell lines 
respectively. The calculated number of cells required in each well for each cell type 
remained constant for each independent chemosensitivity assay subsequently carried 
out for all agents tested.    
3.2.2 Determination of the effects of low dose DMSO on the growth of cells and 
of the baseline control growth rate 
The effect of different concentrations of DMSO on each cell type was determined, 
since the majority of the drugs tested required reconstitution in this. It was shown that 
there was no inhibitory or anti-proliferative effect of DMSO at concentrations less 
than 0.25% on all four cell lines (see Figure 3.3). All drugs used were therefore 
reconstituted in 100% DMSO and stored in 10mM solutions. From this stock 
solution, the aliquots of each drug concentration required were made up at 1000 times 
the concentrations actually required. These aliquots were diluted by a factor of 1000  
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Figure 3.3: Growth response of MVEC in culture media containing DMSO 
 
 
 
 
 
 
 
Growth of MVEC following 4 days of incubation with various concentrations of 
DMSO in growth media as determined by MTT proliferation assay. The purpose of 
the experiment was to verify that DMSO did not interfere with growth of cells, 
metabolism of MTT nor the final optical density reading. All absorbance readings 
were performed using a spectrophotometric plate reader at 492nM and individual 
readings were background-subtracted. The growth of untreated cells was taken as 
100% and the growth of DMSO-exposed populations of cells was expressed as a % of 
this. The histogram bars represent mean growth values +/- standard error and 
statistical significance of results is shown. The data shown are representative of at 
least 2 independent experiments, each conducted in triplicate. 
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when used for the daily media+agent change, thus ensuring both correct concentration 
of the drug, and a constant DMSO concentration of 0.1% for all cells treated. 
 
0.1% DMSO in medium therefore acted as control in all experiments, and allowed for 
the baseline control growth rate to be determined. This therefore represents untreated 
cells. After 4 days, the growth rates for MVECs, MCF7, A549 and SK-MEL-2 cells 
were 101.02% (±2.4), 98.36% (±2.89), 108.02% (±3.3) and 105.27% (±1.55) 
respectively. As per Johns study carried out in 2003, the percentage growth of the 
untreated cells after 4 days was normalized to 100%, and the growth of treated cells 
was there after expressed as a percentage of this baseline growth (Johns TG 2003). 
 
3.2.3 Determination of the effects of single anti-angiogenic agents on MVECs 
and cancer cell lines  
3.2.3.1 Sorafenib 
 
Figure 3.4 (summary in table 3.1) shows the anti-proliferative activity of sorafenib 
in the aforementioned cell lines. The lowest assayed dose of sorafenib which 
inhibited the growth of endothelial (MVEC) cells by over 25% compared to control 
cell growth (70.18% of control growth ±2.39), at a highly significant p-value 
(p<0.0001), was 5µM.. IC50 was calculated at 7000nM. SK-MEL-2 and MCF7 cell 
lines showed significant inhibition of proliferation at concentrations as low as 
0.25µM (P < 0.001) with IC50 values of 750nM and 3000nM respectively. A549 cell 
line showed significant inhibition to 28.99% of control growth (±1.52, P<0.001) at 
concentrations of 5µM and above. 
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Figure 3.4: Growth response of cell lines: Sorafenib  
 
 
 
Growth of cell lines following 4 days of treatment with Sorafenib was determined 
by an MTT proliferation assay. All absorbance readings were performed using a 
spectrophotometric plate reader at 492nM and individual readings were 
background-subtracted. Readings at 4 hours post MTT addition were used as final 
readings for growth calculation. The growth of untreated cells was taken as 100% 
and the growth of treated populations of cells was expressed as a % of this. The 
histogram bars represent mean growth values +/- standard error and statistical 
significance of results is shown. The data shown are representative of at least 2 
independent experiments, each conducted in triplicate 
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3.2.3.2 Combretastatin 
 
This caused significant MVEC inhibition (see Figure 3.5 and table 3.1) at 
concentrations of 2.5nM (p<0.01) and above, with a calculated IC50 of 4.2nM. The 
SK-MEL-2 cell line was not affected within the selected dose range thus IC50 was not 
achieved. Both the A549 and MCF-7 cell lines were only significantly inhibited at 1 
nM (p<0.05) and above, and an IC50 value was not attained for either cell line.  
 
3.2.3.3 Bortezomib 
 
This caused significant MVEC inhibition at concentrations as low as 1.56nM 
(p<0.01) and above, with a calculated IC50 of 12.2nM. The SK-MEL-2 cell line was 
dramatically inhibited by Bortezomib, at concentrations of 6.25nM (p<0.01) and 
above, reaching IC50 at a concentration of 4.7nM. A549 cell line had a similar IC50 
value of 5.3nM, and the MCF7 cell line reached their IC50 value at a concentration of 
16.8nM (see Figure 3.6 and table 3.1).  
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Figure 3.5: Growth response of cell lines: Combretastatin  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Growth of cell lines following 4 days of treatment with Combretastatin was determined 
by an MTT proliferation assay. All absorbance readings were performed using a 
spectrophotometric plate reader at 492nM and individual readings were background-
subtracted. Readings at 4 hours post MTT addition were used as final readings for 
growth calculation. The growth of untreated cells was taken as 100% and the growth of 
treated populations of cells was expressed as a % of this. The histogram bars represent 
mean growth values +/- standard error and statistical significance of results is shown. 
The data shown are representative of at least 2 independent experiments, each 
conducted in triplicate. 
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Figure 3.6: Growth response of cell lines: Bortezomib  
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Growth of cell lines following 4 days of treatment with Bortezomib was determined 
by an MTT proliferation assay. All absorbance readings were performed using a 
spectrophotometric plate reader at 492nM and individual readings were background-
subtracted. Readings at 4 hours post MTT addition were used as final readings for 
growth calculation. The growth of untreated cells was taken as 100% and the growth 
of treated populations of cells was expressed as a % of this. The histogram bars 
represent mean growth values +/- standard error and statistical significance of results 
is shown. The data shown are representative of at least 2 independent experiments, 
each conducted in triplicate. 
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3.2.4 Determination of the effects of single cytotoxic drugs given in a metronomic 
schedule on MVECs and cancer cell lines and determination of the metronomic 
dose 
3.2.4.1 Temozolomide 
 
MVECs showed anti-proliferative effects to Temozolomide in a dose-dependent 
manner (Figure 3.7 and table 3.1) with significant effects (80.89% of control growth 
±3.19) seen at a concentration of 10µM and above (P < 0.001). A549, MCF7 and SK-
MEL-2 cell lines all behaved in a dose-dependent manner, none achieving their IC50 
value in the selected dose range. However, both SK-MEL-2 and MCF7 cell lines 
showed a significant response at concentrations as low as 1.25mM to 74.9% ± 1.24 
and 76.82%± 1.53 of control growth respectively (P<0.001).  
Given the literature, and the potential cumulative affect of daily dosing when shifting 
from MTD approach, it was decided that the ‘metronomic’ dose of  temozolomide 
would be taken as 10µM. This is the dose at which statistically significant endothelial 
cell inhibition occurred (p<0.001), and corresponded with less than 15% of the MTD.  
3.2.4.2 Paclitaxel 
 
MVECs showed anti-proliferative effects to Paclitaxel again in a dose-dependent 
manner (Figure 3.8 and table 3.1) with significant effects (p<0.001) seen at a 
concentration of 125 pM. IC50 was achieved at 1.25nM. Both A549 and MCF7 cell 
lines behaved in a similar dose-dependent fashion to the MVECs achieving IC50 
values of 1.45nM and 1.08nM respectively. The SK-MEL-2 cell line showed 
increased sensitivity to paclitaxel than all other three cell lines, with anti-proliferative 
effects observed at  
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Figure 3.7: Growth response of cell lines: Temozolomide 
 
 
 
 
 
Growth of cell lines following 4 days of treatment with Temozolomide was 
determined by an MTT proliferation assay. All absorbance readings were performed 
using a spectrophotometric plate reader at 492nM and individual readings were 
background-subtracted. Readings at 4 hours post MTT addition were used as final 
readings for growth calculation. The growth of untreated cells was taken as 100% and 
the growth of treated populations of cells was expressed as a % of this. The histogram 
bars represent mean growth values +/- standard error and statistical significance of 
results is shown. The data shown are representative of at least 2 independent 
experiments, each conducted in triplicate. 
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Figure 3.8: Growth response of cell lines : Paclitaxel 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Growth of cell lines following 4 days of treatment with Paclitaxel was determined by 
an MTT proliferation assay. All absorbance readings were performed using a 
spectrophotometric plate reader at 492nM and individual readings were background-
subtracted. Readings at 4 hours post MTT addition were used as final readings for 
growth calculation. The growth of untreated cells was taken as 100% and the growth 
of treated populations of cells was expressed as a % of this. The histogram bars 
represent mean growth values +/- standard error and statistical significance of results 
is shown. The data shown are representative of at least 2 independent experiments, 
each conducted in triplicate. 
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31.3pM (p<0.001) and above, and reaching a calculated IC50 at the low concentration 
of 350pM. The MTD of paclitaxel equates to 0.33µM, and a metronomic dose of 
125pM (0.03% of MTD) was selcted based on the MTT data for  MVECs. 
 
3.2.4.3 Vinorelbine 
MVECs showed significant anti-proliferative effects to Vinorelbine at doses as low as 
1nM (p<0.001) and above, with a calculated IC50 value of 16.9nM (Figure 3.9 and 
table 3.1). The SK-MEL-2 and MCF-7 cell lines showed similar sensitivity to 
Vinorelbine as MVECs and showed significant inhibition at 1nM (p<0.001 and 
p<0.01 repectively) and above. A549 cell line was relatively more resistant at the low 
dose of 1nM (96.55%±1.26 ) but displayed significant anti-proliferative effects at 
10nM (p<0.01), achieving an IC50 value of 55nM . All cell lines showed less than 
10% of control growth at concentrations of 100nM and above, and therefore all 
reached IC50 value within the dose range selected. The MTD of vinorelbine equates to 
0.123µM and a dose of 1 nM (0.8% of MTD) was selected as the metronomic dose 
based on the MVEC MTT data. 
3.2.4.4 Etoposide 
 
All cell lines responded to etoposide in a dose-dependent manner (Figure 3.10 & 
table 3.1). MVECs showed significant anti-proliferative effects at concentrations of 
0.16µM (p<0.001) and above, with a calculated IC50 value of 1.4µM. The SK-MEL-2 
cell line displayed increased sensitivity to etoposide than the other cell lines, with 
anti-proliferative effects observed at 0.078µM (p<0.05) and a calculated IC50 of 
0.31µM. A549 and MCF-7 cell lines showed significant anti-proliferative effects at 
0.16µM (p<0.05) giving calculated IC50 values of 0.58µM and 2.6µM, respectively.  
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Figure 3.9: Growth response of cell lines: Vinorelbine 
 
 
 
 
Growth of cell lines following 4 days of treatment with Vinorelbine was determined 
by an MTT proliferation assay. All absorbance readings were performed using a 
spectrophotometric plate reader at 492nM and individual readings were background-
subtracted. Readings at 4 hours post MTT addition were used as final readings for 
growth calculation. The growth of untreated cells was taken as 100% and the growth 
of treated populations of cells was expressed as a % of this. The histogram bars 
represent mean growth values +/- standard error and statistical significance of results 
is shown. The data shown are representative of at least 2 independent experiments, 
each conducted in triplicate. 
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Figure 3.10: Growth response of cell lines: Etoposide 
 
 
 
Growth of cell lines following 4 days of treatment with Etoposide was determined by 
an MTT proliferation assay. All absorbance readings were performed using a 
spectrophotometric plate reader at 492nM and individual readings were background-
subtracted. Readings at 4 hours post MTT addition were used as final readings for 
growth calculation. The growth of untreated cells was taken as 100% and the growth 
of treated populations of cells was expressed as a % of this. The histogram bars 
represent mean growth values +/- standard error and statistical significance of results 
is shown. The data shown are representative of at least 2 independent experiments, 
each conducted in triplicate. 
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The MTD of etoposide equates to 35.8µM and a dose of 0.16µM (0.4% of MTD) was 
selected, based on the MVEC MTT data i.e. that which induced a significant anti-
endothelial response (p<0.001).  
3.2.4.5 Carboplatin 
 
MVECs showed inhibitory effects to Carboplatin at doses of 250µM (p<0.01) and 
above, and did not reach its IC50 value in the dose range selected i.e. less than 33% of 
MTD. SK-MEL-2 and MCF-7 cell lines displayed increased sensitivity to carboplatin, 
with significant anti-proliferative effects seen at 0.1µM (p<0.01) for both cells lines, 
and reaching their IC50 values at concentrations of 20µM and 35µM respectively. 
A549 cell line gave an IC50 value of 72µM, and showed significant anti-proliferative 
effects at 50µM (p<0.01). Since MVECs did not reach their IC50 value in the dose 
range selected, a metronomic dose could not be determined for carboplatin, and it was 
therefore not taken forward for use in combination dosing schedules (seeFigure 3.11 
& summary table 3.1).  
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Figure 3.11: Growth response of cell lines: Carboplatin 
 
 
 
 
 
Growth of cell lines following 4 days of treatment with Carboplatin was determined 
by an MTT proliferation assay. All absorbance readings were performed using a 
spectrophotometric plate reader at 492nM and individual readings were background-
subtracted. Readings at 4 hours post MTT addition were used as final readings for 
growth calculation. The growth of untreated cells was taken as 100% and the growth 
of treated populations of cells was expressed as a % of this. The histogram bars 
represent mean growth values +/- standard error and statistical significance of results 
is shown. The data shown are representative of at least 2 independent experiments, 
each conducted in triplicate. 
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Table 3.1 – Summary table of in vitro single agent data using anti-            
angiogenic and cytotoxic agents. 
 
Agent + dose 
range used 
Cell Line Dose at which 
significant 
growth 
inhibition seen 
P value of 
significant 
growth 
inhibition 
IC50 (if 
reached) 
within dose 
range 
Sorafenib MVEC 5µM P<0.001 7000nM 
(0-10µM) SKMEL2 0.25µM P<0.001 750nM 
 MCF7 0.25µM P<0.001 3000nM 
 A549 5µM P<0.001 7000nM 
CA4P MVEC 2.5nM P<0.01 4.2nM 
(0-25nM) SKMEL2 / / Not reached 
 MCF7 1nM P<0.05 Not reached 
 A549 1nM P<0.05 Not reached 
Bortezomib MVEC 1.56nM P<0.01 12.2nM 
(0-100nM) SKMEL2 6.25nM P<0.01 4.7nM 
 MCF7 12.5nM P<0.01 16.8nM 
 A549 6.25nM P<0.01 5.3nM 
Temozolomide MVEC 10µM P<0.001 Not reached 
(0-50µM) SKMEL2 1.25mM P<0.001 Not reached 
 MCF7 1.25mM P<0.001 Not reached 
 A549 10mM P<0.01 Not reached 
Paclitaxel MVEC 125pM P<0.001 1.25nM 
(0-20nM) SKMEL2 31.3pM P<0.001 350pM 
 MCF7 62.5pM P<0.01 1.08nM 
 A549 62.5pM P<0.01 1.45nM 
Vinorelbine MVEC 1nM P<0.001 16.9nM 
(0-10µM) SKMEL2 1nM P<0.001 12.5nM 
 MCF7 1nM P<0.01 12.9nM 
 A549 10nM P<0.01 22.1nM 
Etoposide MVEC 0.16µM P<0.001 1.4µM 
(0-5µM) SKMEL2 0.078µM P<0.05 0.31µM 
 MCF7 0.16µM P<0.05 2.6µM 
 A549 0.16µM P<0.05 0.58µM 
Carboplatin MVEC 250µM P<0.01 Not reached 
(0-500µM) SKMEL2 0.1µM P<0.01 20µM 
 MCF7 0.1µM P<0.01 35µM 
 A549 50µM P<0.01 72µM 
*MVEC – microvascular endothelial cell line; SKMEL2 – melanoma cell line; MCF7 – breast                  
cancer cell line; A549 – lung cancer cell line. All results based on 3 independent experiments 
carried out in a minimum of triplicate. Agents in red    are those which are specifically anti-
angiogenic or molecularly-targeted and therefore dose-ranges      are based on the clinical dose or 
previous phase I data. Agents in black are cytotoxic agents, where dose ranges were chosen based 
on less than 33% of the phase I MTD data (as per metronomic) and also using previous in vitro 
MTT data as a guide. 
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         3.3 Discussion 
 
The results have show that all five of the chosen orally bioavailable chemotherapeutic 
agents, each from a different class of compound, possess anti-endothelial properties 
when given in an ECS. Carboplatin however, seems to possess less of an anti-
endothelial effect than the other four. The results are discussed in detail in this 
section. The three chosen specific agents, as expected, exhibit significant anti-
endothelial effects at drug concentrations well within their normal clinical dose range, 
and each of their chemosensitvity assays acts as a baseline against which to compare 
potential synergistic effects.  
 
Single anti-angiogenic agents 
Sorafenib has received much attention in recent years and has shown promising 
results in Phase I-III clinical trials both as single agent and when used in combination, 
particularly in renal and lung cancer and malignant melanoma (Wilhelm S et al 2004; 
Clark J et al 2005; Mross K et al 2006). The clinical oral dose is 200 - 400mg twice 
daily, giving plasma concentration of 2.9mg/l. This is equivalent to 5000nM and as 
shown by our in vitro data, is also the dose which induces a significant anti-
endothelial effect in the MVEC model. The fact that our in vitro dose-escalation data 
corresponds to the clinically safe dose in phase I trials, adds weight to our findings 
and to the use of this model. 5000nM was therefore the dose chosen to be carried 
forward into combination studies. 
 
Combretastatin 
This agent has shown promising results in phase I and II trials and is currently in 
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phase III combinatorial trials for use in thyroid cancer. In a phase I trial of CA4P on a 
5 day schedule, with dose levels ranging from 6mg/m2 to 75mg/m2, the MTD was 
found to be 65mg/m2 (Stevenson J et al 2003). As previously stated, in vivo studies 
showed an  anti-vascular effects of CA4P seen at concentrations less than one-tenth 
of the MTD (Dark G et al 1997). Results as shown in figure 3.5, indicate that CA4P 
caused significant MVEC inhibition at concentrations as low as 2.5nM (p<0.01). 
CA4P shows a concentration dependent effect, with a reduction in endothelial and 
tumour cell numbers, although the tumour cells were inherently more resistant than 
the MVECs. A dose of 5nM was chosen to be carried forward into combinatorial 
studies, as this dose caused statistically significant MVEC inhibition with a p value of 
<0.001, and is well within the clinical dose range. 
 
Bortezomib 
This non-specific anti-angiogenic agent has also shown promising results in clinical 
trials to date. In this study, significant MVEC inhibition was seen at concentrations as 
low as 1.56nM (p<0.01), less than 25% of the translated clinical dose. However, as 
expected, neoplastic cells were very susceptible to proteosome inhibition since its 
mechanism of action results in dysregulation of the cell cycle. The three cancer cell 
lines all reached their IC50 value in the dose range selected, corresponding to 
concentrations significantly smaller than the clinical dose. 
Since Bortezomib was used here for comparative purposes, and is not a true anti-
angiogenic agent, it was not carried forward for use in further combination studies. 
 
Single chemotherapeutic agents 
The five agents studied all showed promising anti-endothelial effects when given in 
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extended dosing schedules. IC50 values were reached for all agents, except 
carboplatin, well within the MTD and the arbritrary 33% MTD assigned to 
metronomic dosing. 
 
Temozolomide has already been used in clinical extended-dosing schedules, showing 
promising results in treating brain and skin malignancies. In this study, it 
demonstrated significant anti-proliferative effects on MVECs at 10µM which equates 
to less than 15% of MTD (p<0.001). Other in vitro studies on HUVECs showed 
temozolomide to cause inhibition at doses as low as 2.5µM (1-5% of MTD, p<0.001) 
(Lam T et al 2007), at 5µM (differentiation) and at 50µM (proliferation) (Kurzen H et 
al 2003). The HUVEC defined ‘metronomic’ dose in these two examples is lower 
than that seen in the MVEC model. As previously explained in chapter 2, MVECs are 
more akin to tumour vasculature, having a greater degree of contact inhibition and 
relevant surface receptors than HUVECs, which may explain the difference in results 
and their slightly increased resistance.  
 
In a Phase I trial for treatment of advanced glioma temozolomide was assessed for its 
potential in an extended dosing schedule. A 7-week daily oral schedule (75mg/m2/day 
for 7 weeks – 50% MTD) was compared with a traditional 5-day regimen 
(200mg/m2/day repeated every 28 days) (Brock C et al 1998). Overall response rates 
were similar, but the extended dosing schedule resulted in a lower incidence of 
toxicities and a 2.1-fold greater drug exposure over a 4-week period, showing its 
potential for use in extended dosing schedules. 
 
Paclitaxel demonstrated an IC50 of 1.25nM for MVECs, which was also higher than 
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that of the HUVEC models of Bocci et al and Lam et al (Bocci G et al 2002; Lam T 
et al 2007) which showed IC50 values of 96pM and 228pM respectively. Previous 
pharmacokinetic studies involving paclitaxel have shown that 6 hour infusions and 24 
hour infusions, each administered once every 3 weeks, resulted in an MTD of 
250mg/m2 and corresponding Cmax values of 13µM and 1µM respectively (Rowinsky 
EK et al 1992).  The data suggests that paclitaxel may be used at less than 15% MTD 
as part of a combined ‘metronomic’ protocol to induce a significant anti-endothelial 
response. Bocci et al demonstrated that ECS with several cytotoxic agents including 
paclitaxel caused significant apopotosis in endothelial cells after 6 days of treatment 
(Bocci G et al 2002). These results provide evidence to justify the use of paclitaxel in 
metronomic schedules.  
 
Vinorelbine demonstrated an IC50 of 16.9nM for MVECs, although significant anti-
endothelial effects were displayed at 1nM (p<0.001) correlating to less than 10% 
MTD. It also demonstrated anti-melanoma effects, with significant inhibition 
demonstrated in the SK-MEL-2 cell line at 1nM (p<0.05). Previous in vitro studies 
have shown that another vinca alkaloid, vinblastine, possesses anti-angiogenic 
properties when applied at very low, non-toxic doses of 0.25-1pM in the HUVEC 
model (Vacca A et al 1999). Along side this, further in vitro studies in human 
melanoma cell lines have reiterated this finding, where by four vinca alkaloids 
including vinorelbine were found to induce IC50 values at very low doses ranging 
from 1pM to 10nM (Photiou A et al 1992). Pharmocokinetic studies involving 
vinorelbine compared a 20 minute intravenous infusion of 25mg/m2with gel capsules 
at a dose of 80mg/m2. Efficacy and safety profiles were similar for both routes, with 
Cmax values of 133.4 ±42.3ng ml-1 (Marty M et al 2001; Whitehead RP et al 2004).  
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Etoposide demonstrated an IC50 of 1.4µM for MVECs, although the first signs of 
endothelial inhibition occurred at 0.078µM (p<0.01), corresponding to less than 10% 
of the MTD (Sessa C et al 1995). The SK-MEL-2 carcinoma cell line also showed 
significant inhibition to etoposide at 0.078µM (p<0.01). Both phase I and II trials 
have studied the effect of the orally bioavailable etoposide, particularly in ovarian 
cancer, but not as yet in combinatorial regimens (Markman M et al 1992; Baur M et 
al 2005). Previous pharmacokinetic studies illustrated that oral administration of 
100mg/m2 and 150mg/m2 resulted in Cmax  values of 4.45 and 2.87µg/ml respectively 
(Simon G et al 2006). Several phase II studies using 50mg/m2 etoposide once or twice 
daily for 14-21 days on cancer patients who were previously resistant to standard 
dosing and extended-scheduling demonstrated a positive response to this chronic 
regimen (Markman M et al 1992).  
 
Carboplatin did not show significant endothelial inhibition until a dose of 250µM 
(p<0.01) and therefore did not reach IC50 value for MVECs in the dose range 
selected. This agent was therefore not taken forward for use in combination dosing 
schedules. Phase II and III trials have shown promising data when administering 
Carboplatin in low-dose schedules, but only when combined with other cytotoxics or 
radiotherapy (Jeremic B et al 1996). This was in the treatment of non-small cell lung 
cancer, and the recommended dose was 35mg/m2, with an MTD of 40mg/m2.  
 
Estramustine is a cytotoxic drug presently licensed for use in the treatment of 
hormone-refractory prostatic carcinoma. It is a stable conjugate of oestradiol and 
normustine, and the clinically used form comes as prodrug. It is thought to disrupt 
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microtubule dynamics spindle, and acts at a similar binding site to paclitaxel and 
vinblastine (Laing N 1 et al 997). It has been previously been studied for its anti-
endothelial properties in the HUVEC model (Lam T et al 2007) – suggesting 
inhibitory effects at 1-3µM (p<0.001) which is 50 times below its cytotoxic range. 
 
Estramustine is the agent used in combination with Temozolomide in the clinical part 
of this study (chapter 5), and would ideally have made up the sixth chemotherapeutic 
agent. Unfortunately, since previous work carried out (Maraveyas A et al 2005; Lam 
T et al 2007), the pure substance is no longer available, despite efforts to source this 
from a number of alternative international suppliers. It will however be discussed in 
the clinical context. 
 
All these agents described have good oral bioavailability and are capable of achieving 
anti-endothelial effects at doses well below MTD, holding potential in future 
metronomic schedules. Their anti-angiogenic response in vivo will be difficult to 
assess, and will rely on the development of accurate surrogate markers of tumour 
vasculature. Certainly, some clinical results so far indicate that prolonged oral 
regimens can improve drug therapeutic index, along with the benefits of reduced 
cytotoxic effects (Markman M et al 1992; Brock C et al 1998; Gasparini et al 2001; 
Whitehead RP et al 2004). 
 
Throughout this aspect of the study, it became apparent that within the ‘empirical 
metronomic range’ there were a number of doses with significant anti-endothelial 
effect. It was necessary to reach a decision on which dose to take further to 
combination regimens, taking into account the literature ‘mantra’ of 1- 33% and also 
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the given potential cumulative doses (when shifting from MTD to daily dosing) a 
patient could receive. It was therefore decided that the first dose level with highly 
significant (p<0.001) MTT inhibition of MVECs compared to baseline would be 
taken forward to combination, provided it did not exceed 15% of MTD (as expected 
from the published literature range). It is accepted that this in itself is an arbitrary 
method of establishing a dosing level, but in this respect, there was no guidance in the 
literature. There is also the concern that many of the known data used as reference 
values were based on conventional pharmacokinetics. Conventionally drug schedules 
are bi-weekly, weekly, or every three or four weeks. Taking a dose as high as 33% of 
a drug that is normally given (for example) on a 3 weekly basis, could result in 
extremely high levels of cumulative dosing if this was extrapolated to a daily dosing 
schedule. With this in mind, the criteria were set to look for the first MTT assay with 
a reproducible highly significant result. If extrapolation from this dose kept the total 
potential daily exposure in a theoretical clinical setting to below 15% of the MTD 
dose, it was assumed that this would be a reasonable metronomic dose to do further 
experiments with.  
 
In spite of the limitations of an in vitro model such as this, this study yielded results 
which compare favourably with other published works on in vitro dosing of 
metronomic chemotherapy. The aims of this part of the study, as laid out in section 
3.1, have been met. Ideally, this study should be followed up using other assays or 
angiogenesis models, including those that more closely mimic tumour vasculature in 
3-dimensional frameworks (Akhtar N et al 2002), and potentially in animal studies. 
Given the time and financial constraints of this piece of work, neither of these routes 
would have been visable to follow. It is hoped however, that further work can develop 
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from this study. Using one cell line for each cancer type studied was also a limitation 
of this work. However, this is a basic model and in order to improve statistical 
significance and the quality of the data, each drug concentration for each cell line was 
tested in sextuplicate. The MVECs, despite again being of from one cell line, are 
representative of endothelium which are common to all cancers and vasculature. It is 
hoped that the use of microvascular cells in this study, which more closely resemble 
tumour vasculature than large endothelial cells e.g HUVECs, will add weight to our 
findings. The limitations of in vitro work must however always be remembered in this 
case.  
 
Chapter 4 will describe the results of the combinations of sorafenib and 
combretastatin with the chemotherapeutic agents. As mentioned earlier in this 
discussion, Bortezomib will not brought forward to test in the combination regimens 
since, although it is a molecularly-targetted agent, it was not designed to specifically 
target tumour vasculature, and was purely used for comparative purposes here. 
The approach taken in this study does not further our understanding of the 
mechanisms of action of these agents, nor does it replace or even reflect the clinical 
setting (Maraveyas A et al 2005). It is however a potential framework, which is easily 
reproducible and reliable on which to base further in vivo studies and from which to 
initiate phase I anti-angiogenic trials. 
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Chapter 4 
 
Chemotherapeutic and anti-angiogenic agents given in an extended-dosing 
schedule in combination using the in vitro MVEC model. 
 
4.1 Aims and Introduction 
 
The aims of the second part of the in vitro study described in this chapter are: 
1. Using the in vitro MVEC model, to test the potential synergistic effects of 
combining the multi-kinase inhibitor, sorafenib, with the chemotherapeutic agents 
selected for this study (see chapter 3). This was using the established ‘metronomic’ 
dose of each agent, as described in chapter 3. 
2. Using the in vitro MVEC model, to test the potential synergistic effects of the 
vascular-targetting agent, combretastatin with the chemotherapeutic agents selected 
for this study (see chapter 3). This was using the established ‘metronomic’ dose of 
each agent, as described in chapter 3. 
3. To determine if an additive inhibitory effect on growth was seen in any of the cell 
lines, when comparing single-agent data to the combination regimens and to rule out 
combinations that show little or no synergy. 
 
 
All clinical studies to date looking at metronomic scheduling confirm its excellent 
safety profile (see section 1.3.2). With few exceptions (Krzyzanowska M et al 2007), 
results of these studies have been considered worthy of further clinical evaluation. 
The published metronomic protocols are commonly complemented with 
antiangiogenic agents (see section 1.3.3), or agents with antiangiogenic properties 
attributed to them. These have included cyclooxygenase-2 (COX-2) inhibitors, 
glitazones, thalidomide and bevacizumab (Hau P et al 2007; Kesari S et al 2007; 
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Garcia A et al 2008). 
 
This chapter shows the results of combination schedules of both sorafenib and 
combretastatin with the traditional chemotherapeutic agents given at ‘metronomic’ 
dose, as determined in chapter 3. This may provide some support to clinical evidence 
of useful combinations, and also potentially provide a starting point for designs of in 
vivo or phase I combinatorial studies in this confusing era of multi-targeted therapy.  
 
4.1.1 Efficacy of metronomic scheduling of cytotoxic drugs in combination with 
anti-angiogenic agents: trial evidence to date 
 
There have been numerous studies in recent years investigating the efficacy of 
combination regimens, with metronomic and antiangiogenic being the key goals of 
these treatment schedules. 
 
The most interesting results to date have been achieved when metronomic 
chemotherapy was combined with bevacizumab (Burstein H et al 2005; Rocca A et al 
2007; Garcia A et al 2008). Other important studies have included the use of 
metronomic cyclophosphamide (Lord R et al 2007) and cyclophosphamide with 
methotrexate and trastuzumab – a recombinant humanised anti-erbB2/HER-2 
monoclonal antibody (Orlando L et al 2006; Lord R et al 2007). This regimen was 
shown to have some efficacy and  minimal toxicity in advanced breast cancer 
patients, although a larger trial is required to confirm this (Bocci G et al 2005; 
Orlando L et al 2006).   
 
Importantly, many of the recent combinatorial clinical studies do not pose 
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justification or rationale for the chosen optimal ‘antiangiogenic’ dose for the 
cytotoxic agent, and empiricism seems yet again to be the basis of dose-choice. With 
respect to dosing, the analysis of circulating endothelial (progenitor) cells or intra-
patient dose-escalation have been proposed (Mancusco P et al 2006). Further 
refinement of this is required, along with better tools to monitor the antiangiogenic 
effects of metronomic regimens.  
 
The choice of combination partners can be guided by the safety profile of such 
agents, taking into account the risk of pharmacokinetic interference, ease of 
administration and cost. Also, individual patient requirements need to be taken into 
account to determine which are most likely to benefit from combination metronomic 
schedules e.g. adjuvant versus palliative or bulky versus residual disease.  
 
4.1.2 Rationale for selection of drug combinations for this in vitro model  
 
For the purposes of the combination studies, sorafenib is the only specific 
antiangiogenic used, given its known mechanism of action – as previously described 
in chapter 3. In the single agent data, sorafenib showed significant anti-endothelial 
effects within its clinical dose range, as anticipated. Combretastatin is used as the 
other main combinatorial agent due to the general use and development of this drug in 
the antiangiogenic arena and the general ‘acceptance’ that it classifies as an 
antiangiogenic rather than a cytotoxic However the mechanism of action of 
combretastatin remains far from clear, and the metronomic dose for this agent was 
therefore established prior to combinatorial studies. Both sorafenib and 
combretastatin have been studied in combination regimens (Amaravadi RK et al 
2007; Eisen T et al 2007; Yeung S et al 2007; Nathan P et al 2008). 
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As discussed in section 3.3, the choice of cytotoxic agents taken forward into 
combinatorial schedules for this study was based on the significant anti-endothelial 
effects seen by chosen agents at doses well below 33% of MTD (see section 3.3. and 
table 2.1). These chosen agents in clinical practice are almost all licenced for use as 
oral agents (except for paclitaxel), with known oral bioavailablity profiles and well 
described toxicity profiles. This study could therefore provide valuable preclinical 
evidence for potential synergistic regimens that can be taken on to further studies.  
  
4.2 Results 
 
4.2.1 Determination of in vitro synergy between cytotoxic agents and Sorafenib 
4.2.1.1 Temozolomide  
A synergistic effect of combined low dose Temozolomide (10µM) with Sorafenib 
(5µM) is seen in this model (see Figure 4.1 & table 4.1). Temozolomide at 10µM 
resulted in MVEC cell growth to 80.89% (±3.19) of control. Sorafenib alone at 5µM 
resulted in MVEC cell growth to 70.18% (±2.39) of control. However, in 
combination at these concentrations, there is a very significant (P<0.001) growth 
inhibition to 43.02% (±3.72) of control. Additive inhibitory activity was also seen in 
SK-MEL-2 cell growth, with 55.26% (±2.43) seen with Temozolomide alone, 
40.09% (±1.76) seen with Sorafenib alone and again a very significant (p<0.001) 
24.91% (±2.43) of control seen for the combination of both agents. Significant 
inhibitory response was also seen in the A549 cell line MCF7 cell lines, although was 
equivalent to the effect induced by sorafenib alone.  
In summary, significant synergy between Temozolomide (at 15% MTD) and 
Sorafenib (at clinical dose) was demonstrated in MVEC and melanoma cell lines.   
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Figure 4.1: Growth response of cell lines: sorafenib and metronomically-dosed 
Temozolomide 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Growth of cell lines following 4 days of treatment with metronomically-dosed 
Temozolomide with sorafenib was determined by an MTT proliferation assay. All 
absorbance readings were performed using a spectrophotometric plate reader at 
492nM and individual readings were background-subtracted. Readings at 4 hours post 
MTT addition were used as final readings for growth calculation. The growth of 
untreated cells was taken as 100% and the growth of treated populations of cells was 
expressed as a % of this. The histogram bars represent mean growth values +/- 
standard error and statistical significance of results is shown. The data shown are 
representative of at least 2 independent experiments, each conducted in triplicate. 
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4.2.1.2 Paclitaxel 
A synergistic effect of combined low dose Paclitaxel (125pM) with Sorafenib (5µM) 
is seen in this model (see Figure 4.2 & table 4.1). When Paclitaxel and Sorafenib are 
combined at the predetermined doses (seen in Fig 2B), there is significant synergy 
(P<0.001) seen in both the MVEC and SK-MEL-2 cell lines. Paclitaxel (125pM) and 
Sorafenib (5µM) resulted in MVEC cell growth to 76.43% ±1.41 and 70.18%±2.39 of 
control growth respectively. However, in combination - at these concentrations, -
1.34% (±4) of control MVEC growth is seen. An additive inhibitory effect was also 
seen in the MCF7 cell line, with 2.13% (±2.52) seen with Sorafenib alone, 72.68% 
(±1.44) seen with Paclitaxel alone and -35.82% (±2.62) seen with combined agents. 
There was no significant additive response over above that seen with sorafenib alone 
in the A549 cell line. 
In summary, significant synergy between Paclitaxel (at doses < 15% MTD – 125pM) 
and Sorafenib was demonstrated in both MVEC and SK-MEL-2 cell lines, and to a 
lesser extent, in the MCF7 cell line.   
 
4.2.1.3 Vinorelbine  
An additive anti-endothelial effect of combined low dose Vinorelbine (1nM) with 
Sorafenib (5µM) is seen in this model (see Figure 4.3 and table 4.1). When 
Vinorelbine and Sorafenib are combined at the predetermined doses (seen in Fig 2C), 
there is no significant anti-endothelial additive or synergistic response seen. However, 
synergistic activity was seen in the SK-MEL-2 and MCF7 cell lines, with 58.69% 
(±2.84) and 82.92% (±3.11) of control growth with Vinorelbine (1nM) given alone. 
However, in combination with Sorafenib, -61.67% (±4.74) and -249.41% (±7.31) of 
control growth was seen. There was no additive effect seen in the A549 cell line over 
and above that seen with sorafenib alone.  
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Figure 4.2: Growth response of cell lines: sorafenib and metronomically-dosed 
Paclitaxel 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Growth of cell lines following 4 days of treatment with metronomically-dosed 
Paclitaxel with sorafenib was determined by an MTT proliferation assay. All 
absorbance readings were performed using a spectrophotometric plate reader at 
492nM and individual readings were background-subtracted. Readings at 4 hours post 
MTT addition were used as final readings for growth calculation. The growth of 
untreated cells was taken as 100% and the growth of treated populations of cells was 
expressed as a % of this. The histogram bars represent mean growth values +/- 
standard error and statistical significance of results is shown. The data shown are 
representative of at least 2 independent experiments, each conducted in triplicate. 
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Figure 4.3: Growth response of cell lines: sorafenib and metronomically-dosed 
Vinorelbine 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Growth of cell lines following 4 days of treatment with metronomically-dosed 
Vinorelbine with sorafenib was determined by an MTT proliferation assay. All 
absorbance readings were performed using a spectrophotometric plate reader at 
492nM and individual readings were background-subtracted. Readings at 4 hours post 
MTT addition were used as final readings for growth calculation. The growth of 
untreated cells was taken as 100% and the growth of treated populations of cells was 
expressed as a % of this. The histogram bars represent mean growth values +/- 
standard error and statistical significance of results is shown. The data shown are 
representative of at least 2 independent experiments, each conducted in triplicate. 
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In summary, significant synergy between Vinorelbine (at doses < 10% MTD) and 
Sorafenib was demonstrated in SK-MEL-2 and MCF7 cell lines, but not in MVEC or 
A549 cell lines. 
 
4.2.1.4 Etoposide 
A synergistic effect of combined low dose Etoposide (0.16uM) with Sorafenib (5µM) 
is seen in this model (see Figure 4.4 and table 4.1). Significant anti-endothelial 
effects were observed when Etoposide and Sorafenib are combined (see Fig 2D). In 
this model, Etoposide alone resulted in MVEC cell growth to 65.52% (±2.57) and 
Sorafenib alone, in 70.18% (±2.39) of control. However, in combination, there is a 
significant (P<0.001) increase in growth inhibition to -40.09 (±5.13) of control. 
Additive inhibitory activity was also seen in the SK-MEL-2 cell line, with 61.55% 
(±1.4) with Etoposide alone, 40.09% (±1.76) with Sorafenib alone and in 
combination, a significant 3.84% (±1.28) of control growth. A549 and MCF7 cell 
lines showed no additive growth inhibition with this combination. 
 
In summary, significant synergy between Etoposide (at doses < 10% MTD) and 
Sorafenib was demonstrated in MVEC and SK-MEL-2 cell lines.   
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Figure 4.4: Growth response of cell lines: sorafenib and metronomically-dosed 
Etoposide 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Growth of cell lines following 4 days of treatment with metronomically-dosed 
Etoposide with sorafenib was determined by an MTT proliferation assay. All 
absorbance readings were performed using a spectrophotometric plate reader at 
492nM and individual readings were background-subtracted. Readings at 4 hours post 
MTT addition were used as final readings for growth calculation. The growth of 
untreated cells was taken as 100% and the growth of treated populations of cells was 
expressed as a % of this. The histogram bars represent mean growth values +/- 
standard error and statistical significance of results is shown. The data shown are 
representative of at least 2 independent experiments, each conducted in triplicate. 
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4.2.2 Determination of in vitro synergy between cytotoxic agents and 
Combretastatin 
 
4.2.2.1 Temozolomide  
MVEC growth was inhibited by 80.89% of control growth (±3.19) at the metronomic 
dose 10µM of single agent Temozolomide (p<0.001). When combined with 
combretastatin, no synergistic or additive effect is seen in any of the cell lines (see 
Figure 4.5 ).  
 
4.2.2.2 Paclitaxel 
MVEC growth was inhibited by 23.6% when treated with 125pM Paclitaxel alone, 
whilst addition of 5nM CA4P resulted in 60% endothelial cell inhibition compared to 
the untreated cell population (p<0.001). Therefore the combination schedule 
demonstrated a significant enhancement of growth inhibition of MVECs compared to 
the single chemotherapeutic schedule. However, treatment of MVECs with 5nM 
CA4P alone had an improved response compared to the combinational schedule 
achieving a percentage endothelial cell inhibition of 66.5%. Paclitaxel therefore had 
an inhibitory effect on the CA4P growth inhibition. Addition of 5nM CA4P to 125pM 
Paclitaxel resulted in a statistically significant antagonistic effect in the SK-MEL-2 
(p<0.001), A549 (p<0.001) and MCF7 (p<0.001) cell lines compared to 125pM of 
paclitaxel alone (see Figure 3.8). Single paclitaxel treatment at 125pM resulted in 
42.2% SK-MEL-2, 22.4% A549 and 27.3% MCF-7 cell inhibition (compared to the 
corresponding untreated cell population), whilst in combination with 5nM CA4P, the 
percent cell inhibition in the SKMEL-2, A549 and MCF-7 cell lines was 9.0%, 10.4%  
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Figure 4.5: Growth response of cell lines: combretastatin and metronomically-
dosed Temozolomide 
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Growth of cell lines following 4 days of treatment with metronomically-dosed 
Temozolomide with CA4P was determined by an MTT proliferation assay. All 
absorbance readings were performed using a spectrophotometric plate reader at 
492nM and individual readings were background-subtracted. Readings at 4 hours post 
MTT addition were used as final readings for growth calculation. The growth of 
untreated cells was taken as 100% and the growth of treated populations of cells was 
expressed as a % of this. The histogram bars represent mean growth values +/- 
standard error and statistical significance of results is shown. The data shown are 
representative of at least 2 independent experiments, each conducted in triplicate. 
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and 18.6% respectively (see Figure 4.6 and table 4.1). In summary, this in vitro 
combination showed no evidence of increased anti-endothelial activity than CA4P as 
a single agent, but did show some favourable anti-malignant cell responses. 
 
4.2.2.3 Vinorelbine 
Treatment of MVECs with 1nM vinorelbine alone caused 41.9% endothelial cell 
inhibition, whilst addition of 5nM CA4P resulted in 64.2% endothelial cell inhibition 
compared to the untreated MVEC population (see Figure 4.7 and table 4.1). The 
combinational drug schedule therefore achieved significant enhanced growth 
inhibition (p<0.001) compared to the single vinorelbine treatment. Again, treatment 
of MVECs with 5nM CA4P alone had a better effect than the combination regime in 
achieving endothelial cell inhibition. Addition of 5nM CA4P to 1nM vinorelbine 
resulted in a significant antagonistic effect in the SK-MEL-2 and MCF-7 cell lines 
(p<0.001) compared to vinorelbine treatment alone. Single vinorelbine treatment 
resulted in 41.3% SK-MEL-2 and 17.1% MCF7 cell inhibition (compared to 
untreated cells) but in combination with 5nM CA4P, the SK-MEL-2 cell line 
proliferated by 11.1% and the MCF-7 cell line was inhibited by 0.02% compared to 
the corresponding untreated cell populations. For the A549 cell line, no significant 
synergy was demonstrated between 5nM CA4P and 1nM vinorelbine compared to 
1nM vinorelbine treatment alone. 
In summary, antiendothelial effects with this combination were unremarkable, but 
significant synergy was seen in the SK-MEL-2 and MCF7 cell lines. 
4.2.2.4 Etoposide  
When treated with 0.16µM etoposide alone, MVEC growth was inhibited by 34.5%  
while addition of 5nM CA4P resulted in 66.5% endothelial cell inhibition compared  
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Figure 4.6: Growth response of cell lines: combretastatin and metronomically-
dosed Paclitaxel 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Growth of cell lines following 4 days of treatment with metronomically-dosed 
Paclitaxel with CA4P was determined by an MTT proliferation assay. All absorbance 
readings were performed using a spectrophotometric plate reader at 492nM and 
individual readings were background-subtracted. Readings at 4 hours post MTT 
addition were used as final readings for growth calculation. The growth of untreated 
cells was taken as 100% and the growth of treated populations of cells was expressed 
as a % of this. The histogram bars represent mean growth values +/- standard error 
and statistical significance of results is shown. The data shown are representative of at 
least 2 independent experiments, each conducted in triplicate. 
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Figure 4.7: Growth response of cell lines: combretastatin and metronomically-
dosed Vinorelbine 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Growth of cell lines following 4 days of treatment with metronomically-dosed 
Vinorelbine with CA4P was determined by an MTT proliferation assay. All 
absorbance readings were performed using a spectrophotometric plate reader at 
492nM and individual readings were background-subtracted. Readings at 4 hours post 
MTT addition were used as final readings for growth calculation. The growth of 
untreated cells was taken as 100% and the growth of treated populations of cells was 
expressed as a % of this. The histogram bars represent mean growth values +/- 
standard error and statistical significance of results is shown. The data shown are 
representative of at least 2 independent experiments, each conducted in triplicate. 
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to the untreated cell populations (see Figure 4.8 and table 4.1). Therefore, the 
combined drug schedule demonstrated a significant improvement in growth inhibition 
of MVECs (p<0.001) compared to the single chemotherapeutic schedule. Again, 
treatment of MVECs with 5nM CA4P alone had a greater effect than the combined 
schedule (compared to the untreated MVEC population). For the A549 cell line, a 
slight but significant improved growth inhibition (p<0.05) was observed in the 
combinational regime, achieving an MVEC inhibition of 17.1% compared to the 
untreated cell population, whilst single agents etoposide (0.16µM) and CA4P (5nM) 
achieved 11.2% and 13.4% cell inhibition, respectively (see Figs 3.10 and 3.5). No 
significant synergy or additive inhibitory activity was demonstrated between the 
combinational regime and single etoposide schedule for the MCF-7 cell line. 
However, addition of 5nM CA4P to 0.16µM etoposide resulted in a statistically 
significant antagonistic effect in the SK-MEL-2 cell line (p<0.001) compared to 
etoposide treatment alone. Single 0.16µM etoposide treatment alone achieved 38.5% 
SK-MEL-2 cell inhibition, single 5nM CA4P treatment achieved 11.3% SK-MEL-2 
cell inhibition and the combinational schedule achieved SKMEL-2 cell inhibition of 
12.6%. Therefore, the addition of 5nM CA4P to 0.16µM etoposide appears to have 
negated the cell inhibitory potential of etoposide in this particular cell line.    
In summary, the use of this combination in the in vitro model described showed no 
significant synergistic activity in the cell lines used.  
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Figure 4.8: Growth response of cell lines: combretastatin and metronomically-
dosed Etoposide 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Growth of cell lines following 4 days of treatment with metronomically-dosed 
Etoposide with CA4P was determined by an MTT proliferation assay. All absorbance 
readings were performed using a spectrophotometric plate reader at 492nM and 
individual readings were background-subtracted. Readings at 4 hours post MTT 
addition were used as final readings for growth calculation. The growth of untreated 
cells was taken as 100% and the growth of treated populations of cells was expressed 
as a % of this. The histogram bars represent mean growth values +/- standard error 
and statistical significance of results is shown. The data shown are representative of at 
least 2 independent experiments, each conducted in triplicate. 
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Table 4.1: Summary Table of results of combinations of antiangiogenics 
and cytotoxics given at metronomc dose in the in vitro model. 
 
 
 
 
 
 
 
 
 
 
 
Agent 
Combination 
Cell line Single 
agent – 
cytotoxic 
(% growth 
inhibition 
+/- SE) 
Single agent – 
antiangiogenic 
(% growth 
inhibition +/- 
SE) 
Combination 
– (% growth 
inhibition +/- 
SE + p value) 
Additive 
effect 
seen 
MVEC 80.89+/-
3.19 
70.18+/-2.39 43.02+/-3.72 
p<0.01 
Yes 
SKMEL2 55.26+/-
2.43 
40.09+/-1.76 24.91+/-2.43  
p<0.001 
Yes 
MCF7 55.8+/-5.3 2.3+/-6.4 -8.3+/-4.1 
p<0.01 
Yes 
Temozolomide 
(10µM) + 
Sorafenib 
(5µM) 
A549 No additive effect 
MVEC 76.43+/-
1.41 
70.18+/-2.39 -1.34+/-4 
p<0.001 
Yes 
SKMEL2 58.2+/-2.2 40.09+/-1.76 -180+/-8.0 
p<0.001 
Yes 
MCF7 72.68+/-
1.44 
2.3+/-6.4 -35.82+/-2.62 
p<0.01 
Yes 
Paclitaxel 
(125pM) + 
Sorafenib 
(5µM) 
A549 No additive effect 
MVEC No additive effect 
SKMEL2 58.69+/-
2.84 
40.09+/-1.76 -61.67+/-4.74 Yes 
MCF7 82.92+/-
3.11 
2.3+/-6.4 -149.41+/-
7.31 
Yes 
Vinorelbine 
(1nM) + 
Sorafenib 
(5µM) 
A549 No additive effect 
MVEC 65.52+/-
2.57 
70.18+/-2.39 -40.09+/-5.13 
p<0.001 
Yes 
SKMEL2 61.55+/-
1.4 
40.09+/-1.76 3.84+/-1.28 
p<0.001 
Yes 
MCF7 No additive effect 
Etoposide 
(0.16µM) + 
Sorafenib 
(5µM) 
A549 No additive effect 
MVEC 
SKMEL2 
MCF7 
All cytotoxic 
agents + 
CA4P (5nM)   
A549 
No additive effect seen with any of the cytotoxics 
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4.3. Discussion 
 
This chapter has investigated the potential synergistic effects of extended continuous 
low dose chemotherapy in combinination with sorafenib and combretastatin.  
  
The rationale behind combination regimens as they appear in clinical trials is 
currently wholly empirical. The underlying mechanisms of action of such 
combinations and whether synergistic action exists are poorly understood. One can 
speculate from the molecular knowledge of specific single agents’ mechanism of 
action, and assume that certain agents are likely to be effective in specific tumours, 
but again, this is an empirical approach, showing little understanding of or 
justification for multi-targeted therapies (Maraveyas A et al 2005). Further studies are 
thus required which determine and potentially predict which agents may be 
synergistic, and for what reason at a molecular level. It is with this in mind, that the 
aim of this chapter was to assess the in vitro combination regimens for their efficacy.  
 
For the Temozolomide / Sorafenib combination, significant synergistic enhancement 
of the inhibitory effect of these agents in both the MVEC and the SK-MEL-2 cell 
lines was found. The combination out-performed each single agent in these cell lines 
by an additional 37.87% and 30.35% (p<0.001) respectively (see figure 4.1). 
Temozolomide is an alkylating agent, and there is growing clinical evidence to 
support the use of alkylating agents, including cyclophosphamide, in metronomic 
combination regimens (Orlando L et al 2006; Eisen T et al 2007; Lord R et al 2007; 
Rocca A et al 2007; Garcia A et al 2008) . Further framework studies, as this one 
described, may be useful for agents similar in order to demonstrate the potential 
validity of current combinations and to potentially give clues to finding new 
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synergistic regimens. 
 
As previously described, the scientific rationale for using Sorafenib in the treatment 
of melanoma is clear (Egberts F et al 2008).  Single agent trials in melanoma were 
disappointing (Flaherty K et al 2005), although were very promising in other solid 
malignancies e.g. liver and renal cell carcinoma (Escudier B et al 2005; Llovet J et al 
2007; Llovet J et al 2008). In melanoma, a two or even three-hit strategy will no 
doubt be more effective. Flaherty poses the hypothesis that the 
Temozolomide/Sorafenib duo work well together through BRaf inhibition and 
apoptotic pathways, but that ideally a second targeted agent, rather than a cytotoxic, 
would likely induce a more profound response (Tuma R 2006). This combination 
used in metastatic melanoma already holds promise in phase II clinical trials 
(Amaravadi RK et al 2007). When combined with the parent compound DTIC, 
Sorafenib has produced further encouraging improvements in progression free 
survival (McDermott D et al 2008). This randomised double-blind phase II study 
showed no difference in overall survival with the combination, but significant 
improvement in PFS rates at 6 and 9 months, and in TTP (median, 21.1 v 11.7 
weeks). The regimen was also well tolerated with a manageable toxicity profile. In an 
even more recent phase II trial of temozolomide and sorafenib in advanced melanoma 
patients with or without brain metastases, an extended schedule of temozolomide 
showed a moderate (but not significant) difference in PFS compared to a standard 
dosing regimen (Amaravadi R et al 2009).  Phase III results are needed to determine 
true clinical synergy.   
 
With regards to the Paclitaxel / Sorafenib combination, over 70% synergistic 
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enhancement of the inhibitory effect of these agents was seen in MVEC, SK-MEL-2 
and MCF7 cell lines (see figure 4.2). As previously stated, paclitaxel is a mitotic 
inhibitor which has been shown to induce anti-endothelial effects at concentrations 
lower than those required to inhibit tumour cell proliferation (Drevs J et al 2004; 
Albertsson P et al 2006). Its combination with Sorafenib in clinical trials has, to date, 
shown mixed results. In 2008, a phase III trial evaluating the benefit of adding 
sorafenib to the combination of carboplatin and paclitaxel for the treatment of non-
small cell lung cancer, was halted due to a higher mortality being seen in the 
sorafenib group.  Interestingly, our in vitro study also showed no synergistic activity 
with this combination in the A549 (lung cancer) cell line which was in fact the only 
cell line which did not show a positive response to the combination. Comparison 
between in vitro single cell line studies and clinical trials can only be observational 
and not translational, until intermediate studies can add weight to data, but it is 
nevertheless an interesting observation in this study. The Paclitaxel / Sorafenib 
combination is now also being studied in phase II trials for stage IV melanoma and 
metastatic breast cancer, with results awaited. Paclitaxel has shown a modest effect in 
the treatment of metastatic melanoma to date, but is currently only used as a second-
line therapy and in combination with carboplatin (Rao R et al 2006). Results of phase 
III trials of these agents used as second-line treatment in melanoma, showed no 
improvement in PFS or ORR with the addition of sorafenib (Agarwala S et al 2007).  
In vitro evidence may well have provided a sound basis for these combinations prior 
to them reaching the in vivo setting.Results of this same triple combination are 
currently awaited from an active trial in patients with stage IV melanoma of the eye.  
 
The Vinorelbine / Sorafenib combination showed no significant enhanced 
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endothelial response, but did show over 100% enhanced response to single agents 
with the melanoma and breast cancer cell lines (see figure 4.3). Clinical trials to date 
in vinorelbine-based melanoma treatment have been mainly focussed on single agent 
or multi-chemotherapeutics, without an anti-angiogenic agent. So far, results have 
been disappointing (Retsas S et al 1996; Whitehead R et al 2004). Anti-angiogenic 
style phase II study results are awaited. In other solid malignancies, such as breast 
cancer, phase II phase II trials of vinorelbine in combination with antiangiogenics i.e. 
trastuzumab show promise (Chollet P et al 2007). Interestingly, these early trials 
using anti-angiogenic agents often involve conventional dosing of chemotherapeutics, 
which as previously explained, would seem to negate the efficacy of such an 
approach. Since our in vitro model showed no enhanced anti-endothelial effect with 
this combination, further studies comparing conventional and metronomic schedules 
may provide further information on agent and dose synergy. This emphasises the 
importance of a screening tool to determine which chemotherapeutics may be suitable 
for the metronomic response. 
 
The Etoposide / Sorafenib combination showed a significantly enhanced response 
compared to single agents in both the MVEC and SK-MEL-2 cell lines by over 55% 
(see figure 4.4). Of all the sorafenib-chemotherapy combinations, this combination 
showed the greatest anti-endothelial synergistic effect. This was greater than the 
effect seen in both the temozolomide and paclitaxel combinations. This suggests that 
the combination has a very active anti-endothelial effect, and would potentially 
warrant future study in both the in vivo and clinical setting. In designing such future 
studies, it would be important to start where etoposide has known phase III data (eg 
small cell lung, ovarian and prostate cancer) although, as with all anti-angiogenic 
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clinical trials, monitoring of efficacy and response remains a challenge (Artal-Cortes 
A et al 2004). Chapter 5 will discuss the potential use of CECs and CEPs in 
monitoring response in anti-angiogenic, metronomic regimens.  The findings from the 
melanoma cell line data could be compared to an earlier phase II etoposide / cisplatin 
trial in patients with melanoma that showed no additional clinical efficacy (Eton O et 
al 1991). It may be that an in vitro screening tool for combination regimens may help 
to eliminate ineffectual combinations from heading to the clinical stage. 
  
The effects of combining Combretastatin, a non-specific anti-angiogenic agent, were 
not as successful as that observed with a specifically targeted agent such as Sorafenib. 
These results concur with the findings of Lam et al who compared the effects of 
combining a specific anti-VEGFR-2 monoclonal antibody to a non-specific farnesyl 
transferase inhibitor in a combinational schedule with low dose cytotoxics in an in 
vitro HUVEC model (Lam T et al 2007). With respect to the effects of combinational 
therapy involving CA4-P and the low dose cytotoxic agents on the 3 carcinoma cell 
lines, in the majority of cases, an antagonoistic effect was seen in comparison to the 
single therapy schedules (see figures 4.5-4.8). In particular, CA4-P in combination 
with vinorelbine resulted in 11.1% proliferation (compared to untreated cell 
populations) in the SK-MEL-2 cell line, whilst both single agents demonstrated anti-
proliferative effects upon this cell line (see figures 3.5 and 3.9). Therefore, although 
CA4-P combined with low dose chemotherapy resulted in some anti-endothelial 
effects, the adverse effects demonstrated in the cancer cell lines suggests that CA4-P 
may have reduced the efficacy of the cytotoxics, making the combinations unsuitable 
in this in vitro model.  
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Chemotherapeutic activity has, in the past, been shown to diminish with decreased 
tissue oxygenation and blood flow (Horsman M et al 1991). Since CA4-P is known to 
cause tumour vascular disruption, it has the potential to disrupt or even diminish the 
efficacy of cytotoxics (Dark G et al 1997). With an in vitro model, it is impossible to 
assess these pathophysiological mechanisms of action, and therefore further in vivo 
work would be required to specifically look at whether vascular disruption truly limits 
chemotherapeutic efficacy. There is pre-clinical evidence however to show excellent 
synergy between carboplatin and CA4-P in rodent models, but this combination was 
terminated in a phase I clinical trial due to early dose-limiting toxicity (Bilenker J et 
al 2005). Through these combination studies, we have excluded carboplatin as it was 
shown in the single agent studies to be a drug with no obvious metronomic profile. 
Moreover we have failed to find any combretastatin chemotherapy combination better 
than combretastatin alone. The limitations of the in vitro study model have however 
prevented the assessment of combretastatin’s mechanism of action on vasculature, 
and without more reliable in vivo or clinical data, the combinations can not be ruled 
out as being inappropriate. However, if further pre-clinical work, based on these 
findings, suggested similar futility from such combinations, it may prevent phase I 
trials, based on empiricism, from being undertaken.  
 
The study has however shown that at least four sorafenib chemotherapy combinations 
have a synergistic antiendothelial and antiproliferative effect, of which the most 
striking was that of sorafenib and etoposide as discussed above. These results can 
provide a starting framework from which further in vivo and clinical studies can take 
place. 
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Although in vitro work will never fully translate to human studies, here we 
demonstrate a logical approach, using clinically relevant agents at achievable doses 
and in relevant combinations. In this potentially confusing era of multi-targeted 
combinational therapy, new agents are being developed almost every week. 
Oncologists require a framework or at least a justifiable starting point to select drug 
combinations and doses for patients with all malignancies (Maraveyas A et al 2005). 
The work in the last 2 chapters delineates one potential such approach, and may well 
aid the early elimination of ineffectual or even deleterious combinations. Since 
combinatorial options are huge, alternative, potentially more effectual options are 
plentiful, provided they are at least given the chance at an in vitro level first.  
 
The other important issue here is that true antiangiogenic approaches are being used 
in only a handful of new combination trials (Glode L et al 2003; Gille J et al 2005; 
Colleoni M et al 2006; Kesari S et al 2007; Lord R et al 2007). Instead, many multi-
agent trials are using conventionally-dosed chemotherapy - which as previously 
described is pro-angiogenic - with specific anti-angiogenics in the hope of achieving 
success (International Adis 2008; McDermott D et al 2008). These are often based on 
intuition and empirisicim rather than a true scientific justification for the regimen. It 
would seem counter-productive to pursue such proangiogenic-antiangiogenic 
combinations given the current molecular understanding of tumour biology. This 
reiterates and emphasises the urgency for screening tools and surrogate markers of 
angiogenesis.    
    
Throughout the last two chapers, the limitations of using in vitro models such as 
MVECs or any other endothelial cell type to represent tumour endothelium have been 
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emphasised. As previously mentioned, we feel that there is a valid argument to use 
the MVEC model over the HUVEC model, since cells of microvascular origin more 
accurately reflect angiogenesis in vivo (Salcedo R et al 2000). However, neither 
model take into account the anatomical complexity of tumour-related vasculature, 
which includes other essential stromal and vessel-wall components.In vivo animal 
models can take into account the pharmacodynamic dimension that this model would 
not be able to provide. In vitro models will never truly represent the in vivo process, 
although in vitro chemosensitivity assays do play an important role in the 
development of regimens and add weight to clinical trials (Browder T et al 2000; 
Bocci G et al 2002; Lam T et al 2007). In vivo studies looking at drug combinations 
in the future, could potentially use similar in vitro screening tools in order to have 
some evidence, although rudimentary, on which to base in vivo their work. Our work 
demonstrates that the effects of ECS can be significantly enhanced with addition of a 
specific agent that targets molecules involved in angiogenesis. It is a readily 
available, reproducible and technically simple in vitro screening system for drugs 
used in cancer treatment, either as single or combination agents.  
 
This model does not supplant or obviate the need of in vivo work. It can however 
prioritise more promising regimens and in some cases demonstrate clearly 
antagonistic combinations that would not be justified to be studied further otherwise. 
The question of ethics of taking ineffective combinations to further study if at a 
cellular level they are actually shown to be antagonistic is clearly raised. With limited 
resources for further in vivo studies, our data would clearly prioritise which 
combinations should be preferred over others. For example from this work the 
combination of sorafenib and etoposide would be prioritised for further study in 
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relevant cancer settings. 
 
Since there are an ever increasing number of traditional cytotoxic and molecularly-
targeted agents, the task of categorising all agents is vast. However, it is important to 
produce patterns of synergistic responses between agents and eventually move 
forward to determine changes in down-stream proteins that are pertinent to specific 
agents. Analysis of the proteome may well prove to uncover unknown targets of both 
specific and non-specific agents, and also shed light on mechanisms of synergy or 
antagonistic effects (Rosenblatt K et al 2004). This may also provide further 
justification for tailor-made regimens designed for specific patients and tumours, 
aiming for maximum efficacy rather than maximum cytotoxicity. 
 
In conclusion, further studies need to be undertaken to define the mechanisms of 
action of different anti-angiogenic agents, which cytotoxics are suitable for the 
metronomic approach and to determine true synergistic responses that may, in the 
future, be taken forward to the clinic. Cancer as a whole remains the second leading 
cause of death in the developed world. A cure may still be a distant hope, but the 
metronomic, multi-targeted approach has potential for producing a chronic disease 
state. 
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Chapter 5 
Isolation of CECs and CEPs in patients with metastatic melanoma on 
metronomically-dosed chemotherapy versus conventionally-dosed 
chemotherapy. 
 
5.1 Aims and Introduction 
 
The aims of this chapter are: 
1. To test methodology and to optimise the technique of isolating CECs and 
CEPs from whole blood. 
2. To isolate CECs and CEPs from whole blood samples of patients recruited 
into the scientific sub-study (as described in chapter 2). 
3. To compare CEC and CEP levels between patients on metronomically-
dosed and conventionally-dosed chemotherapy. 
 
 
Angiogenesis is now known to be central to tumour biology. As described throughout 
previous chapters, it is the discovery of this that has led to the development of a 
multitude of molecularly-targeted anti-angiogenic agents. Accompanying this, there is 
an increasing demand for surrogate markers that reflect tumour vasculature and its 
response to treatment (Ruegg C et al 2003). The endpoints of classical anti-cancer 
trials no longer give sufficient discriminative powers in antiangiogenic trials. 
Currently, the National Cancer Institute recommends that RECIST (Response 
Evaluation Criteria in Solid Tumours) is used to discriminate response. This criteria 
involves the use of Xray, CT and MRI to measure target lesions, and despite attempts 
to improve this system using 3D technology, it remains an inadequate evaluation tool 
in the context of antiangiogenic trials  (Therasse P et al 2009).  
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In the last decade, there have been over 100 molecules (e.g. VEGF, angiogenin, D-
dimer) that have shown antiangiogenic activity in preclinical studies, with only a 
handful showing measurable anti-tumour activity in clinical trials (Bocci G et al 
2004; Sandler A et al 2006; Motzer RJ et al 2007). Table 5.1 shows a list of agents 
which have been shown to inhibit tumour angiogenesis (Horsman M et al 2010). 
Identification and validation of molecular and cellular markers remains essential, 
particularly in determining long-term efficacy of antiangiogenic regimens. 
 
Two such markers, circulating endothelial cells and circulating endothelial progenitor 
cells (CECs and CEPs – see section 1.2.3 and 1.2.5), have been identified and 
continue to be validated as potentially useful markers of tumour vasculature activity 
(Raia V et al 2007). There is accumulating evidence from both pre-clinical and 
clinical studies that they play an important role in tumour growth and 
neovascularisation, as discussed in section 1.2.5 (Carmeliet P and Lutton 2001; Lyden 
D et al 2001; Rafii S et al 2002; Davis DW et al 2003; Beerepoot L et al 2004; Peters 
B et al 2005; Duda D et al 2006; Yu D et al 2007; Calleri A et al 2009). Several 
assays, based on manual or automated immunomagnetic isolation or flow cytometry, 
have been described for the detection and quantification of these cells to date. The 
different assays described are subject to errors in sampling, preparation and analysis 
(Strijbos M et al 2008; Michael A et al 2010). Although a consensus on the optimal 
technique is still lacking, the number of studies assessing CECs and CEPs in cancer 
patients is rapidly expanding, and more recently, showing varying trends dependent 
on which anti-angiogenic agent is being studied, making their biomarker value 
deferential (Farace F et al 2007; Duda D et al 2008; Michael A et al 2010).  
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Table 5.1: List of agents shown to inhibit tumour angiogenesis 
 
Angiogenesis Inhibitors 
 
Tissue inhibitors of MMP (TIMP) 
Thalidomide, Lenalidomide, Pomalidomide 
Suramin and analogues 
Fumagillin and TNP470 analogue 
Cytokines 
CAI 
Endostatin 
Angiostatin 
Thrombospodin 
Arginine Deiminase 
Anginex 
Anti-VEGF antibodies (Bevacizumab / Avastin) 
Anti-VEGFR antibodies (DC101) 
BAY 43-9006 (Sorafenib/ Nexavar) 
SU5416 (Semaxanib) 
SU6668 
SU11248 (Sunitinib / Sutent) 
PTK787/ZX222584 (Vanatanib) 
ZD6474 (Vandetanib / Zactima) 
GW786034 (Pazopanib / Votrient) 
AZD2171 (Cediranib / Recentin) 
Robo4 
EGFR inhibitors 
COX-2 inhibitors 
mTOR inhibitors 
Chemotherapy (metronomic) e.g. temozolomide 
 
 
 
 
Table adapted from (Horsman M et al 2010) 
 
 
 
 186
5.1.1 Rationale for and potential applications of the enumeration of CECs and 
CEPs in clinical oncology 
The role of angiogenesis in tumour growth has already been covered in depth (see 
chapter 1). The role of CECs and CEPs will be described in detail in this section, 
along with the rationale behind their enumeration in malignant melanoma.  
 
Increases in number of circulating endothelial cells (CECs) and progenitors (CEPs) 
have been reported not only in association with malignancies, but also in various 
pathological conditions e.g inflammatory arthritis and macular degeneration (Kerbel 
R 2000). CEC and CEP kinetics have been shown in preclinical and clinical studies to 
correlate with angiogenesis assays and to be a potential predictive tool for clinical 
outcomes in patients undergoing anti-angiogenic treatment (Rugo H et al 2006; 
Farace F et al 2007; Duda D et al 2008).  
 
CECs have a mature phenotype and are probably derived from blood vessel wall 
turnover (Lin Y et al 2000). This is a rare population, accounting for approximately 1 
in 1000 circulating blood cells (or 0-20 CECs per mL) in the healthy individual 
(Blann AD et al 2005). It is a stable cell population, with the exception of a two-fold 
increase in women during the active menstrual cycle, associated with uterine 
remodelling (Mancusco P et al 2001).  A subpopulation of CECs shows a progenitor-
like phenotype. These have been shown to be able to incorporate into cancer vessel 
walls, although at low frequencies (Davidoff AM et al 2001). Some studies suggest 
that CEPs are paramount in promoting cancer vasculogenesis and are responsible for 
most endothelial cell proliferative potential (Ruzinova M et al 2003; Duda D et al 
2006). However, as previously described in section 5.1, low cell numbers of CECs 
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and CEPs, render assays highly susceptible to errors in sampling, preparation and 
analysis (Strijbos M et al 2008). Several groups, for instance, have demonstrated the 
negative impact of venepuncture, as traumatically detached CECs contribute 
significantly to CEC counts (Goon P et al 2006; Rowland JL et al 2007). Because of 
the low numbers, enrichment steps are helpful, although inevitably lead to cell loss 
and underestimation of actual CEC/ CEP numbers.  
 
Both these cell types pose as potentials for drug- targets to induce an anti-angiogenic 
response. Figure 5.1 shows potential routes via which traditional chemotherapy drugs 
can achieve anti-angiogenic effects. As previously described, VEGF is a potent 
mobiliser of CECs and a pro-survival factor for differentiated, activated endothelial 
cells. Inhibition of VEGF or VEGFR has been shown to be clinically effective in 
treating renal cell carcinoma, which is a highly-vascular type of tumour (Board R et 
al 2007; Motzer RJ et al 2007; Escudier B et al 2008) . 
The introduction of monoclonal antibodies (e.g.CD146) (Dignat-George and Sampol 
J 2000) with specificity for endothelial cells has led to the development of two main 
techniques for CECs and CEPs to be isolated: immunomagnetic bead selection and 
flow cytometry. Over the last two decades, immunomagnetic bead selection has 
continued to be developed (George F et al 1992; Dignat-George and Sampol J 2000; 
Woywodt A 2006). It initially involved the coupling of magnetic dynabeads to an 
anti-CD146 monoclonal antibody and then mixing them with peripheral blood. 
Unbound cells are washed out, but bound cells are magnetically retained. CECs are 
identified by the expression of von Willibrand factor (a blood glycoprotein involved 
in haemostasis) and the absence of CD45 (a transmembrane protein tyrosine 
phophatase present on all differentiated  
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Figure 5.1: Chemotherapy antiangiogenic targets 
 
a) targeting bone-marrow derived proangiogenic cells that adhere to the walls 
of new blood vessels and stimulate further growth via paracrine mechanisms 
b) targeting cycling endothelial cells present in sprouting capillaries of tumours 
c) bone-marrow derived CEPs that incorporate into the lumens of growing 
vessels and differentiate into endothelial cells.  
 
Diagram adapted from (Ferrara N and Kerbel 2005). 
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haematopoietic cells except erythrocytes and plasma cells) (Bertolini F et al 2006). 
This technique has been revised and refined, with multiple surface markers (eg 
CD146, CD31, CD34) being used to define CEC populations  by multiparameter flow 
cytometry (Blann AD et al 2005; Strijbos M et al 2008). 
 
There is however, a lack of consensus on a common endothelial cell phenotype. To 
date, the numerous studies investigating CECs and CEPs use a broad spectrum of cell 
markers e.g. CD31 (Beerepoot L et al 2004), CD34 (Furstenberger G et al 2006), 
VWF (Woywodt A et al 2006) for CECs and CD34 and CD133 (Yin A et al 1997) 
for CEPs. Published assay techniques define CECs as positive for CD146 (Mancusco 
P et al 2006). There is however, data to suggest that CD146 is expressed on vascular 
endothelium but not on viable CECs (Duda D et al 2006). There is also evidence that 
CD146 is also expressed on active lymphocytes, which are frequently increased in 
cancer patients, therefore skewing the results of studies using this as their cellular 
marker (Elshal M et al 2005; Duda D et al 2006). For these reasons, CD146 was not 
used as the cell marker in this study.  
 
CEPs are present at a lower percentage in comparison to mature CECs and remain 
proliferative in nature. They are CD133 positive compared with mature CECs  which 
are negative for this marker (Rafii S et al 2002), but a clear distinction between CEPs 
and haematopoietic stem cells (HSCs) is hampered by their expression of CD133, 
making this a current limitation in the sub-set isolation process. At the current time, 
the best way to distinguish between CEPs and HSCs is by their function rather than 
by their phenotype alone (Peters B et al 2005; Mancusco P et al 2006; Roodhart J et 
al 2010).  
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Preclinical studies have previously indicated that the counting of CECs and CEPs can 
be used to identify the optimal biological dose (OBD) in cancer-bearing mice treated 
with low-dose metronomic chemotherapy (Shaked Y et al 2005). Other studies have 
shown that, with antiangiogenic therapy, the number of these cells changes. Beaudry 
et al showed that with VEGF-inhibition in tumour bearing mice, the number of 
mature CECs increased (Beaudry P et al 2005). Further clinical studies have shown 
increased numbers of mature CECs in patients with progressive cancer, and increased 
apopototic CECs in patients on metronomic therapy. Enumeration of these cells has 
therefore been shown to have a potential role in therapeutic and monitoring strategies, 
particularly in anti-angiogenic cancer treatment (Kerbel RS and Kamen 2004; 
Dellapasqua S et al 2008; Roodhart J et al 2010).  
 
The key differences between MTD regimens and metronomic therapy have been 
described in the introduction to this thesis (see section 1.3.1). In contrast to MTD 
chemotherapy, metronomic chemotherapy regimens maintain the low levels of viable 
CECs for longer periods of time due to the absence of break periods (associated with 
surges in tumour neoangiogenesis) (Carmeliet 2003). The addition of an anti-
angiogenic agent to the traditional MTD regimens has been shown to prevent the 
rebound mobilisation of CEPs after MTD therapy (Browder T et al 2000; Bertolini F 
et al 2003; Kerbel RS and Kamen 2004; Schenider M et al 2005). Bertolini and 
colleagues showed in a preclinical study that metronomic chemotherapy was 
associated with a consistent decrease in CEP numbers and viability and a more 
durable inhibition of tumour growth although the clinical significance of this remains 
uncertain. (Bertolini F et al 2003). Beaudry’s preclinical study indicated that anti-
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angiogenic drugs might have dual effects on CECs and CEPs, such as an increase in 
CEC count that parallels the inhibition of CEP mobilisation in the peripheral blood 
(Beaudry P et al 2005).  
 
CEC and CEP enumeration correlate well with preclinical gold standard angiogenesis 
assays and hold potential for OBD determination and disease monitoring. The 
application of CEPs as a potential vehicle for anticancer treatments has also been 
studied (Ferrari N et al 2003; Dome B et al 2006).  Provided that an adequately 
validated, sensitive and specific assay is used, the detection and enumeration of CECs 
and CEPs in patients with solid malignancies offers a wide spectrum of applications. 
Some of these are detailed below: 
a) Prognostic marker  
It has been observed that some cancer patients, including breast, hepatocellular, renal 
cell and colorectal cancers, show higher CEC counts than healthy controls, whereas 
patients with stable disease have lower numbers, equivalent to disease-free 
individuals (Duda D et al 2008; Rugo H et al 2005; Malka D et al 2007, Farace F et 
al 2007). This area requires further study in large randomised controlled trials that 
include anti-angiogenic regimens. As the field progresses, individual differences need 
to be taken into consideration, but CECs may well serve as a common indicator of 
disease relapse .   
b) Marker for therapy-induced response 
Radiological assessments to look at tumour size as a marker of antitumour effects of 
therapy are now thought to be insufficient, despite recent advances in RECIST 
(Therasse et al P 2009). This is particularly true in the case of anti-angiogenic 
regimens, where enhanced progression-free periods have been observed, yet response 
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rates as defined by conventional imaging, were minimal (Yang J et al 2003). More 
sensitive indicators of response are therefore needed. Diminished CEC levels have 
been shown in mice treated with endostatin, an angiogenesis inhibitor (Schuch G et al 
2003). CEC and CEP kinetics and viability have also shown to predict clinical 
response in some metronomic regimens (Dome B et al 2006; Mancusco P et al 2006; 
Dellapasqua S et al 2008; Roodhart J et al 2010). 
c) Guideline for optimal drug dosing  
The OBD is the dose that is feasible to be safely applied to humans and likely to yield 
biological effects. This dosing method supports the metronomic theory as described 
in chapters 3 and 4  (Bertolini F et al 2003; Maraveyas A et al 2005; Lam T et al 
2006).. Thus the concept of MTD will need to be redefined as a dose that can be 
administered safely over a long duration . Changes in CEC and CEP counts after dose 
escalation might provide useful insights in establishing the OBD when assessing anti-
angiogenic agents. One study showed that the OBD, determined by assessment of 
tumour microvessel density and analysis of tumour blood flow, resulted in the largest 
decrease in CEC numbers. Also, administration of varying amounts of endostatin (a 
‘broad-spectrum’ antiangiogenic) resulted in a clear ‘U-shaped’ dose-response curve 
on CEC percentage (Celik I et al 2005). See Figure 5.2. Clinical studies have since 
shown the prevention of CEP and CEC mobilisation when using the OBD or 
metronomic approach to dosing (Stoelting S et al 2008).  
 
d) Marker for vascular toxicity 
With the suggestion from some studies that the incidence of cardiovascular events has 
now emerged as one of the most important sequelae of long-term anti-cancer therapy, 
the use of CEC and CEP measurements to predict this has been suggested. In vitro  
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         Figure 5.2: Inhibition of CECs by Endostatin – the ‘U-shaped curve’ 
This study was carried out in vivo (mouse-model) and clearly shows that there is a 
range of dosing of Endostatin where CEC mobilisation / viability is kept to a 
minimum, but that too high a dose can actually induce CEC stimulation / 
mobilisation. This is a biphasic dose-response curve, not a linear one. It is similarly 
shown by IFN-α as reported by Slaton et al 1999. 
 
 
 
 
 
 
 
 
Diagram taken from (Celik I et al 2005). 
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and clinical evidence suggests that cytotoxic agents can directly damage endothelium 
(van Heeckeren W et al 2006). Commonly used agents such as cisplatin, etoposide 
and bleomycin can cause thickened arteries, Raynaud’s syndrome, increased VWF 
and plasma C-reactive protein, associated with endothelial cell dysfunction (Nuver J 
et al 2005). Monitoring CECs throughout treatment might give a closer insight into 
the vascular toxicity profile of chemotherapeutic agents. This data could be used to 
select less vasotoxic treatments, especially for those patients likely to require long-
term therapy e.g. germ-cell cancers, lymphoma  or for those with coexisting 
cardiovascular morbidity. 
 
Figure 5.3 shows the hypothesis of CEC kinetics with treatment. It is thought that 
with the onset of anti-angiogenic therapy, mature CECs initially increase (mainly 
apoptotic CECs) where as CEPs decrease. As tumour load reduces, CECs are also 
reduced. Relapse or failure of response to treatment may be marked by an increase in 
both of these cell populations .  
With anti-angiogenic therapy being currently one of the key areas of interest in 
modern clinical oncology, particularly in the multi-targeted regimens, such 
biomarkers are essential, particularly in solid malignancies where new treatment 
strategies are urgently needed. This is certainly the case for malignant melanoma. 
   
5.1.2 Rationale behind comparing conventional-dose chemotherapy to 
metronomically-dosed chemotherapy in melanoma 
 
Advanced melanoma remains uniformly fatal and systemic therapy induces durable  
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Figure 5.3: Hypothesis of CECs kinetics with treatment  
Hypothesis of CECs kinetics with treatment 
(A) predicted change in mature CECs and CEPs that could accompany antiangiogenic 
treatment. On treatment initiation, CECs tend to increase and CEPs decrease. As 
tumour burden decreases, so does the mature CEC count. It is possible that tumour 
relapse may be indicated by a surge in both cell types. The initial CEC surge is 
accounted for by a surge in CEC apoptosis (B). 
 
 
 
 
Diagram taken from (Bhatt R et al 2007). 
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responses in a small minority of patients. The introductory section on the oncologists 
challenge in treating melanoma describes this in more detail (section 1.4.5). There 
remains an urgency to find better regimens and to compare their efficacy with older 
conventional regimens. Dacarbazine (DTIC) has historically been the first line single-
agent chemotherapy drug for advanced melanoma. Its reported response rates of 20% 
have been dispelled by randomised controlled trials that confirm response rates of 
only 7.2-7.5% (Avril MF et al 2004; Bedikian A et al 2006). Despite this, DTIC 
remains the only cytotoxic drug approved by the U.S Food and Drug administration 
for the treatment of metastatic melanoma, and is still the mainstay of many 
combination regimens (see section 1.4.5 and 3.1.2.1). 
 
Temozolomide, as discussed in section 3.1.2.1, has shown equivalent efficacy to 
DTIC in terms of objective response rate, time to progression and overall disease free 
survival (Middleton M et al 2000). So far, only a moderate difference in PFS 
compared to a standard dosing regimen when in combination with sorafenib has been 
shown in melanoma patients, as discussed in section 4.3 (Amaravadi R et al 2009). 
 
The lack of viable alternatives has often driven the conduct of combination trials in 
melanoma rather than true biologic rationale based on laboratory or clinical evidence 
of synergistic activity. Modest phase II results have led to disappointing phase III 
results. These have been mainly using sorafenib and bevacizumab, in combination 
with DTIC, Temozolomide and other cytotoxics (Amaravadi RK et al 2007; Escudier 
B et al 2008; McDermott D et al 2008; Amaravadi R et al 2009; Hauschild A et al 
2009). As previously discussed, such failures may be attributed to empiricism of trials 
rather than because of proof of synergy or mechanism of action through tissue studies 
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(Maraveyas A et al 2005; Gogas H et al 2007). Pre-clinical work is therefore essential 
in this confusing era of multi-targeted combination regimens.  
 
This pilot study therefore aims to enumerate CECs and CEPs in patients with 
metastatic melanoma receiving metronomically-dosed chemotherapy. This patient 
group was compared to those receiving conventional chemotherapy based on MTD, 
and also to healthy controls with the objective to see whether we could identify any 
difference in the kinetics of these circulating markers. The treatment protocol devised 
for this study was based on a dose escalation schema to achieve the metronomic or 
OBD (Maraveyas A et al 2005; Lam T et al 2007) (see section 2.2.1, table 2.1.). 
Enumeration of CECs and CEPs in the chosen patient groups before, during and after 
treatment was carried out, aiming to obtain proof of principle data. 
  
This chapter focuses on the clinical arm of the study of anti-endothelial treatment in 
patients with stage IV metastatic malignant melanoma. The patient group is described 
in more detail in Table 5.2, but in summary they fall into 2 groups - one receiving 
conventional MTD chemotherapy (DTIC plus vindesine) and the other receiving 
extended-schedule oral temozolomide and estramustine (see table 2.2). The 
metronomic group were patients recruited into the study at level 5a and 6 (see table 
2.2) of the dose-escalation scheme of the the phase I/II study of temozolomide and 
estramustine. At these dosing levels, (described in section 2.2.1) no conventional 
bone marrow toxicity (as monitored by serial full blood count measurements) had 
been seen and 33% of MTD was not exceeded, as per metronomic principles.  
 
 
 198
Table 5.2: Summary table of study participants and their demographics 
*Conventional  – DTIC+Vindesine; *Metronomic – Temozolomide+Estramustine (at dose level 5a/6) 
 
 
 
 
 
Patient Age at  
presentation
Sex Primary site & 
Breslow thickness 
Site of metastatic disease Stage/TNM 
start of 
study 
 
Conventional MTD*DTIC-Vindesine* 
 
1 48 M 
 
R chest – 4.7mm Axillary (1/20 nodes), 
pulmonary+mediastinal 
IV 
T4N1M1b 
2 63 M Back – 1.9mm Axillary (1/20 nodes),  
pulmonary   
IV 
T2bN1aM1b
 
3 35 F L heel – 2.35mm Groin (5/15 nodes), pulmonary, 
mediastinal, local recurrences 
 
IV 
T3aN3M1b
4 58 F R loin –   
inconclusive  
Breslow but S100+ 
R inferior pubic ramus (associate
pathological fracture). Refer to 
case report Appendix 4.  
IV 
T?N0M1c 
Metronomic ‘Level 5a and 6 Temozolomide –estramustine-* 
 
1 70 M R flank – 5 mm Hepatic + pulmonary IV 
T4N0M1c 
 
2 52 F Posterior neck 
-0.52 mm, Right  
abdomen – 3.1 mm 
Axillary, multiple pulmonary IV 
T3N1aM1b
3 39 F L foot – 5.4 mm  L groin, hepatic IV 
T4N2aM1c 
 
4 67 M L inner canthus 
 eye – 2.3mm  
L neck nodes, hepatic, 
local recurrence 
IV 
T2N1bM1c 
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5.2 Optimisation methodology and control samples 
 
The initial stages of CEC and CEP isolation involved a series of optimisation 
experiments. For this, blood samples were first taken from an additional 4 healthy 
volunteers – not those used as the study control group (table 5.3).  These volunteers 
were seen at the ‘benign skin lesion clinic’. They were all given the relevant 
information sheet and consent form (LREC number 06/Q1105/38; HEY number 
R0397; see Appendix 2.3 and 2.4) prior to participating. Additional samples from 3 
patients outside the study group with known stage III or IV metastatic melanoma 
were also used in the optimisation process. These were surplus samples from a 
previous similar study carried out within the department studying the impact of 
Interferon alpha on CECs and CEPs.  Ethical approval had already been gained for 
this previous study (LREC number 05/Q1105/76) and therefore all participants were 
fully informed and consented. Blood samples had been collected and stored using the 
same methodology as used in this study. 
 
5.2.1 The freeze-thaw process optimisation 
The freeze-thaw process (see section 2.2.2.4) was initially optimised to ensure frozen 
vials had a high yield of live cells. Yield was improved by using all reagents at 4oC 
throughout, by increasing centrifugal force to 1500rpm and by increasing washing 
steps from one to three to minimise debris. These steps ensured that cell yield 
averaged around 1x107 per vial. There was a moderately better cell yield (1.5-
1.7x107) seen when working with fresh blood directly through all steps rather than 
with frozen samples. However, given the infrequency of patients entering this 
particular study, the random times of their clinic attendances – often changed at short 
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notice, the high cost of reagents and the short expiry dates on microbeads and 
antibodies, this was deemed an impractical way to work. The optimised freeze-thaw 
process was therefore used, and samples processed in batches. 
 
Table 5.3: Healthy volunteer demographics 
 
 
 
5.2.2 Microbead-cell adherence 
The next stage of optimisation involved ensuring that the endothelial cells were 
actually adhering to the specific microbeads. This was confirmed by microscopic 
examination and by using a magnet adjacent to the microscope slide. Visible 
movement was seen under microscopic examination of the cell-bead duo towards the 
magnet when this manoeuvre was carried out, providing evidence for the adherence 
of the microbeads to endothelial cell walls. 
 
5.2.3 Optimising selection 
The depletion and positive selection stages were looked at, to ensure that CECs and 
CEPs were not being lost in the process. From a control sample (healthy volunteer) of 
3x107 cells/mL, cell counts showed 1.7x107 cells/mL in the CD45 positive fraction 
and 1.6x106 cells/mL in the CD45 negative fraction. The CD45 positive fraction was 
Healthy volunteer Age Sex 
1 67 M 
2 32 F 
3 50 M 
4 29 F 
 201
then incubated with CD34-FITC and CD133-PE to see if any of the wanted cells 
(CECs and CEPs) were retained in the column. The CD34 negative fraction collected 
after positive selection for CD34 was also incubated with CD34-FITC and CD133-PE 
to see if any of the wanted cells had passed through the column, either due to bead-
saturation or for other reasons.  
 
Next, the CD45 depleted sample chosen for use was checked for the presence of stray 
CD45 positive cells using CD45 microbeads and CD45 FITC to ensure that the initial 
depletion process had been satisfactory and that the results were not skewed by a high 
proportion of CD45 positive cells. This showed that 0.01% of the CD45 positive 
fraction contained CD34 positive cells and that 0.06% of the CD45 negative fraction 
contained CD45 positive cells. 
 
5.3 Results  
The aim of this scientific ‘pilot’ sub-study was to compare the numbers of CECs and 
CEPs (measured in cells/µL of whole blood) between the conventionally-dosed and 
the metronomically-dosed patient groups at different stages in their treatment cycles.  
A control group of age and sex matched healthy volunteers was also used for 
comparative purposes.   
 
Results for the ‘conventionally-dosed’ and ‘metronomically-dosed’ patient groups are 
as shown, with healthy volunteer results listed below. Results are displayed below in 
table 5.4. 
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Table 5.4: Results of CEC/CEP enumeration in the study groups 
 
 
Patient  CEC/CEP baseline 
(cells per µL) – 
 Week 0 
CEC/CEP  
mid-treatment  
(cells per µL) – 
 Week 6 
CEC/CEP  
post-treatment 
(conventional) or 
at 3 months 
(metronomic)  
(cells per µL) – Week 12  
Conventional     
1 8.14 /  0.68 5.43 / 0.59 11.53 / 0.88 
2 13.27 / 0.23 9.62 / 0.21 15.27 / 0.51 
3 17.16 / 0.19 12.83 / 0.13 18.34 / 0.46 
4 17.45 / 0.31 10.33/ 0.26 2.32 / 0.38 
Metronomic    
1 8.00 / 0.03 9.00 / 1.65 11.67 / 0.95 
2 4.27 / 0.12 13.81 / 0.1  15.26 / 0.12 
3 3.03 / 0.09 9.32 / 0.12 9.06 / 0.08 
4 10.92 / 0.62 12.88 /  0.61 8.54 / 0.54 
Healthy Controls  
1 1.01 / 0.0 
2 1.12 / 0.0 
3 0.45 / 0.02 
4 0.86 / 0.0 
 
 
 
*results are based on mean of duplicates and expressed in cells / µL of whole 
blood. 
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As can be seen from the results, there were 4 participants in each study group. CEC 
and CEP were estimated in both the control and treatment groups to obtain baseline 
(pre-treatment) data. The metronomic group were all chemo naïve for the pre-
treatment sample. Repeated measurements of CEC and CEP were made from the two 
treatment groups mid-treatment (6 week cohort) and post-treatment (12 week cohort) 
– see table 2.2 for dosing schedule.  
 
5.3.1 Analysis of results 
Kolmogorov-Smirnov tests indicated that the distributions of the estimates of CEC/µl  
and CEP/µl did not deviate from normality justifying the use of parametric statistics. 
There was significant variability between all groups in both CEC and CEP numbers, 
reflected by wide confidence intervals. Detailed statistical results can be seen in 
appendix 3. 
 
The mean CEC (at baseline) was lower in the control (healthy) group (0.86±0.3) than 
in the conventional and metronomic treatment groups (14.01±4.3 and 6.55±3.6 
respectively). There was no significant difference between the mean CEP estimates in 
the control and treatment groups (p=0.103) (see figure 5.4 and 5.5).   
 
The mean difference between the pre-treatment minus the mid-treatment CEC 
estimates for the conventional group was positive, indicating that the mid-treatment 
CEC was lower than the pre-treatment CEC (see figure 5.6). The mean difference 
between the pre-treatment minus the mid-treatment CEC estimates for the 
metronomic group was negative, indicating that the mid-treatment CEC was higher 
than the pre-treatment CEC. 
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Figure 5.4: Comparison of the baseline (pre-treatment) mean CEC/µl ± 95% 
confidence intervals in the three groups (n=4 each group). 
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Figure 5.5: Comparison of the baseline (pre-treatment) mean CEP /µl ± 95% 
confidence intervals in the three groups (n=4 each group). 
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Regime 1: Conventional  
Regime 2: Metronomic 
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Figure 5.6: Comparison of the differences (pre-treatment minus mid-treatment) 
between the mean CEC/µl ± 95% confidence intervals in two groups of cancer 
patients (n=4 each group). 
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Acquired histogram examples of patient 4 from the conventional group and patient 1 
from the metronomic group demonstrate this finding (see figure 5.7a and b). 
 
The mean difference between the pre-treatment minus the post-treatment CEC 
estimates for the conventional group was positive, indicating that the post-treatment 
CEC was lower than the pre-treatment CEC (see figure 5.8). The mean difference 
between the pre-treatment minus the post-treatment CEC estimates for the 
metronomic group was negative, indicating that the post-treatment CEC was higher 
than the pre-treatment CEC.  
 
The mean difference between the pre-treatment minus the mid-treatment CEP in the  
 206
Figure 5.7: FACS-generated histograms: patient results 
a) Patient 4 on conventional treatment: a reduction in mid-treatment CEC levels is 
seen. This was the only patient in the conventional group to remain disease free at 3 
years 
  Pre-treatment CEC followed by mid-treatment CEC (negative control shown as 
green peak to the left). 
                
 
 
 
Figure 5.7: 
 
b) Patient 1 on metronomic treatment: a minimal reduction in mid-treatment CEC 
levels is seen.  
 
Pre-treatment CEC followed by mid-treatment CEC  
     
 
 
 
                 
 
Negative control shown as green peak to the left 
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Figure 5.8: Comparison of the differences (pre-treatment minus post-treatment) 
between the mean CEC/µl ± 95% confidence intervals in the two groups of 
cancer patients (n=4 each group). 
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conventional group was positive indicating that the mid-treatment was lower than the 
pre-treatment, however in the metronomic group, this was negative, indicating that 
the mid-treatment was higher than the pre-treatment (see figure 5.9).  
 
The mean difference between the pre-treatment minus the post-treatment CEP in the 
conventional group was negative, indicating that the post-treatment CEP was higher 
than the pre-treatment. This was also the case for the metronomic group, indicating 
that the post-treatment CEP was also higher than the pre-treatment (see figure 5.10).  
 
Accepting that the study is a very small pilot the following tentative conclusions can  
be drawn from the statistical analysis of these results: 
 
• The mid-treatment CEC was significantly lower than the pre-treatment CEC in the 
conventional group, whereas it was significantly higher than the pre-treatment CEC in 
the metronomic group. The effect size was substantive (see figure 5.7 for example 
histograms). 
• There were no significant differences between the pre-treatment mean CEC and the 
post-treatment mean CEC in the two groups of patients.  Similarly, there were no 
significant differences between the pre-treatment mean CEP and the mid-treatment 
mean CEP or the post-treatment mean CEP in the two groups. The effect sizes were 
relatively small. 
• There was a general trend for CEC to be relatively more variable than CEP, and for 
the effect sizes of CEC to be larger than CEP, with respect to both time and treatment. 
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Figure 5.9: Comparison of the differences (pre-treatment minus mid-treatment) 
between the mean CEP/µl ± 95% confidence intervals in two groups of cancer 
patients (n=4 each group). 
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Figure 5.10: Comparison of the differences (pre-treatment minus post-
treatment) between CEP/µL ± 95% confidence intervals in two groups of cancer 
patients (n=4 each group). 
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Patient 4 from the conventional group showed a different pattern of CEC levels 
throughout treatment to the other patients in this group.  This patient had a further fall 
in CEC levels at week 12. Interestingly, this patient is the only one from the group 
that had a partial response to treatment and remained disease free at 3 years. She did 
however  develop metastatic end-stage disease subsequent to this period (see 
appendix 4 for case report). Figure 5.7 demonstrates this patient’s mid-treatment fall 
In CECs.  
. 
5.4 Discussion 
This study has involved setting up and optimising a methodology for isolating and 
enumerating CEPs and CECs, as set out in the study aims. In terms of the 
methodology, several groups have previously demonstrated the negative impact of 
venepuncture (Goon P et al 2006; Rowland JL et al 2007). In addition, the whole 
blood samples may have produced a better cell yield had the work not required the 
use of the freeze-thaw process. Because of low cell numbers, enrichment steps were 
used, but these steps can also lead to cell loss. This was considered and cell loss was 
tested in the optimisation experiments.  
 
This is a very small scientific study with many limitations, but designed as a 
hypothesis-generating study. A significantly larger sample of stage IV melanoma 
patients would be required in order to test the usefulness of this tool as a potential 
biomarker. This could again be a sub-study of a much larger randomised study where 
clinical end-points can be correlated to the changes seen. This would also require the 
metronomic group to be on an equivalent oral version of the conventional group 
agents. In this case, our two treatment groups are on different agents, although the 
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DTIC and temozolomide are very similar agents.  
 
Previous studies have shown great variabilities in cell counts, dependent on 
variability in sample processing, antibody used, setting of gates and differences in 
equipment and FACS machines. In order to compare results between studies, it would 
be necessary to have a uniform approach, or for an assay to be developed that could 
be reproducible and precise. In the interim, comparing trends may be more useful, 
and seeing if CEC and CEP levels truly correlate with a clinical anti-angiogenic 
response to treatment. At the moment, our main tools for reponse to anti-angiogenic 
treatments include microvessel density (as discussed in section 1.2), vascular-specific 
radiological screening (e.g. dynamic CT and PET scans), and blood tests such as 
serum VEGF and VEGFR2 measurements. The lack of a ‘gold standard’ VEGF 
detection test is a significant hindrance to the clinical utility of VEGF measurements. 
Along with this, VEGF levels also fluctuate with temperature and clotting duration, 
making it currently an unreliable biomarker  (Fuhrmann-Benzakein E et al 2000; Jubb 
A et al 2006).  
  
This small study is however, a potentially useful starting point for further work. As 
previously discussed, it is imperative that reliable assays for biomarkers are 
developed to be used in monitoring patients with malignant melanoma and other 
cancers. This work should only be seen a generating some more hypotheses and 
providing some intriguing early ‘proof of principle’ data only. It is the first study to 
focus on CEC and CEP enumeration in the context of metronomic versus 
conventional therapy in malignant melanoma. Other studies quantifying these cells 
have tended to look at them in the context of metronomic, anti-angiogenic regimens 
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e.g low-dose cyclophosphamide, methotrexate +/- thalidomide (Mancusco P et al 
2006).   
  
When looking at previous related work, Mancoso et al detected increased amounts of 
CECs in cancer patients using flow cytometry (Mancusco P 2001). CECs numbers 
were shown to decrease in patients with lymphoma after complete remission 
following chemotherapy, and also after mastectomy in breast cancer patients. 
Mancusco’s work also showed that patients with progressive cancer of varying types 
– including 3 patients with melanoma - have more CECs than age and sex matched 
healthy volunteers (95 patients, 438 ± 65 CEC/ml; P<0.001 by Mann-Whitney test). 
This finding was also seen in the results of this study, with healthy controls having a 
mean CEC value of 0.86 CEC/µL, and patients with melanoma having pre-treatment 
mean CEC value of 10.28 CEC/µL. Another finding from previous work was that 
patients with stable disease showed comparable amounts of CECs to healthy 
volunteers (17 patients, 179 ± 61 CEC/ml; P=0.69 by Mann-Whitney test) (Beerepoot 
L et al 2004; Rowland JL et al 2007). This comparison could only be made with 
patient 4 (conventional treatment), since this was the only patient that had stable 
disease (for 3 years) post-treatment. This patient did however, have lower CEC values 
post-treatment (2.32 CEC/µL) although, unfortunately in the final stages of this thesis 
write-up, developed metastatic disease  (see appendix 4 for further detail).  
 
Other studies have looked at metastatic breast cancer patients, and have suggested 
that CEC levels are increasingly thought to reflect response to anti-angiogenic 
treatment, and that an increase at week 3 whilst on an anti-angiogenic regimen 
(including bevacizumab) predicted a worse PFS (0.015) (Rugo H et al 2005; Rugo H 
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et al 2006). Along with breast cancer, the predictive value of CECs / CEPs have also 
been assessed in the context of  hepatocellular carcinoma, renal cell carcinoma, 
colorectal cancer and pancreatic cancer, with varying results (Iyer R et al 2006; 
Mancusco P et al 2006; Farace F et al 2007; Malka D et al 2007; Bidard F et al 2010; 
Matsusaka S et al 2010). For example, Mancusco et al showed that the CEC count 
after 2 months of continuous therapy (low dose cyclophosphamide and methotrexate) 
was a good predictor of disease-free and overall survival. In this study, patients with 
CEC >11µg-1 blood after 2 months of this regimen, had a significantly improved 
survival. Another recent study showed that CEC count was associated with improved 
time-to-progession, at a threshold of 20 CEC/4mL (p<0.01). This was in metastatic 
breast cancer (n=67) in patients being treated with bevacizumab and chemotherapy 
(Bidard F et al 2010).  
 
A number of studies have also shown a general trend (Bertolini F et al 2003; 
Furstenberger G et al 2006) to suggest that conventional chemotherapy evokes both 
an acute and a late systemic host response composed of release of CECs, CEPs and 
other factors. In the study by Furstenberger et al, MTD chemotherapy was shown to 
dramatically decrease CECs, where as pro-angiogenic CEP mobilisation was 
increased in drug-free periods. The extent of this CEC and CEP release seems to 
correlate with reponse to treatment and prognosis (Roodhart J et al 2010).  
 
Another observation from this study was that the mid-treatment CEC level was 
significantly lower than the pre-treatment level in the conventional group, whereas 
the mid-treatment CEC level was significantly higher than the pre-treatment level in 
the metronomic group.  A hypothetical model for CEC kinetics (see figure 5.3) was 
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proposed by Bhatt et al (Bhatt R et al 2007), and is consistent with clinical data 
(Mancusco P 2006) with a large initial large surge in CEC apoptosis secondary to 
anti-angiogenic treatment. Similarly, Celik et al demonstrated a dose-response 
relationship between endostatin, an anti-angiogenic, and CEC mobilisation (Celik I 
2005). See figure 5.2.  
 
Given the limitations of this study in terms of its very small size and minimal cell 
verification with additional markers (as discussed earlier in this chapter), it is not 
possible to say whether there are valid, clinically-relevant trends in the data. It is also 
not possible to draw conclusions from the results in terms of clinical outcome. Given 
the care taken to optimise the technique, it is hoped that the data is valid within the 
context of this study, and within the context of metastatic melanoma, in which 
biomarkers and new treatment strategies are urgently needed. 
 
As discussed in the introduction to this chapter, there are numerous technical issues 
related to the methodology of CEC/CEP isolation. Cell numbers of CECs and CEPs 
are already low in peripheral blood. There was a significant possibility that cell 
numbers were reduced by the freeze-thaw process of sample preparation, and during 
the enrichment steps. Optimisation experiments did however attempt to detect and 
minimise cell loss by means of the enrichment steps by analysing samples that were 
to be discarded to check for the presence of CECs/CEPs (see section 5.2). A major 
disadvantage of this technique is that it is labour-intensive, requiring precise multiple 
steps, making it unsuitable for high throughput monitoring. 
 
The lack of consensus on a common endothelial cell phenotype, as discussed in the 
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introduction, also poses problems for inter-study comparisons and validity of data. 
The methodology used in this study allowed specific cellular isolation of CECs and 
CEPs from whole blood. The methodology, however, lacks the detailed phenotyping 
of cells with additional markers for full verification (i.e CD146, CD31 or VEGFR2) 
(Furstenberger G et al 2006; Mancusco P et al 2006). For enumeration of the total 
number of CECs, and not a particular subpopulation, it is necessary to identify 
markers that are specific for and constantly expressed on CECs. See table 5.5 for 
markers used in CEC assays in previous studies, showing the diversity of markers and 
their level of expression.  No marker to date fulfils these necessary criteria 
completely, and as such, results between different studies are not comparable. It 
seems that only a multiparametric, concurrent investigation using a multitude of 
relevant antibodies can fully differentiate between CECs, CEPs and haematopoietic 
cells (Bertolini F et al 2006). For the purposes of a small study such as this, the 
practicalities of using multiple antibodies without larger sample numbers, could not 
be justified, although may have added weight to the findings.  
CD133 is the sole antigen discovered to date, that is expressed in CEPs and 
subsequently downregulated in mature CECs (Rafii S et al 2002; Mizrak D et al 
2008). In this study, the CEP measurements were unremarkable, with no particular 
observational variances. CEPs were defined as CD45-CD34+CD133+. They too were 
likely diminished by the freeze-thaw and enrichment steps. Other studies have 
suggested that CEP levels appear to increase in response to anti-angiogenic agents 
(Beaudry P et al 2005; Farace F et al 2007). In this study, the effect of a molecularly-
targeted antiangiogenic agent was not being assessed, and it may be that when such 
an agent e.g sorafenib, was added into the treatment regimen, CEP levels become 
more relevant as a biomarker. 
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Table 5.5: Markers used in CEC assays 
 
Marker Description Subtype 
association 
Expression
level 
 
Coexpression References 
CD31 PECAM-1 Panendothelial ++a P, 
panleukocyte 
(Beerepoot L 2004) 
 
CD34 Stem cell 
 marker 
Panendothelial ++a S (Furstenberger G 2006) 
 
CD36 Collagen 
 receptor 1 
Microvascular +a P,E,M,D (Moroni G 2005) 
 
CD54 ICAM-1 Inflammation +a L,M (Dixon G 2004) 
 
CD62-E E-selectin Inflammation ++ _ (Dixon G 2004) 
 
CD62-P P-selectin Inflammation + P (Corcoran T 2006) 
 
CD105 Endoglin Angiogenesis, 
malignant 
++a S,Mb (Rowland JL 2007) 
CD106 VCAM-1 Inflammation,  
malignant 
+a _ (Dixon G 2004) 
CD137 ILA/4 Malignant + Lb,D (Seaman S 2007) 
 
CD144 VE-Cadherin Panendothelial +a _ (Smirnov D 2006) 
 
CD146 MelCAM Panendothelial ++a Lb (Dignat-George F 2007) 
 
CD202b Tie-2 Angiogenesis (+)a _ (Smirnov D 2006) 
 
CD276 B7-H3 Malignant + D,Mb (Seaman S 2007) 
 
CD309 VEGFR-2 Angiogenesis (+)a S (Beerepoot L 2004) 
 
V-WF  Panendothelial ++a P (Woywodt A 2006) 
 
UEA-1  Panendothelial ++ - (Woywodt A 2006) 
 
 
PECAM-1=platelet/endothelial cell adhesion molecule1, ICAM-1=intracellular adhesion molecule 1, 
VCAM-1=vascular endothelial cellular adhesion molecule 1, ILA/4=inducible by lymphocyte 
activation/4, MelCAM=melanoma-associated cellular adhesion molecule, Tie-2=angiopoietin-1,2,4 
receptor, B7-H3=B& homologue 3, VEGFR-2=vascular endothelial growth factor receptor 2, 
S=haematopoietic cells, P=platelets, M=monocytes, E=erythrocytes, D=dendritic cells. Expression 
levels: ++=strong, +=moderate, (+)=weak. aIndicates data based on flow cytometric results from 
authors, bIndicates presencew on activated cells. 
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There is also a huge variation in reported numbers of CECs and CEPs, due to both the 
diverse nature of the diseases studied and the non-standardised methodology. For 
example, immunobead and density centrifugation methods tend to show values of 
around 10 CECs/mL in healthy controls, where as with flow cytometry, numbers are 
up to 1000 fold increased (Mancusco P 2001; Goon P et al 2005). In this study, CEC 
numbers in healthy controls were 0.45 -1.12 cells per µl of whole blood. Through 
researching the varying methodologies used previously and through optimisation 
experiments, it was found that data inconsistencies are possible at any stage in the 
processing of each sample. The increasingly available automated isolation and 
staining techniques e.g. CellTracks Autoprep and CellTracks Analyser II system 
(Immunico Corp, PA, USA), were initially designed to detect circulating tumour 
cells. These techniques are non-operator dependent, and are fully automated. They 
can then be followed by gene expression profiling to demonstrate endothelial markers 
(Smirnov D et al 2006; Rowland JL et al 2007)  These automated techniques are 
highly costly and only appropriate for larger numbers of samples, and therefore not 
appropriate for  use in this study. However, a recent study published by Ali et al, 
looked at a group of 76 consecutive breast cancer patients. This study used the 
automated CellSearch system that allows a more standardised analysis of CECs and 
showed that baseline CEC levels might be useful in predicting response to 
chemotherapy (Ali AM et al 2011). 
 
The use of flow cytometry requires sequential gating and fluorescence-compensation 
strategies. This increases inter-laboratory variability and therefore reduces validity of 
cross-study comaprison. There is extensive variability in CEC values reported in the 
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literature as a consequence of this (Blann AD et al 2005). Another mandatory step in 
the assay development is validation of the true endothelial origin of cells designated 
CEC by that assay. For this purpose, several unique features of endothelial cells can 
be used, including their ability to scavenge acetylated low-density lipoproteins. Other 
options include the identification of specific surface markers or gene-expression 
profiling e.g. vascular endothelial cadherin (VE-cadherin), which is present in CECs 
(Smirnov D et al 2006). This was not done as part of the study, since optimisation and 
proof of concept were the major components of work involved. However, specific 
validation of CEC and CEP phenotypes is possible and is likely to add weight to 
findings in larger studies. 
 
This was a small, but unique study. Until this study, CEC and CEP enumeration in 
stage IV melanoma patients on metronomic versus conventional treatment regimens 
has not been investigated. It is one of few metronomic schedules that has been used in 
the treatment of stage IV melanoma and is the only study to be based on dose-
escalation schema rather than an empirical percentage of MTD. Whether or not CEC 
and CEP enumeration can be used for the purpose of prognostic indication will 
ultimately rest on validation of this methodology in a larger trial (ideally in a 
substudy to an RCT) with correlation of the biological outcome to clinical endpoints. 
This testing will always be the vital test of any predictive marker of cancer treatment 
and CECs-CEPs in melanoma are not exempt. This observational, ‘proof of concept’ 
study adds to the expanding body of evidence related to anti-endothelial therapy, not 
just in melanoma, but in all adult solid malignancies. It is hoped to inspire further 
work into this field. 
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Chapter 6 
 
Summary and conclusions 
 
The aims of the in vitro study as described in chapter 3 and 4 were: 
1. To establish the in vitro model, using micro-vascular endothelial cells 
2. To test the anti-endothelial and anti-cancer effects of oral chemotherapeutic agents 
and specific anti-angiogenic agents given in an extended low dosing schedule, given 
as single-agents  
3.  To determine the ‘metronomic’ dose of oral chemotherapeutic agents based on the 
dose at which significant anti-endothelial effects were seen. Suitable single-agents, at 
these determined doses, will be taken forward to use in combination with specific 
anti-angiogenics (described further in chapter 4). 
4. Using the in vitro MVEC model, to test the potential synergistic effects of 
combining the multi-kinase inhibitor, sorafenib, with the chemotherapeutic agents 
selected for this study. 
5. Using the in vitro MVEC model, to test the potential synergistic effects of the 
vascular-targetting agent, combretastatin with the chemotherapeutic agents selected 
for this study. 
6. To determine if an additive inhibitory effect on growth was seen in any of the cell 
lines, when comparing single-agent data to the combination regimens and to rule out 
combinations that show little or no synergy. 
 
All the chemotherapeutic agents used in this study have good oral bioavailability and 
are capable of achieving anti-endothelial effects at doses well below MTD. This 
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makes them potentially suitable for use in future metronomic schedules. Their anti-
angiogenic response in vivo will be difficult to assess, and will rely on the 
development of surrogate markers of tumour vasculature. 
 
Throughout this aspect of the study, it became apparent that within the ‘empirical 
metronomic range’ there were a number of doses with significant anti-endothelial 
effect. The MVEC model was optimised in order to ensure that data was reliable and 
that these effects were reproducible. It was decided, for reasons explained in chapter 
3,  that the first dose level with highly significant (p<0.001) MTT inhibition of 
MVECs compared to baseline would be taken forward to combination as the 
‘metronomic dose’, provided it did not exceed 15% of MTD (as expected from the 
published literature range). It was accepted that this in itself was an arbitrary method 
of establishing a dosing level, but in this respect, there was no guidance in the 
literature.  
 
In terms of combinations, as described in chapter 4, the etoposide / sorafenib 
combination showed a significantly enhanced response compared to single agents in 
both the MVEC and SK-MEL-2 cell lines by over 55% (see figure 4.4). Of all the 
sorafenib-chemotherapy combinations, this combination showed the greatest anti-
endothelial synergistic effect. This was greater than the effect seen in both the 
temozolomide and paclitaxel combinations. This suggests that the combination may 
potentially warrant future study in both the in vivo and clinical setting. The effects of 
combining combretastatin, a non-specific anti-angiogenic agent, were not as 
successful as that observed with a specifically targeted agent such as sorafenib. This 
may be supporting evidence for its lack of efficacy in such combinations when used 
 222
in the in vivo setting.  
 
In spite of the limitations of an in vitro model such as this, the study yielded results 
which compared favourably with other published works on in vitro dosing of 
metronomic chemotherapy (Lam T et al 2007). With an in vitro model, it is 
impossible to assess pathophysiological mechanisms of action, and therefore further 
in vivo work would be required to assess efficacy of combinations. This study does 
not further our understanding of the mechanisms of action of these agents, nor does it 
replace or even reflect the clinical setting. It is however hoped that preliminary in 
vitro studies such as these, can provide a logical starting point for initiating in vivo 
and phase I studies. They may also aid in preventing phase I trials, based on 
empiricism, from being undertaken. Since combinatorial options are huge, alternative, 
potentially more effectual options are plentiful, provided they are at least given the 
chance at an in vitro level first. The aims of this in vitro study, as laid out above, were 
therefore achieved.  
 
It is hoped that future work from this study can use this screening tool to produce 
patterns of synergistic responses between agents and eventually move forward to 
determine changes in down-stream proteins that are pertinent to specific agents. 
Analysis of the proteome may well prove to uncover unknown targets of both specific 
and non-specific agents. This may also provide further justification for tailor-made 
regimens designed for specific patients and tumours, aiming for maximum efficacy 
rather than maximum cytotoxicity. 
 
The aims of the clinical study as described in chapter 5 were: 
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1.To test methodology and to optimise the technique of isolating CECs and CEPs 
from whole blood. 
2.To isolate CECs and CEPs from whole blood samples of patients recruited into the 
scientific sub-study (as described in chapter 2). 
3. To compare CEC and CEP levels between patients on metronomically-dosed and 
conventionally-dosed chemotherapy. 
 
This study was a very small, but unique study. Until this study, CEC and CEP 
enumeration in stage IV melanoma patients on metronomic versus conventional 
treatment regimens has not been investigated. It is one of few metronomic schedules 
that has been used in the treatment of stage IV melanoma and is the only study to be 
based on dose-escalation schema rather than an empirical percentage of MTD. 
Considering the mechanism of action of metronomic regimens and of antiangiogenic 
inhibitors, one of the most important problems faced is the choice of the OBD. 
Tumour stabilisation rather than objective response is probably a more appropriate 
endpoint, as well as TTP (Gasparini G et al 2005; Jubb A et al 2006).  
 
Whether or not CEC and CEP enumeration can be used for the purpose of defining 
the OBD or as prognostic indicators will ultimately rest on validation of this 
methodology in a larger trial (ideally in a substudy to an RCT) with correlation of the 
biological outcome to clinical endpoints. There are a number of unresolved questions 
on the determination of CECs and CEPs: a) the sensitivity and reproducibility of the 
methods used; b) the challenge if tumours may mobilise sufficient CEPs to even be 
detected in clinical practice; c) the best antigen panel for the characterisation of these 
cells.  
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The aims of this observational, ‘proof of concept’ study have been achieved. The 
results could have been enhanced in a number of ways, as discussed in chapter 5, and 
in particular, by employing additional verification techniques, including use of further 
cellular markers of identification. It is work that adds to the expanding body of 
evidence related to anti-endothelial therapy, not just in melanoma, but in all adult 
solid malignancies. It is hoped that further work into this field will focus on further 
stream-lining of methodology along with accurate verification. Assessment of these 
potential biomarkers in trials that employ the combinatorial, metronomic approach 
has already showed promise. Malignant melanoma trials adopting this approach, 
along with use of specific anti-angiogenic agents should aim to assess CECs and 
CEPs in a larger cohort of patients, ideally comparing groups with and without a 
specific anti-angiogenic agent. 
 
In conclusion, this thesis has focussed on novel anti-endothelial strategies in 
malignant melanoma and the principles and applications of metronomic 
chemotherapy. The in vitro aspect of this study has promise to be used as a pre-in 
vivo screening tool in assessing potential compound synergy. It may also assist in 
excluding futile combinations. The CEC / CEP isolation study has generated a 
hypothesis for the use of these cells as biomarkers when adopting anti-angiogenic and 
metronomic strategies in malignant melanoma. Ideas for future work in both these 
aspects of the study have been suggested.  
 
Considering the complex angiogenesis regulatory network that involves multiple 
angiogenic factors produced by various cell types, any antiangiogenic therapy aimed 
 225
at a single angiogenic factor is unlikely to be effective, as laid out in this thesis. 
Metronomic chemotherapy can provide an ideal way of administering chemotherapy 
in combination with many different types of biologic targeted therapies, 
antiangiogenic agents, signal-transduction inhibitors (e.g trastuzumab), aromatase 
inhibitors (e.g. letrozole), COX-2 inhibitors (e.g. celecoxib) and immunotherapeutic 
tumour vaccines.  
 
Throughout the completion of this thesis, my own views on the future of cancer 
therapy have been changed. It seems to me that unless molecularly-targeted 
approaches continue to be enhanced and pursued, drug-based cancer treatment as we 
know it will continue in a state of mediocracy. Logical dosing strategies rather than 
empiricism have been shown to have a greater patient benefit in terms of quality of 
life and lower toxicity profiles. The conventional mass cytotoxic approach is both 
out-dated and unscientific.  Molecularly-targeted, tumour-specfic cocktails designed 
on an individual patient basis may well be the future of modern oncological 
treatment.  
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Appendices 
Appendix 1: Media and Reagents used in MVEC experiment 
MVECs - Medium 199 (500mL) with Earle’s salts, L-glutamine (5mL) and sodium 
bicarbonate (Sigma, U.K.)  
25mL microvascular endothelial growth supplement (TCS Cellworks Ltd, U.K.)  
5mL antibiotic (gentamicin/amphotericinB) supplement (TCS Cellworks Ltd, U.K.). 
Cancer cells - RPMI 1640 Medium (500mL) with L-Glutamine (5mL) 
100 U/ml Penicillin and 100µg/ml Streptomycin (Sigma, UK) (5mL) 
10% (v/v) HiFBS (50mL) 
Freeze medium – MVECs 
20% (v/v) BSA – 10mL 
10% (v/v) Dimethyl-Sulfoxide (DMSO) (Sigma, UK) – 5mL 
70% MVEC Medium 199 - 30mL + ‘antibiotics + growth factors’ TCS Cellworks Ltd 
– 5mL 
Freeze medium – cancer cells 
40% (v/v) HiFBS – 20mL 
10% (v/v) Dimethyl-Sulfoxide (DMSO) (Sigma, UK) – 5mL 
50% RPMI 1640 Medium with L-Glutamine + antibiotics – 25mL 
Phosphate Buffered Saline (PBS) pH 7.2 (1L) 
5.84g NaCl 
4.72g Na2HPO4 
2.64g NaH2PO4.2H2O 
made up to 1L with distilled water 
Lysis Buffer 
Dimethylformamide-water,44:56 v/v containing 0.3M sodium dodecyl sulfate, pH 6.7 
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MTT 
250mg thiazolyl blue tetrazolium bromide  
50mL sterile distilled water 
filtered, wrapped in foil and stored in refrigerator (light-sensitive) 
Attachment factor for MVECs 
0.1% (w/v) gelatin in sterile phosphate buffered saline 
TrypLE™ Select (Invitrogen) 
1x concentration of recombinant enzyme ‘rProtease’ in PBS with 1mM EDTA  
PBS/0.25% (w/v) BSA/Azide (500ml) for FACS 
1.25g BSA 
3.12ml of 10% (w/v) sodium azide (NaN3) made up to 500ml with sterile PBS 
Freeze medium for PBMCs 
90% fetal bovine serum – 45mL and 10% dimethyl sulfoxide (DMSO)-5mL  
Thaw medium for PBMCs 
90% RPMI + 10% FBS 
MACS Buffer (kept at 2-80C) 
500mL  phosphate-buffered saline (PBS)  
0.5% bovine serum albumin (BSA) – 250mg 
2mM EDTA – 0.6g 
FACS Buffer 
500mL of phosphate buffered saline (PBS) 
1.25g bovine serum albumin (BSA) and 3.12mL Azide 
FcR Blocking Reagent (kept at 2-8oC) contains PBS, pH 7.2, 0.5% BSA and 2mM 
EDTA  
Appendix 2.1: Information sheet for study patients 
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Version 1 (2/8/2006) 
 
A new way of monitoring and predicting the severity of melanoma 
by measuring specific cells. 
 
    PATIENT INFORMATION LEAFLET  
 
I would like to invite you to take part in a research study. It would be much 
appreciated if you could read the following information to understand why the 
research is being done and what it involves. I will be happy to explain 
anything that you do not understand. Please take as much time as you need 
to read the information and make a decision. 
 
What is the purpose of this study? 
 
We have been trying to develop better tests that might help to monitor and 
predict the outcome in patients with melanoma. This study aims to develop a 
test to isolate three different types of cells from the blood stream. The actual 
numbers of these cells may reflect the severity of melanoma.  
 
We already know that there are melanoma cells circulating in the blood 
stream of some patients with the disease. There are also two other types of 
cells which have been previously shown to increase in the blood stream in 
certain tumours and diseases. These two cell types (endothelial) are the 
building-blocks of new blood vessels. New blood vessels are made in most 
tumours in order that growth and spread can be sustained. Therefore 
quantifying these cells may well be a useful tool when looking at growth and 
spread of melanoma.  
 
Measuring these three cell types may also help to monitor the effectiveness of 
chemotherapy i.e. when treatment is working, cell numbers go down and vice 
versa.  
   
To carry out this study and measure these cells, it is necessary to collect 
three blood samples. We are therefore inviting you and other patients who are 
also due to start chemotherapy to take part in this melanoma study. This 
would require three samples of blood to be taken; one before chemotherapy, 
one during and one after chemotherapy.   
 
Why have you been chosen? 
As you are aware, you have been diagnosed as having a type of skin cancer 
called malignant melanoma. Studies have shown that there is a significant 
risk that melanoma can seriously shorten life if it has spread elsewhere in the 
body or if it has reoccurred.  Your oncology doctor has recommended that 
you start treatment with a combination of chemotherapy drugs to try to reduce 
the chance of the disease spreading any further. 
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What will happen if you decide to take part? 
 
If you decide to take part in this study, your treatment plan would not be 
affected. We would like to collect three 50 ml blood samples (each a small 
cup full) during your usual outpatient clinic visits if you agree to participate. 
This would be done at the same time as the routine blood tests are taken, so 
there would be no extra needle-sticks or hospital visits required. 
 
If you choose to participate, your involvement in the study will be complete at 
around eight weeks after your chemotherapy has finished.  Further blood 
tests for research purposes after this will not be necessary. You may 
however need to continue having monitoring blood tests for the melanoma 
and not for research. 
 
If you are willing, we would like to continue to review your notes regularly over 
the next few years to record any data that is relevant to your diagnosis and 
treatment. 
 
What do you have to do? 
 
Other than having these three blood tests taken, you do not have to do 
anything different to patients not involved in the study. 
 
Do you have to take part? 
 
No, of course not. Your participation is a matter of your choice.   
Your treatment will not be affected whether you do or do not take part. 
 
Are there any risks involved? 
 
No. There are no risks to you.  
 
Are there any benefits of taking part? 
 
There will not be any clinical benefit to you, but we hope that it will benefit 
patients with melanoma in the future.  
 
What if something goes wrong? 
 
If, for any reason, you are unhappy with the treatment you receive by any 
member of staff, you should, of course, follow the routine hospital complaints 
procedure. Your legal rights for claiming compensation for any injury where 
you can prove negligence is not affected. 
 
Confidentiality 
 
Details of yourself, your present and past treatment as well as your 
participation in the study will be kept in the strictest confidence. These details 
will be recorded in a case file to be retained by the Plastic Surgery 
Department and on a protected database for the duration of the research 
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study - anticipated to last approximately two years. A copy of your consent 
form for this study will also be kept with this information.  
 
What will happen to the results of the research study? 
 
The results of this research will be completely confidential, and no personal 
details will be divulged. These results will be analysed and written in my 
research degree thesis (MD). The findings may be presented at learned 
societies or published in scientific journals. In such cases the information will 
only identify you with a number and not your name or other personal details.  
 
We would like to thank you for your attention so far and hopefully for your 
participation in this study. 
 
By signing the accompanying consent form you will be giving your 
agreement to be entered into this research study.  
 
Your rights 
Your participation in this study is voluntary. If you decide not to enter the 
study your treatment will not be affected.  
 
Who is organising and funding the research? 
This research study is organised jointly by  
Dr Alexandra Murray   
 
In association with: 
THE PLASTIC SURGERY DEPARTMENT  
(Castle Hill Hospital, Cottingham)  
Mr PRW Stanley, Mr N Hart, Mr A Platt, Mr M Riaz 
 
THE ACADEMIC ONCOLOGY DEPARTMENT 
(Princess Royal Hospital, Hull) 
Dr A Maraveyas 
The doctors conducting this study are not being paid to include you in this 
study. 
Contact for further information. 
Please feel free to contact the research doctor - Miss Alexandra Murray, 
if you have any queries. 
 
The Department of Plastic Surgery, 
Castle Hill Hospital, Castle Road, Cottingham, Hull, HU16 5JQ. 
 
Tel: (01482) 875875 ext 2707 
Mobile: 07779727984 
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Appendix 2.2: Consent form for study patients 
 
CONSENT FORM -  Version 1 (2/8/2006) 
 
A new way of monitoring and predicting the severity of melanoma by 
measuring specific cells. 
 
 
Principle Investigator/Researcher:                  Dr Alexandra Murray 
 
<Patients Name and Address> 
……………………………….. 
……………………………….. 
………………………………..                                      Please initial boxes  
I confirm that I have read and understood the patient information sheet dated 
(2/8/2006 version 1) for the above study and have had the opportunity to ask 
questions. 
? 
I understand that details of my current melanoma treatment will be examined 
as part of the above study and may be viewed by responsible members of the 
research team. I give my permission for these individuals to have access to 
my records. 
? 
I also give consent for storage of clinical information about me on a password 
protected computer-database for the duration of the study. I understand that 
this information will be coded and anonymous. 
                   ? 
I give permission for 3 samples of blood to be taken           ? 
I understand that my participation is voluntary                                     ? 
I agree to take part in the above study              ? 
 
______________________  ______________  _______ 
         Name of Patient   Signature             Date 
______________________  ______________  _______ 
  Name of Research Doctor  Signature    Date 
_______________________          ______________               ________ 
 Name of interpreter (if required)       Signature                            Date 
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Appendix 2.3: Information sheet for healthy volunteers 
Version 2 (7/9/2006) 
 
A new way of monitoring and predicting severity of melanoma by  
measuring specific cells. 
 
    VOLUNTEER INFORMATION LEAFLET  
 
I would like to invite you to take part in a research study. It would be much 
appreciated if you could read the following information to understand why the 
research is being done and what it involves. I will be happy to explain 
anything that you do not understand. Please take as much time as you need 
to read the information and make a decision. There is absolutely no obligation 
to participate. If you decide not to participate now then please feel free to do 
so. If you decide not to participate after reading this information sheet, then 
that is not a problem at all. Your time and effort is much appreciated. 
 
What is the purpose of this study? 
 
We have been trying to develop better tests that might help to monitor and 
predict the outcome in patients with melanoma. This study aims to develop a 
test to isolate three different types of cells from the blood stream. The actual 
numbers of these cells may reflect the severity of melanoma.  
We already know that there are melanoma cells circulating in the blood 
stream of some patients with the disease. There are also two other types of 
cells which have been previously shown to increase in the blood stream in 
certain tumours and diseases. These two cell types (endothelial) are the 
building-blocks of new blood vessels. New blood vessels are made in most 
tumours in order that growth and spread can be sustained. Therefore 
quantifying these cells may well be a useful tool when looking at growth and 
spread of melanoma.  
Measuring these three cell types may also help to monitor the effectiveness of 
chemotherapy i.e. when treatment is working, cell numbers go down and vice 
versa.    
We are therefore inviting you and other volunteers to give one sample of 
blood to test for these cell types. It is essential that we have a control group of 
healthy volunteer blood samples against which to compare patient blood 
samples. This will highlight any technical errors with cell pick-up rate and 
strengthen our research. 
 
What will happen if you decide to take part? 
 
We would like to collect one 50 ml blood sample (a small cup full) at a time 
convenient to you, if you agree to participate. There is absolutely no 
obligation to participate, and this is purely a voluntary study. 
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If you choose to participate, your involvement in the study will be complete 
after this one sample has been taken. 
 
Do you have to take part? 
No. You do not have to take part at all.  
Are there any risks involved? 
There is always the possibility of a little bleeding or bruising after having a 
blood test. 
Are there any benefits of taking part? 
There will not be any immediate clinical benefit to patients with melanoma, 
but we hope that it will benefit patients in the future.  
Confidentiality 
Details of yourself and your participation in the study will be kept in the 
strictest confidence. These details will be recorded in a case file to be 
retained by the Plastic Surgery Department and on a protected database for 
the duration of the research study - anticipated to last approximately two 
years. A copy of your consent form for this study will also be kept with this 
information.  
 
What will happen to the results of the research study? 
The results of this research will be analysed and written up (anonymously) in 
my research degree thesis (MD). The findings may be presented at learned 
societies or published in scientific journals. In such cases the information will 
only identify you with a number and not your name or other personal details.  
We will keep you informed of any positive findings from the study. 
 
By signing the accompanying consent form you will be giving your 
agreement to be entered into this research study.  
 
Your rights 
 
Your participation in this study is completely voluntary – there is no obligation 
to take part.   
 
Who is organising and funding the research? 
 
This research study is organised jointly by  
Miss Alexandra Murray (07779727984) 
In association with: 
THE PLASTIC SURGERY DEPARTMENT  
(Castle Hill Hospital, Cottingham)  
Mr PRW Stanley, Mr N Hart, Mr A Platt 
THE ACADEMIC ONCOLOGY DEPARTMENT 
(Princess Royal Hospital, Hull) 
Dr A Maraveyas 
 
The doctors conducting this study are not being paid to include you in this 
study. 
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Appendix 2.4: Consent form for healthy volunteers 
 
CONSENT FORM – Version 1 (2/8/2006) 
 
A new way of monitoring and predicting the severity of melanoma by  
measuring specific cells. 
 
 
Principle Investigator/Researcher:         Miss Alexandra Murray 
 
<Patients Name and Address> 
……………………………….. 
……………………………….. 
………………………………..                                Please initial boxes 
  
I confirm that I have read and understood the volunteer information sheet 
dated (Version 1 2/8/2006) for the above study and have had the opportunity 
to ask questions. 
? 
I give consent for the storage of information gained from my blood sample to 
be stored on a password protected computer-database for the duration of the 
study. I understand that this information will be coded and anonymous. 
                            ? 
I give permission for one sample (50ml) of blood to be taken            ? 
 
I understand that my participation is entirely voluntary                       ? 
 
I agree to take part in the above study                      ? 
 
 
_____________________  ______________  __________           
Name of volunteer    Signature   Date 
_____________________  ______________  __________ 
 Name of research doctor            Signature    Date 
_____________________            ______________               __________ 
 Name of interpreter (if required)      Signature                            Date 
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        Appendix 3: Statistical analysis for clinical study (chapter 5) 
 
Descriptive statistics for the numbers of CEC/µl of whole blood 
 
   Patient group Sample size Sample Kolmogorov-
Smirnov test   
Mean Standard 
deviation 
    Control  
   (Healthy) 
4 Baseline Z = .604 
p = .859 ns 
0.86 0.293 
Pre-treatment 
 
Z = .532 
p = .940 ns 
14.01 4.349 
Mid-treatment Z = .518 
p = .952 ns 
9.55 3.073 
  Conventional 4 
Post-treatment Z = .462  
p = .983 ns 
11.86 
 
6.945 
Pre-treatment 
 
Z = .475 
p = .988 ns 
6.55 3.596 
Mid-treatment Z = .518 
p = .952 ns 
11.25 2.449 
     Metronomic 4 
Post-treatment Z = .500 
p = .964 ns 
11.49 4.987 
 
 
Descriptive statistics for the numbers of CEP/ µl of whole blood 
 
        Pt group Sample size Sample Kolmogorov- 
Smirnov test   
Mean Standard 
deviation 
Control 
(Healthy) 
4 Baseline Z = .729 
p = .662 ns 
0.005 0.010 
Pre-treatment 
 
Z = .651 
p = .791 ns 
0.35 0.224 
Mid-treatment Z = .647 
p = .796 ns 
0.29 0.020 
  Conventiona1 4 
Post-treatment Z = .670 
p = .761 ns 
0.56 0.221 
Pre-treatment 
 
Z = .773 
p = .589 ns 
0.22 0.273       Metronomic 4 
Mid-treatment Z = .511 0.62 0.726 
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p = .956 ns   
Post-treatment Z = .541 
p = .932 ns 
0.42 0.409 
 
ns No significant deviation from normality at p = .05 
Kolmogorov-Smirnov tests indicated that the distributions of the estimates of CEC 
and CEP did not deviate from normality justifying the use of parametric statistics. 
 
Results of One-way ANOVA to compare the baseline (pre-treatment) mean 
CEC/µl in the three groups of patients   
 
 
Sum of Squares
Degrees 
Freedom    Mean Square
Variance  
ratio 
  F 
Significance
p 
Effect 
Size 
Eta 2 
Between groups 347.635 2 173.818 16.328 .00    .784 
Within groups 95.807 9 10.645  
Total 443.442 11   
 
Welch’s 
Statistic 
 
Degrees of Freedom 
 
Significance 
p 
 
19.799 2 4.044        .008* 
 
* Significant difference at p = .05  
 
Results of Dunnet’s T3 post-hoc test for multiple comparison of the mean 
CEC/µl estimates in the control and treatment groups 
 
Comparison of means 
 
Mean Difference
 
Significance 
p 
Treatment regimen 1       -13.14 .021*    Control (Healthy)   
Treatment regimen 2 -5.69 .115ns 
Treatment regime 1   Treatment regimen2 7.45 .103ns 
 
* Significant difference at p = .05.    ns No significant difference  at p = .05 
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Appendix 4: Case report  
 
This is the case report of ‘patient 4’ on conventional treatment discussed in chapter 5. 
 
A 70 year old female was referred to the skin cancer multi-disciplinary team 
following excision of a lesion from the right lower flank area in March 2007. This 
lesion was shown by the referring hospital to be highly malignant with greater than 
60% proliferative index and brisk mitotic activity including atypical mitoses. S100 
positivity suggested the strong possibility of melanoma. Complete excision was not 
possible to be commented on, nor was there a possibility of commenting on whether 
this was a primary or secondary lesion. A wide local excision and sentinel node 
biopsy was carried out by the local plastic surgery department early in May 2007. 
There were also reports that the patient had experienced some symptoms of pain in 
the right pelvic area since March 2007. Plain X-ray was carried out to reveal a lytic 
lesion in the right inferior pubic ramus, associated with a pathological fracture. 
 
CT scan taken in May 2007 preoperatively revealed a large right flank mass 
measuring 4.2x2.6cm in the actual plane. A Trucut biopsy of this lesion was shown 
histologically to be metastatic melanoma. The patient was then referred for 
radiotherapy to the right symphysis pubis, 20 Gy in 5 fractions.  
 
In view of progressive disease, the patient consented to start on dacarbazine and 
vindesine chemotherapy. At this point, the patient also consented to participate in the 
scientific sub-study for enumeration of CECs and CEPs. She remained relatively well 
throughout treatment on the conventional regimen. 
 
CT scan revealed stable apprearances of the pubic ramus in April 2008. In July 2008, 
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there were signs of bony healing, and some atypical nodular changes in the lower 
lungs, but no clear evidence of metastases. CT scan in July 2009 revealed no change 
and stable disease. She therefore remained stable for 2 years. However, unfortunately 
in May 2010, further metastatic deposits were noted and disease progressed rapidly. 
 
*Additional signed informed consent was gained from the patient for use of this 
case report in my thesis.   
 
   
 
 
 
 
